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The book is divided into six sections. The first three sections focus on the 
pathophysiology of the disease, showing anatomo- and histopathological aspects, 
experimental models and signaling pathways and programmed cell death related to 
pheochromocytoma. The fourth discusses some specific aspects of clinical presentation, 
with emphasis on clinical manifestations of headache and heart. The fifth section 
focuses on clinical diagnosis, laboratory and imaging, including differential diagnosis. 
Finally, the last section discusses the treatment of pheochromocytoma showing clinical 
cases, a case about undiagnosed pheochromocytoma complicated with multiple organ 
failure and other cases about catecholamine-secreting hereditary tumors. Thus, this 
book shows the disease “pheochromocytoma” in a different perspective from the 
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Cardiovascular diseases are the major cause of mortality in developed and developing 
countries. Hypertension is the most prevalent of all cardiovascular diseases, the major 
risk factor for cardio and cerebrovascular injury and the third cause of disability. It is 
likely to be involved in 50% of the deaths due to cardiovascular diseases. Genetic and 
environmental factors are involved in more than 90% of cases, characterizing essential 
hypertension. About 5 to 10% of hypertension cases are represented by cases of 
secondary arterial hypertension. In this situation, pheochromocytoma, a catechomine-
secreting tumor that is located in the adrenal medulla (pheochromocytoma) or in the 
extra adrenal paraganglionic tissue (paranganglioma) presents prevalence varying 
from 0.01% to 0.10% of the hypertensive population, and an incidence of two to eight 
cases per million people per year. 
When I received the invitation to be editor of a book on pheochromocytoma, a disease 
that represents small percentage of cases of secondary hypertension, I was worried 
with the development of the book and always wondered what would be the interest 
for the medical community. As the chapters were presented and developed by the 
authors, this worry has disappeared, because despite its rarity, pheochromocytoma 
presents a different clinical picture and several opportunities for clinical and basic 
research. Certainly, the level of the authors of this book also did make it an excellent 
topic to be discussed, in addition to chapters with new approaches about the clinical 
presentation and in the field of experimental research. 
The book is divided into 6 sections covering the main aspects of clinical practice and 
other issues related to translational research. I hope readers enjoy this book and I 
expect it is a reference in the area. 
 
Dr. Jose Fernando Vilela Martin, MD PhD,  
Head of Internal Medicine Division,  
Coordinator of Hypertension Clinic,  
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Macro and Microscopic Aspects 
Fernando Candanedo-Gonzalez, Leslie Camacho-Rebollar  
and Candelaria Cordova-Uscanga 
Department of Pathology, Oncology Hospital,  
National Medical Center Century XXI, 
Mexico City,  
Mexico 
1. Introduction 
In 1886, Fränkel first described pheochromocytoma at autopsy 1. The term 
pheochromocytoma was coined by Poll in 1905 to describe the dusky (pheo) color (chromo) 
of the cut surface of the tumour when exposed to dichromate 2. Not until 1926 did Mayo 
3 at the Mayo Clinic and Roux 4 in Switzerland successfully remove these adrenal 
tumours. Interestingly, neither of these tumours was diagnosed preoperatively. 
Pheochromocytomas are rare catecholamine-producing neuroendocrine tumours arising 
from the chromaffin cells of the embryonic neural crest mainly of adrenal medulla or the 
extra-adrenal chromaffin tissue (paraganglia). Which synthesize, store, metabolize, and 
usually but not always secrete catecholamines.  
1.1 Incidence 
Population studies report an annual incidence of between 0.4 and 9.5 new cases per 100,000 
adult persons each year 5,6,7, which constitute a curable form of hypertension in 0.1 to 1% 
of hypertension patients 8. Of patients with pheochromocytoma discovered only at 
autopsy, 75% died suddenly from either myocardial infartion or a cerebrovascular 
catastrophe. Moreover, one third of the sudden deaths occurred during or immediately after 
unrelated minor operations 9,10. Referrals for pheochromocytoma have been reported to 
be increasing, likely as a result of improved detection. 
1.2 Clinical features 
The majority of pheochromocytomas are sporadic in origin (80-90%) but may be associated 
with other diseases. Classically, pheochromocytomas has been termed a “10% tumour 
because roughly 10% of these tumours are malignant, multifocal, and bilateral, arise in 
extra-adrenal sites, and occur in children. However, recent evidence suggests the percentage 
of familial tumours is considerably higher 11.  
1.3 Classic presentation 
The classic triad of pheochromocytoma presentation is episodic headache, sweating, and 
palpitations. Manifestations of catecholamine excess form a wide spectrum of symptoms in 
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these patients, the foremost being hypertension. Persistent hypertension is frequently 
considered part of the presentation. Also is typically found with a diverse set of symptoms, 
which may include anxiety, chest and abdominal pain, visual blurring, papilledema, nausea 
and vomiting, orthostatic hypotension, transitory electrocardiographic changes, and 
psychiatric disorders. As to be expected, these symptoms are not always present and 
certainly do not always constitute a diagnosis. Nonfunctioning pheochromocytomas are 
distinctly uncommon; nearly all patients with these tumours, at least in retrospect, 
demonstrate some characteristic symptom or sign, especially accentuated at the time of 
operative tumour manipulation. Diagnosis of pheochromocytoma includes detection of 
catecholamines in urine and plasma and radiological tests such as computed axial 
tomography, nuclear magnetic resonance imaging and metaiodobenzylguanidine 
scintigraphy. Laparoscopic techniques have become standard for treatment of tumours of 
the adrenal glands 12.  
2. Pathology features 
2.1 Macroscopy findings 
Nearly 90% of pheochromocytomas are usually confined to the adrenal gland, and may 
appear encapsulated. In sporadic pheochromocytomas, even though lobulated, the tumour 
is actually a single neoplasm. In contrast, familial tumours are often bilateral and usually 
multicentric 13. Pheochromocytomas are of variable size, ranging from 3 cm to 5 cm in 
diameter but can be more than 10 cm 14. The weight may range from < 5g to over 3,500g, 
the average in patients with hypertension being 100g 15. The cut surface is usually soft, 
yellowish white to reddish brown. The larger tumours often have areas of necrosis, 
hemorrhage, central degenerative change, cystic change and calcification. The normal gland 
can be seen in most cases but is sometimes attenuated (Fig. 1).  
 
 
Fig. 1. Adrenal Pheochromocytoma. The round tumour extends torwards the adrenal cortex 
but is macroscopically well defined. Focal degenerative change and central hemorrhage is 
present. Attached adrenal remnant is also present.  
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The other 10 to 15% of cases are found in the neck, mediastinum and heart, or along the 
course of the sympathetic chain. The most frequent extra-adrenal site is the aortic 
bifurcation, the so-called organ of Zuckerkandl 16.  
2.2 Histopathology 
Microscopically, the tumour cells are characteristically arranged in well-defined nest 
(“Zellballen”) or trabecular pattern bound by a delicate fibrovascular stroma, or a mixture of 
the two (Fig. 2A). Diffuse or solid architecture can also be seen. A true capsule does not 
usually separate the tumour from the adjacent adrenal but a pseudocapsule may be present, 
or the tumour may extend to the adrenal capsule. The border with the adjacent cortex may 
be irregular, with intermingling of tumour cells with cortical cells. 
The tumour cells vary considerably in size and shape and have a finely granular basophilic 
or amphophilic cytoplasm. The nuclei are usually round or oval with prominent nucleoli 
and may contain inclusion-like structure resulting from deep cytoplasmic invaginations. 
Cellular and nuclear pleomorphism is sometimes prominent (Fig. 2B) 17. Spindle cells are 
present in about 2% of cases, usually as a minor component. Haemorrhage and 
haemosiderin deposits are common. Mitotic figures are rare, with an average of one per 30 
high power fields reported in clinically benign lesions 18.  
 
 
    
A             B 
Fig. 2. Benign pheochromocytoma. A) Well-defined nest of cuboidal cells are separated by 
highly vascularized fibrous septa (“zellballen”). A granular, basophilic cytoplasm is usually 
identified surrounding slightly irregular nuclei; B) nuclear pleomorphisms are sometimes 
prominent. 
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Specific diagnosis is usually based on morphology and confirmed by immunohisto-
chemistry. Pheochromocytomas are positive for chromogranin A. Other neural markers 
such as synaptophysin have been reported to be variably positive in cortical tumours. The 
absence of positivity for epithelial membrane antigen helps distinguish pheochromocytoma 
from renal cell carcinoma. Immunostaining for S100 protein will demonstrate sustentacular 
cells 19 which are usually arranged around the periphery of the cell nests where there is an 
alveolar arrangement (Fig. 3).  
 
 
   
A          B 
Fig. 3. Immunohistochemical staining. A) Positive cytoplasmic immunostain for 
chromogranin in the pheochromocytoma; B) Immunostain for S-100 protein shows intense 
dark staining of elongated nuclei of sustentacular cells. These are usually located near 
vascular channels. 
3. Familial pheochromocytoma 
Pheochromocytomas are considered to be unique neuroendocrine tumours since they can 
occur as part of several familial tumour syndromes. It is now recognized that the frequency 
of germline mutations in apparently sporadic presentations is as high as 15%–24% 11,20. 
However, the genetic basis of the majority of sporadic pheochromocytomas remains largely 
uncharacterized.  
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Familial pheochromocytomas are often multifocal or bilateral and generally present at an 
earlier age than sporadic pheochromocytoma. Germline mutations in six genes have been 
associated with familial pheochromocytoma, namely, the von Hippel-Lindau gene (VHL), 
which causes von Hippel-Lindau (VHL) syndrome, the RET gene, leading to multiple 
endocrine neoplasia type 2 (MEN 2), the neurofibromatosis type 1 gene (NF1), associated 
with neurofibromatosis type 1 (NF1) disease, and the genes encoding subunits B and D (and 
also rarely C) of mitochondrial succinate dehydrogenase (SDHB, SDHD, and SDHC), which 
are associated with familial paraganglioma/PPC. The recent description of mutations of the 
succinate dehydrogenase gene (SDH) has demonstrated a much stronger hereditary 
component than formerly thought. Currently, up to 24% of pheochromocytomas may have a 
genetic predisposition 11,20.  
The genetic susceptibility of malignant and benign pheochromocytomas is similar. However, 
advances in molecular genetics continue to underscore the importance of hereditary factors in 
the development of pheochromocytoma and propensity to malignancy. Malignant tumours 
have been reported in patients with germline mutations of RET, VHL, NF1 and the SDH genes 
21,22. On the other hand, malignant pheochromocytomas in the setting of MEN 2 occur less 
frequently than sporadic tumours 23,24,25,26. Which suggesting certain groups are 
predisposed to malignant disease. For example, patients with SDHB mutations are more likely 
to develop malignant disease and nondiploid tumours have also been found to be associated 
with malignancy. Gene expression and protein profiling are beginning to identify the genetic 
characteristics of malignant pheochromocytoma. However, the genetic changes that induce 
malignant disease remain unclear. 
4. Malignant disease 
Most pheochromocytomas are benign and curable by surgical resection, but some are 
clinically malignant 27. The pathologist cannot determine whether a tumour is benign or 
malignant based on histological features alone. Although extensive invasion of adjacent 
tissues can be considered an indicator of malignant potential, local invasiveness and 
malignant disease are not necessarily associated. Currently, there are no prognostic tests 
that can reliably predict which patients are at risk of developing metastatic disease. The 
World Health Organization tumour definition of a malignant pheochromocytoma is the 
presence of metastases, at site distant where chromaffin cells do not normally exist 28. 
Metastases occur most frequently to bone, liver, lungs and regional lymph nodes, and can 
appear as many as 20 years after initial presentation, which implies that life-long follow-up 
of patients (Fig. 4) 29.  
Some studies have suggested that the presence of necrosis, vascular invasion, extensive local 
invasion, and high rate of mitotic figures may indicate a malignant behavior in 
pheochromocytoma. Indeed, a recent study by Thompson used clinical features, histologic 
findings, and immunophenotypic studies to indentify parameters that may help distinguish 
benign from malignant pheochromocytoma of the Adrenal Gland Scaled Score (PASS) as a 
scoring system to differentiate benign from malignant pheochromocytomas. PASS is 
weighted for 12 specific histologic features that are more frequently identified in malignant 
pheochromocytomas. Factors such as tumour necrosis, high mitotic rate, tumour cell 
spindling, and vascular invasion are included in this scoring system (Fig. 5). Thompson 
found that tumours with ≥4 were biologically more aggressive than tumours with a PASS 
<4, which behaved in a benign fashion (Table 1) 30.  
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Fig. 4. Malignant pheochromocytoma. A and B) Multiple liver and lungs metastatic lesions 
were shown by computed tomography; C) Transition from the metastatic 
pheochromocytoma component (*) to the liver within the same section; D) By 
immunohistochemical was confirmed the presence of a metastatic pheochromocytoma with 
the characteristic chromogranin immunoreactivity in the pheochromocytos and the S-100 
















Fig. 5. Invasive malignant pheochromocytoma. A) A thick fibrous capsule is transgressed by 
the neoplastic cells with extension into surrounding addipose connective tissue in malignant 
pheochromocytoma; B) Extension into a vascular spaces is noted in a malignant 
pheochromocytoma. 
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Fig. 5. Invasive malignant pheochromocytoma. A) A thick fibrous capsule is transgressed by 
the neoplastic cells with extension into surrounding addipose connective tissue in malignant 
pheochromocytoma; B) Extension into a vascular spaces is noted in a malignant 
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Microscopic feature Score 
Extension into peri-adrenal adipose tissue 2 
Presence of large nests or diffuse growth 
(>10% of tumour volume)† 2 
Central tumour necrosis (in the middle of large nests or confluent necrosis) 2 
High cellularity 2 
Tumour cell spindling even when focal  2 
Cellular monotony 2 
Mitotic figures >3/10 high-power field 2 
Atypical mitotic figures 2 
Vascular invasion* 1 
Capsular invasion 1 
Profound nuclear pleomorphism 1 
Nuclear hyperchromasia 1 
Total 20 
*Defined by direct extension into vessel lumen, intravascular attached tumour thrombi, and/ or tumour 
nests convered by endothelium identified in a capsular or extracapsular vessel. 
†Defined as 3-4 times the size of a zellballen or the normal size of the medullary paraganglia nest. 
Table 1. Pheochromocytoma of the Adrenal Gland Scoring Scale (PASS) 30. 
Additional markers that might be useful prognostic indicators in the pathological 
assessment of these tumours are sought. However, some studies with markers for important 
events in the cell cycle showed that less p21/WAF1 expression and aneuploidy correlated with 
malignant pheochromocytomas 31,32,33.  
4.1 Prognosis and predictive factors 
The rarity of this tumours and the resulting fragmented nature of studies, typically 
involving small numbers of patients, represent limiting factors to the development of 
effective treatments and diagnostic or prognostic markers for malignant disease.  The 
prognosis for patients with benign pheochromocytoma is primarily dependent upon a 
successful surgical resection and extend of preoperative complications related to 
hypertension. The usual prognosis of malignant pheochromocytoma is poor, with a 45-55% 
5-year survival 30,34,35,36,37,38. However, some patients may have indolent disease, with 
life expectancy of more than 20 years 39. Until further studies identify precise biological 
markers that can accurately predict the clinical behaviour of catecholamine-secreting 
tumours, it may be advisable for all pheochromocytoma patients to undergo lifelong 
hormonal monitoring and imaging studies to detect recurrence and metastases 40.  
5. Composite pheochromocytoma 
Ordinary pheochromocytoma is composed of polygonal to spindled cells arranged in an 
alveolar, trabecular, or solid pattern, often with a typical Zellballen appearance. Composite 
pheochromocytomas account for only 3% of both adrenal and extra-adrenal 
pheochromocytomas and can be associated with MEN 2A and phakomatoses 41,42. 
Composite pheochromocytoma is a rare tumour composed of typical pheochromocytoma 
and other components, most often neuroblastoma 43, ganglioneuroblastoma, or 
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ganglioneuroma in adult cases, and pediatric were very rare. Rare cases have displayed 
pheochromocytoma with other coexisting neural or neural crest–derived tumours such as 
malignant peripheral nerve sheath tumour. Little is known about the biologic potential, 
outcome, or molecular genetic profile.  
Because composite pheochromocytoma clinically resembles a typical pheochromocytoma, 
diagnosis is frequently made by the pathologist. The median age is 16 yr (9 to 24 yr) 43. 
The pathologic diagnosis of composite pheochromocytomas creates a clinical dilemma 
because it is not known whether the neuroblastic component results in therapeutic and 
prognostic implications different from those in ordinary pheochromocytoma. 
Neuroblastoma is the most immature of the neuroblastic tumours; the others are 
ganglioneuroblastoma and ganglioglioma (Table 2). These tumours are differentiated based 
on the amount of schwannian stroma and the presence or absence of ganglion cell 
differentiation. This dual phenotype is supported by light microscopy and corroborated by 
immunohistochemistry and ultrastructural findings. Prognosis of coexistence with 
pheochromocytoma and ganglioneuroblastoma or neuroblastoma is variable. 
 
Coexistence with No. of cases % 
Ganglioneuroma 41 70 
Ganglioneuroblastoma 7 11 
Neuroblastoma 4 9 
Schwannoma 4 7 
Neuroendocrine carcinoma 1 2 
Total 57 100 
Table 2. Cases of composite pheochromocytoma of adrenal gland 43. 
6. New insights on pheochromocytoma 
The molecular events involved in the malignant transformation of pheochromocytoma are 
poorly understood. There are also no reliable and uniformly accepted histopathologic 
criteria to distinguish benign from malignant pheochromocytoma. Unsupervised cluster 
analysis showed 3 main clusters of tumors that did not have complete concordance with the 
clinical and pathologic groupings of pheochromocytomas. Supervised cluster analysis 
showed almost completely separate clustering between benign and malignant tumours. The 
differentially expressed genes with known function belonged to 8 biologic process 
categories; signal transduction, transcription, protein transport, protein synthesis, smooth 
muscle contraction, ion transport, chemotaxis, and electron transport. Gene set enrichment 
analysis revealed significant correlation between the microarray profiles of malignant 
pheochromocytomas and several known molecular pathways associated with 
carcinogenesis and dedifferentiation. Ten differentially expressed genes had high diagnostic 
accuracy, and 5 of these genes (CFC1, FAM62B, HOMER1, LRRN3, TBX3, ADAMTS) in 
combination distinguishing benign versus malignant tumours. Differentially expressed 
genes between benign and malignant pheochromocytomas distinguish between these 
tumours with high diagnostic accuracy. These findings provide new insight into the genes 
and molecular pathways that may be involved in malignant pheochromocytomas 44. 
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7. Future directions 
Much attention has recently been devoted to pheochromocytoma as the understanding of 
this disease continues to improve. If it becomes widely available, it would greatly aid in the 
staging and management of malignant disease. Continually improving detection methods, 
especially screening of high-risk populations, will only contribute to the treatment and 
knowledge of these conditions in the future. It has become clear that many apparently 
sporadic pheochromocytomas have a genetic component. Not only has there been a great 
deal of attention directed toward the hereditary components, but better predictive molecular 
factors have been identified for malignant pheochromocytoma, which could lead to more 
effective genetic testing. In addition, microarray studies have identified a set of genes 
preferentially expressed in malignant pheochromocytoma. The combination of an 
identifiable hereditary component along with an understanding of the genetic and 
molecular defects in sporadic pheochromocytoma makes this a promising model and 
approach for insights into other cancers. The future is wide open for improvements in the 
understanding and treatment of this disease. 
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or parasympathetic paragangliomas, further categorised by site. Although it was the first 
adrenal tumor to be recognised, the term phaeochromocytoma was introduced many years 
later by Pick in 1912. The name is based on the fact that the tumors get dark brown after 
exposure to potassium dichromate because of chromaffin reaction.  
2. The usual adrenal medulla 
2.1 Anatomy 
The human adrenal glands are located in retroperitoneum superomedial to kidneys. They 
are composite endocrine organs made up of cortex and medulla which have different 
embriyonic origin, function and histology. On fresh or  formalin fixated cut surface the two 
portions, a relatively thick outer yellow cortex and inner, pearly gray medulla, is readily 
visible. The medulla is mainly situated in head and partly body of the organ . It may 
variably extend to tail and focally to alae. It’s  weight comprises about 8%-10% of the total. 
Medulla is of neuroectodermal origin and secretes and stores catecholamines, especially 
epinephrine. 
2.2 Histology  
On histological examination the cortex-medulla junction is sharp with no intervening 
connective tissue but the border is irregular. The medulla is mainly composed of chromaffin 
cells (phaeochromocytes, medullary cells) that are arranged in tight clusters and trabeculae 
seperated by a reticular fiber network. Embriyologically, they are modified sympathetic 
postganglionic neurons which have lost their axons. They are all innervated by cholinergic 
endings of preganglionic symptathetic neurons. There are sustentacular cells at the 
periphery of clusters which can only be demonstrated by immunostaining for S-100 protein.  
The chromaffin cells are polygonal to columnar and larger than cortical cells. They have 
basophilic cytoplasm which have fine secretory granules and/or  vacuoles. These granules 
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oxidizing agents such as potassium dichromate and ferric chloride. This staining is called 
chromaffin reaction which is replaced by formaldehyde methods for detection of 
catecholamins because of its relatively low sensitivity. 
Among chromaffin cells are randomly scattered individual or group of parasympathetic 
ganglion cells that are often associated with a nerve. Small clusters of cortical cells are also a 
usual component of the medulla. Small groups of lymphocytes and plasma cells may be 
seen within the medulla but their significance is unknown. 
2.3 Ultrastructure  
Ultrastructural examinations have shown that epinephrine and norepinephrine are secreted 
by two different types of cells. Epinephrine secreting cells have smaller, moderately 
electron-dense granules that are closely applied to their limiting membranes. 
Norepinephrine secreting cells' granules are larger, more electron-dense and  have an 
electron-lucent layer beneath the surrounding membrane forming a halo.  The nuclei  are 
usually larger than cortical cells and have finely or coarsely clumped chromatin. Most nuclei 
are spheroidal and show slight pleomorphism. 
3. The paraganglia   
Sympathetic paraganglia (SP) are distributed along paraaxial regions of the trunk along the 
prevertebral and paravertebral sympathetic chains and in connective tissue in the walls  of 
pelvic organs. However parasympathetic paraganglia (PSP) are found along cranial and 
thoracic branches of the glossopharyngeal and vagus nerves. Among SP the organ of 
Zuckerkandl is characteristic, located at the origin of the inferior mesenteric artery, because 
of being the only macroscopic extraadrenal paraganglia. Similarly PSP are highly variable in 
number and location and don’t have specific names except from carotid bodies which are 
located between the carotid arteries just above the carotid bifurcation. Apart from different 
clinical standpoint SP and PSP are similar at cellular level. 
4. Histopathology of phaeochromocytoma 
Sporadic phaeochromocytomas make up of about  50% of all phaeochromocytomas and 
are usually unilateral and unicentric while more than 50% of familial forms are bilateral 
and coexist with extraadrenal sympathetic and parasympathetic paragangliomas. Patients 
with MEN type 2, VHL or NF type 1 are known to have an increased risk for 
pheochromocytoma. 
4.1 Macroscopic examination 
Gross examination highligts a tumor 3-5 cm in diameter which can be more than 10 cm. 
Tumor  weight may range from a few grams to over 3500g,  with an average of 100 g in 
hypertension patients. The cut surface is solid, gray-white, light tan or dusky red and 
darkens on exposure to air (Figure 1). Hemorrhage, central degeneration, necrosis, cytic 
change and calcification is not uncommon. The adrenal gland can usually be seen 
compressed or incorporated within the tumor. An adrenal gland containing 
phaeochromocytoma should be carefully dissected since diffuse and nodular hyperplasia 
can be found suggestive of a familial form.  
 














Fig. 1. Extra-adrenal paraganglioma with a nodular, tan cut surface. Adrenal gland can be 
encountered in orange above the tumor (by courtesy of  Prof. Dr. Filiz Ozyilmaz). 
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4.2 Microscopic examination 
Microscopically, similar to usual corticomedullary border,cortex-tumor border is irregular 
and there’s a pseudocapsule rather than a true capsule. The most common histologic pattern 
is alveolar (Zellballen) and trabecular or a mixture of the two, bound by a delicate 
fibrovascular stroma (Figure 2). Diffuse or solid pattern can also be encountered. Tumor 
cells resemble usual chromaffin cells but are slightly larger. Sometimes nuclear and cellular 
pleomorphism  is pronounced. Nuclear pseudoinclusions can be seen resulting from deep 
cytoplasmic invaginations. Occasional mitotic figures are present but they don’t exceed 1/30 
hpf. Intracytoplasmic hyaline globules are common. Their presence may aid to differentiate 
phaeochromocytoma from adrenal cortical neoplasms. Interstitial amyloid deposition and 
small amounts of melanin pigment representing neuromelanin may be present . 
Hemorrhage and hemosiderin deposits are common and scattered ganglion cells can be 
encountered. Sometimes tumor cells may undergo lipid degeneration and this may lead to 
confusion with cortical tumors. Exceptionally, the cells of phaeochromocytoma may contain 
a large number of mitochondria which give the cells oncocytic appearance. Spindle shaped 
sustentacular cells form a second cell component of phaeochromocytoma forming a 
peripheral rim around Zellballen, similar to usual adrenal medulla. These cells have been 
encountered more frequently in phaeochromocytomas associated with MEN and benign 
forms. 
Histopathologic diagnosis of phaeochromocytoma is based on morphology but 
immunohistochemical techniques are usually used to confirm the diagnosis. 
Immunopositivity for neuron spesific enolase, chromogranin-A and synaptophysin is 
characteristic. 
Extra-adrenal SP are mostly solitary in adults and histologically resemble adrenal 
counterpart.  Dispersed along the paravertebral sympathetic chain, they are most common 
in the superior (45%) followed by inferior (30%) paraaortic region. Urinary bladder, 
intrathoracic and cervical paragangliomas can occasionally be seen. More than 25% of these 
tumors are functional and usually secrete norepinephrine. Approximately 50% of 
extraadrenal tumors are malignant giving rise to metastases. 
PSP seldomly produce cathecolamine excess. Carotid body and jugulotympanic tumors are 
more common than aortic and vagal lesions. Carotid body tumors are more commonly 
bilateral in familial cases . Also people living at high altitude is ten times at a higher risk for 
paraganglioma because of hyperplastic response to hypoxic stimulus. 
4.2.1 Malignant phaeochromocytoma 
Malignant phaeochromocytomas comprise up to 10% of all phaeochromocytomas. WHO 
2004 classification of endocrine tumors defines malignant phaeochromocytoma only when 
there is metastasis to sites where paraganglial tissue is not otherwise found. As a matter of  
fact there’s  no reliable histological criteria for classifiying phaeochromocytoma as 
malignant at present, therefore  no lesion can be definetly predicted as benign. There are 
new approaches to find significant histologic criteria for defining phaeochromocytoma 
malignant. Large nests of tumor cells, necrosis, high cellularity, cellular monotony, nuclear 
hyperchromasia, macronucleoli, vascular or capsular invasion, increased mitotic figures and 
high Ki-67 proliferation index, extension of tumor into adjacent fat, catecholamine 
phenotype and absence of hyaline globules are all shown to be correlated with malignant 
behaviour in scoring studies in both  phaeochromocytomas and extraadrenal sympathetic 
 
 



















Fig. 2. Typical Zellballen pattern of phaeochromocytoma (HEx200) (by courtesy of  Prof. Dr. 
Filiz Ozyilmaz). 
paragangliomas. Unfortunately none of these criteria give exact discrimination thus 
histological gold standard is still not possessed. 
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4.2.2 Composite phaeochromocytoma 
Composite phaeochromocytoma or paraganglioma refers to histological combination of  
phaeochromocytoma and paraganglioma with features of ganglioneuroma, 
ganglioneuroblastoma, neuroblastoma or peripheral nerve sheath tumour. There are 
fewer than 40 cases in the literature. The tumour was combined with ganglioneuroma in 
80%, and with ganglioneuroma in 20% of all reported cases. They are usually seen in 
adults and symptoms are similar to typical phaeochromocytoma as with genetic 
abnormalities. About 90% occur in adrenal gland and the remainder in the urinary 
bladder. Altough ordinary phaeochromocytomas can contain scattered neuron-like or 
ganglion cells the histopathological diagnosis of composite tumour requires both different 
architecture and cell population. Present evidences show that the origin of neurons in 
these tumours is preexisting chromaffin or paraganglioma cells. Cell culture studies favor 
that both normal and neoplastic human phaeochromocytoma cells can undergo neuronal 
differentiaton. 
4.2.3 Adrenal medullary hyperplasia   
Lastly, diffuse or nodular adrenal medullary hyperplasia may cause exess amount of 
cathecolamine secretion and may lead to clinical phaeochromocytoma. 
5. Conclusion 
It is easy to define usual phaeochromocytoma histopathologically but diagnosing malignant 
forms is problematic. Many studies should be done and moleculer techniques should be 
designed to overcome this dilemma. 
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4.2.2 Composite phaeochromocytoma 
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adults and symptoms are similar to typical phaeochromocytoma as with genetic 
abnormalities. About 90% occur in adrenal gland and the remainder in the urinary 
bladder. Altough ordinary phaeochromocytomas can contain scattered neuron-like or 
ganglion cells the histopathological diagnosis of composite tumour requires both different 
architecture and cell population. Present evidences show that the origin of neurons in 
these tumours is preexisting chromaffin or paraganglioma cells. Cell culture studies favor 
that both normal and neoplastic human phaeochromocytoma cells can undergo neuronal 
differentiaton. 
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5. Conclusion 
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designed to overcome this dilemma. 
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USA 
1. Introduction 
Tumor suppressor genes (TSGs) protect normal cells from tumorigenesis (Lasko et al., 1991; 
Sherr, 2004). Except in cases of haploinsufficiency, heterozygosity for a non-functional TSG 
allele protects a cell from tumor formation because the functional TSG allele produces a 
functional protein. Loss of heterozygosity (LOH) is a mechanism by which the remaining 
wild type tumor suppressor allele is lost, resulting in tumor formation (Lasko et al., 1991; 
Sherr, 2004). Loss of TSG expression may also occur by epigenetic silencing. The probability 
of a "second hit" follows a Poisson distribution with the number of tumors and time of 
incidence being variable in heterozygous carriers (Shao et al., 1999). 
Many TSGs have been identified. Such genes play roles in many cellular functions including 
cell cycle checkpoint control, mitogenic signaling pathways, protein turnover, DNA 
damage, hypoxia and other stress responses (Sherr, 2004). Surprisingly, the SdhB, SdhC, and 
SdhD subunits of the metabolic enzyme succinate dehydrogenase (SDH), have also been 
identified as TSGs for neuroendocrine tumors such as paraganglioma (PGL) and 
pheocheomocytoma (PHEO).  
PGLs are rare (1:300,000) tumors of neuroectodermal origin derived from paraganglia, a 
diffuse neuroendocrine system dispersed from the base of the skull to the pelvic floor 
(Baysal, 2002). PGLs are highly vascularized tumors that can originate in either the 
sympathetic or parasympathetic nervous systems (Baysal, 2002; Pacak et al., 2001).  
Patients with PGL tumors that secrete catecholamines present symptoms of catecholamine 
excess including palpitations. The predominant clinical features of nonchromaffin PGLs are 
cranial nerve palsies and tinnitus; however, a small proportion of these nonchromaffin PGLs 
secrete catecholamines (Dluhy, 2002). A hereditary PGL predisposition is involved in at least 
30% of cases (Maher & Eng, 2002; Bryant et al., 2003). Individuals with familial 
predisposition display at least 40% penetrance and a more severe presentation than those 
with the sporadic form of the disease. Extra-adrenal pheochromocytomas are estimated to 
be malignant in 40% of cases (Young et al., 2002). There is currently no effective cure for 
malignant PGL. 
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Five genes encoding subunits of the succinate dehydrogenase (SDH) complex (SdhA, SdhB, 
SdhC, and SdhD) (Astuti et al., 2001; Baysal et al., 2000; Niemann & Muller, 2000; Burnichon 
et al.) or the enzyme responsible for SdhA flavination (Kaelin, 2009; Hao et al., 2009) have 
been identified as tumor suppressor genes in familial PGL. Sdh gene defects may also be the 
cause of sporadic head and neck PGLs where deletions at the same or closely related loci 
(11q13 and 11q22-23) are observed (Bikhazi et al., 2000). The remaining half of familial PGLs 
result from inherited mutations associated with von Hippel-Lindau (VHL) syndrome, 
multiple endocrine neoplasia type 2 (MEN 2), or neurofibromatosis genes (Inabnet et al., 
2000; Bryant et al., 2003).  
The SDH complex catalyzes the oxidation of succinate (Su) to fumarate (Fu) in the 
tricarboxylic acid (TCA) cycle and delivers the resulting electrons through various carriers 
to the ubiquinone pool of the electron transport chain. These electrons are ultimately 
donated to oxygen to generate water in the process that forms a proton gradient across the 
inner mitochondrial membrane for ATP production. The porcine SDH complex (Fig. 1) has 
been studied by X-ray crystallography (Sun et al., 2005). The largest subunit, SdhA, is a 
flavoprotein of 70 kDa that contains the SDH active site and FAD moiety. A smaller subunit, 
SdhB is an iron-sulfur protein of 30 kDa carrying three dissimilar iron clusters, [2Fe-2S]2+,1+, 
[4Fe-4S]2+,1+, and [3Fe-4S]1+,0+. SdhA/B are anchored to the membrane by SdhC and SdhD (15 
kDa and 12.5 kDa, respectively), which coordinate a heme group and possess a ubiquinone 
binding site essential for electron transport into the respiratory chain.  
 
 
Fig. 1. X-ray crystal structure of SDH complex (Sun et al., 2005). Four subunits labeled and 
indicating the flavin of the catalytic A subunit (FAD), iron-sulfur clusters of the B subunit 
(FeS), and co-enzyme Q (Q) near the C and D subunits. 
A broad spectrum of Sdh mutations has been reported in familial PGL. Mutations in SdhB 
and SdhC lead to non-imprinted autosomal dominant inheritance of familial PGL. Mutations 
in SdhD demonstrate imprinted paternal autosomal dominant inheritance (Baysal et al., 
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2002). The range of mutations in SDH subunit genes identified in familial PGL suggests that 
loss of function of SDH subunits is the common cause of PGL.  
Familial PGL is particularly fascinating because the causative genetic defects in SDH block 
the TCA cycle, enforcing upon the tumor an obligatory Warburg effect (Warburg, 1956). 
Thus, PGL tumor cells must apparently rely on glycolysis as an inefficient source of ATP. 
Familial PGL thus perfectly exemplifies the aerobic glycolysis commonly observed in 
cancer, and studies of PGL have the potential to reveal management strategies for all cancers 
that rely on glycolysis rather than the TCA cycle (Kaelin, 2009).  
PGL causation may involve HIF1 activation and other epigenetic effects. Cells carefully 
regulate oxygen uptake, and respond to hypoxia by altering gene regulation. The master 
regulator of these responses is the heterodimeric basic helix-loop-helix transcription factor 
Hypoxia-Inducible Factor 1 (HIF1). HIF1 regulation involves oxygen-dependent 
prolylhydroxylation (PHD), ubiquitin ligation, and proteasomal degradation of the HIF1α 
subunit under normoxic conditions (Semenza, 2003). Prolylhydroxylation of HIF1α requires 
oxygen, iron, and 2-ketoglutarate (2KG), and the reaction produces succinate (Su) as a 
byproduct. If oxygen becomes limiting, prolylhydroxylation is inhibited, and HIF1α 
accumulates, translocates to the nucleus, and pairs with the constitutively expressed HIF1β 
subunit. Thus, HIF1 stability is directly regulated by oxygen. Hypoxic genes stimulated by 
HIF1 include transporters for increased glucose import (allowing anaerobic growth by 
glycolysis) and genes encoding angiogenesis factors. HIF1 activation is correlated with 
tumor aggressiveness and therapy resistance. 
According to the succinate (Su) accumulation hypothesis (Lee et al., 2005; Maxwell, 2005; 
Selak et al., 2005; Smith et al., 2007; Favier & Gimenez-Roqueplo, 2010), the disruption of 
SdhB yields a catalytically inactive SdhA subunit and Su accumulates in the cell due to loss 
of SDH activity. Su diffuses to the cytoplasm where it acts as an inhibitor of the 2-
ketoglutarate (2KG)-dependent prolyl hydroxylase (PHD) enzymes that use molecular 
oxygen as a substrate to hydroxylate HIF1α prolines for degradation when adequate oxygen 
is present. This class of enzyme reactions generates Su as a product, and is therefore 
susceptible to inhibition by elevated Su concentrations. Loss of SDH activity disables the 
TCA cycle and causes inappropriate HIF1 persistence due to Su inhibition of PHD enzymes. 
The resulting pseudohypoxic state is not tumorigenic in most cell types. However, it is 
hypothesized that chronic pseudohypoxic signaling is a mitogenic tumor initiator in 
neuroendocrine cells because these cells proliferate in a futile homeostatic attempt at a 
hormonal response to perceived hypoxia. Thus, inappropriate HIF1 persistence due to loss 
of SDH function in PGL drives tumorigenesis. HIF1 is therefore a novel target for therapy of 
PGL. 
Our working hypotheses are shown in Fig. 2. We hypothesize that tumorigenic effects of 
succinate accumulation are not limited to inhibition of prolyl hydroxylation (McDonough et 
al., 2006), but also include inhibition of histone demethylation by Jumoni domain (JHDM) 
enzymes (Klose et al., 2006), and inhibition of 5-methylcytosine hydroxylation by TET1 
(Tahiliani et al., 2009). Thus we are interested in model systems to probe how loss of SdhB 
acts as a tumorigenic trigger in neuroendocrine cells. 
To date there have been limited opportunities to understand SDH dysfunction in such 
animal models. Although no human PGL cell lines exist, various studies have been 
undertaken using PGL tumor tissue samples to understand the underlying biochemistry 
and genetics (Benn et al., 2006). Unfortunately, such patient samples are not numerous and 
no systematic approach has been taken in understanding the pathological biochemistry of 
PGL.  
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Mutations in genes encoding SdhB, SdhC, or SdhD in C. elegans, S. cerevisiae, and mammalian 
cell lines have been utilized to examine the reactive oxygen species (ROS) hypothesis and 
the succinate accumulation hypothesis (Guo & Lemire, 2003; Ishii et al., 1998; Ishii et al., 
2005; Lee et al., 2005; Oostveen et al., 1995; Selak et al., 2005). The only available mammalian 
PGL cell lines do not emulate the SDH familial form of PGL. For instance, rat PHEO cell line 
(PC12) (Tischler et al., 2004) and mouse PHEO cell lines (MPC) are available (Powers et al., 
2000). However, PC12 cells are derived from a spontaneous PHEO tumor with functional 
Complex II and MPC cells are derived from neurofibromatosis [(Nf1 +/- heterozygous] 
knockout mice (Tischler et al., 2004). During the course of this project a mouse model of 
SdhD deficiency was developed (Piruat et al., 2004). SdhD +/- mice were found to have 
decreased expression of SdhD and 50% SDH activity in various tissues relative to SdhD +/+ 
mouse tissues (Piruat et al., 2004). Although SdhD +/- mice were found to have carotid body 
glomus cell hyperplasia and organ hypertrophy, no PGL tumor formation was observed 
(Piruat et al., 2004; Bayley et al., 2009).  
 
 
Fig. 2. A. Normal tumor suppressor functions of Fe/O2/2KG-dependent dioxygenases in 
Hif-1α degradation and epigenetic regulation of histone methylation and 5-methylcytosine 
hydroxylation. B. Proposed effects of succinate inhibition in PGL. Simple genetic models of 
Sdh mutant PGL come in the form of model organisms that contain defects in SDH subunits.  
We recently created and studied a yeast model lacking the SdhB subunit of Complex II 
(Smith et al., 2007). As expected for loss of a TCA enzyme, this yeast strain is dependent on 
glycolysis and is unable to survive on non-fermentable carbon sources. The yeast model has 
increased ROS and also shows accumulation of succinate. This succinate accumulation 
poisons at least two 2KG-dependent enzymes that produce succinate as a normal 
 
Mouse Models of Human Familial Paraganglioma 
 
29 
byproduct. Succinate inhibition of such enzymes in mammalian systems (e.g. the 2KG-
dependent prolyl hydroxylase that modifies HIF-1α and JHDMs) has been proposed as a 
completely novel metabolic mechanism of tumorigenesis. Further progress in 
understanding PGL and PHEO could be facilitated by development of animal models to 
allow testing of the ROS and succinate accumulation hypotheses and hypotheses related to 
environment, diet, and pharmaceutical interventions.  
Human SdhB mutations are not associated with a parent-of-origin effect (Baysal, 2001). It has 
also been observed that both SdhB- and SdhD-linked PGL tumors tend to lose SdhB 
expression and have enhanced SdhA abundance (Douwes Dekker et al., 2003). Thus, SdhB 
disruption creates an obvious goal for genetic models. Analysis of causative SdhB mutations 
in human PGL suggests that total loss of SdhB function is the common feature (Baysal, 2001; 
Baysal, 2002; Eng et al., 2003). 
Here we describe the generation of two heterozygous mouse lines carrying a disruption in 
one copy of SdhB. By analogy with human familial predisposition to PGL genetics (Baysal, 
2001; Baysal, 2002), mouse strains heterozygous for functional SdhB are hypothesized to 
display no phenotype, but to be predisposed to PGL development due to random loss of the 
second SdhB allele during development. Based on human PGL genetics, it was hypothesized 
that loss of the second SdhB gene would be oncogenic only in neuroendocrine cells. 
2. Materials and methods 
2.1 Creation of an SdhB targeting vector 
A recombinant targeting vector for mouse SdhB was designed and assembled according to 
standard procedures. SdhB-specific sequences were inserted into the commercial vector 
NTKV1901 (Stratagene) that carries Neo and TK genes for selection of targeted integrants. 
Briefly, two arms homologous to segments of the murine SdhB gene were amplified by PCR 
(Epicentre, Failsafe kit) from mouse genomic DNA with sets of primers containing two 
unique restriction sites. The left homologous arm (Scrambler A) was PCR-amplified with an 
upstream primer that contains a HindIII site, (LJM-2309: GCTAGCA2GCT2G2AGATA-
CAGCTCAGTCTGAGTG3) and a downstream primer that contains a XhoI site, (LJM-2310: 
GCTAGC2TCGAGCATC2A2CAC2ATAG2TC2GCAC2T). The Scrambler A PCR product was 
directly cloned into the targeting vector NTKV1901. The right homologous arm (Scrambler 
B) was PCR-amplified with an upstream primer containing a ClaI site (LJM-2311: 
GCTAGCATCGATG2TG2TGTC2TGCTGTGCTGT3GG) and a downstream primer containing 
a SacII site (LJM-2312: GCTAGC3GCG4A3G2TG4CAGACATAGTAC). The Scrambler B PCR 
product was first cloned into a pGEM-T Easy vector (Promega), then isolated with a SacII 
digest and ligated into the targeting vector. Diagnostic NotI, HindIII/XhoI and SacII 
restriction digests were performed. 
2.2 Extension the SdhB targeting vector 
A forward primer specific for SdhB intron seven that contains the SalI restriction site (LJM-
2599: ATATGTG2TCAGTGCT4C) and a reverse primer specific for a region downstream of 
SdhB exon eight that contains a NotI restriction site (LJM-2595: GCTAGCGCG2-
C2GC2TA2CTCACG2A2G3CA2G2) were used to amplify a Scrambler B extension product by 
PCR (Epicentre, Failsafe kit). The product was cloned into the original targeting vector using 
standard procedures. 
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Mutations in genes encoding SdhB, SdhC, or SdhD in C. elegans, S. cerevisiae, and mammalian 
cell lines have been utilized to examine the reactive oxygen species (ROS) hypothesis and 
the succinate accumulation hypothesis (Guo & Lemire, 2003; Ishii et al., 1998; Ishii et al., 
2005; Lee et al., 2005; Oostveen et al., 1995; Selak et al., 2005). The only available mammalian 
PGL cell lines do not emulate the SDH familial form of PGL. For instance, rat PHEO cell line 
(PC12) (Tischler et al., 2004) and mouse PHEO cell lines (MPC) are available (Powers et al., 
2000). However, PC12 cells are derived from a spontaneous PHEO tumor with functional 
Complex II and MPC cells are derived from neurofibromatosis [(Nf1 +/- heterozygous] 
knockout mice (Tischler et al., 2004). During the course of this project a mouse model of 
SdhD deficiency was developed (Piruat et al., 2004). SdhD +/- mice were found to have 
decreased expression of SdhD and 50% SDH activity in various tissues relative to SdhD +/+ 
mouse tissues (Piruat et al., 2004). Although SdhD +/- mice were found to have carotid body 
glomus cell hyperplasia and organ hypertrophy, no PGL tumor formation was observed 
(Piruat et al., 2004; Bayley et al., 2009).  
 
 
Fig. 2. A. Normal tumor suppressor functions of Fe/O2/2KG-dependent dioxygenases in 
Hif-1α degradation and epigenetic regulation of histone methylation and 5-methylcytosine 
hydroxylation. B. Proposed effects of succinate inhibition in PGL. Simple genetic models of 
Sdh mutant PGL come in the form of model organisms that contain defects in SDH subunits.  
We recently created and studied a yeast model lacking the SdhB subunit of Complex II 
(Smith et al., 2007). As expected for loss of a TCA enzyme, this yeast strain is dependent on 
glycolysis and is unable to survive on non-fermentable carbon sources. The yeast model has 
increased ROS and also shows accumulation of succinate. This succinate accumulation 
poisons at least two 2KG-dependent enzymes that produce succinate as a normal 
 
Mouse Models of Human Familial Paraganglioma 
 
29 
byproduct. Succinate inhibition of such enzymes in mammalian systems (e.g. the 2KG-
dependent prolyl hydroxylase that modifies HIF-1α and JHDMs) has been proposed as a 
completely novel metabolic mechanism of tumorigenesis. Further progress in 
understanding PGL and PHEO could be facilitated by development of animal models to 
allow testing of the ROS and succinate accumulation hypotheses and hypotheses related to 
environment, diet, and pharmaceutical interventions.  
Human SdhB mutations are not associated with a parent-of-origin effect (Baysal, 2001). It has 
also been observed that both SdhB- and SdhD-linked PGL tumors tend to lose SdhB 
expression and have enhanced SdhA abundance (Douwes Dekker et al., 2003). Thus, SdhB 
disruption creates an obvious goal for genetic models. Analysis of causative SdhB mutations 
in human PGL suggests that total loss of SdhB function is the common feature (Baysal, 2001; 
Baysal, 2002; Eng et al., 2003). 
Here we describe the generation of two heterozygous mouse lines carrying a disruption in 
one copy of SdhB. By analogy with human familial predisposition to PGL genetics (Baysal, 
2001; Baysal, 2002), mouse strains heterozygous for functional SdhB are hypothesized to 
display no phenotype, but to be predisposed to PGL development due to random loss of the 
second SdhB allele during development. Based on human PGL genetics, it was hypothesized 
that loss of the second SdhB gene would be oncogenic only in neuroendocrine cells. 
2. Materials and methods 
2.1 Creation of an SdhB targeting vector 
A recombinant targeting vector for mouse SdhB was designed and assembled according to 
standard procedures. SdhB-specific sequences were inserted into the commercial vector 
NTKV1901 (Stratagene) that carries Neo and TK genes for selection of targeted integrants. 
Briefly, two arms homologous to segments of the murine SdhB gene were amplified by PCR 
(Epicentre, Failsafe kit) from mouse genomic DNA with sets of primers containing two 
unique restriction sites. The left homologous arm (Scrambler A) was PCR-amplified with an 
upstream primer that contains a HindIII site, (LJM-2309: GCTAGCA2GCT2G2AGATA-
CAGCTCAGTCTGAGTG3) and a downstream primer that contains a XhoI site, (LJM-2310: 
GCTAGC2TCGAGCATC2A2CAC2ATAG2TC2GCAC2T). The Scrambler A PCR product was 
directly cloned into the targeting vector NTKV1901. The right homologous arm (Scrambler 
B) was PCR-amplified with an upstream primer containing a ClaI site (LJM-2311: 
GCTAGCATCGATG2TG2TGTC2TGCTGTGCTGT3GG) and a downstream primer containing 
a SacII site (LJM-2312: GCTAGC3GCG4A3G2TG4CAGACATAGTAC). The Scrambler B PCR 
product was first cloned into a pGEM-T Easy vector (Promega), then isolated with a SacII 
digest and ligated into the targeting vector. Diagnostic NotI, HindIII/XhoI and SacII 
restriction digests were performed. 
2.2 Extension the SdhB targeting vector 
A forward primer specific for SdhB intron seven that contains the SalI restriction site (LJM-
2599: ATATGTG2TCAGTGCT4C) and a reverse primer specific for a region downstream of 
SdhB exon eight that contains a NotI restriction site (LJM-2595: GCTAGCGCG2-
C2GC2TA2CTCACG2A2G3CA2G2) were used to amplify a Scrambler B extension product by 
PCR (Epicentre, Failsafe kit). The product was cloned into the original targeting vector using 
standard procedures. 
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2.3 ES cell culture and transfection with targeting vectors 
ES cells derived from C57BL/6 blastocysts (E3.5) were transfected with NotI linearized 
targeting vectors, and stable integrants were selected in Geneticin G418 medium as 
described (Hofker & van Deursen, 2002). 
2.4 Southern blotting 
PCR was used to generate a 200-bp probe with homology to intron two of the SdhB gene. 
The probe was labeled by random priming in the presence of [α−32P]-dATP according to 
manufacturer’s instructions (Roche). 10-20 μg of genomic DNA from ES cell clones was 
digested with SacI (New England Biolabs) and the DNA was electrophoresed overnight at 
40 V. Southern blotting of DNA was performed using standard procedures as described 
(Hofker & van Deursen, 2002).  
2.5 Genetic analysis of 129SV/E SdhB:β-Geo disrupted ES cells 
For expression analysis by RT-PCR RNA was harvested from SdhB +/- ES cells with Trizol 
reagent by standard procedures, and reverse transcribed with a pool of nonamers according 
to manufacturer’s instructions (Epicentre). cDNA was amplified with a common forward 
primer specific to SdhB exon one (LJM-2684: CGACG2TCG3TCTC2T2GA2) and either a β-Geo-
specific reverse primer (LJM-2687: AT2CAG2CTGCGCA2CTGT2G3) or an exon two-specific 
reverse primer (LJM-2685: GAGCTGCAGCAGCAGCTGTC) by PCR (Epicentre, Failsafe 
kit). For mapping of the gene integration point by PCR genomic DNA from SdhB +/- ES 
cells was precipitated with lysis/precipitation buffer [50 mM Tris-HCl (pH 8.0), 100 mM 
EDTA (pH 8.0), 100 mM NaCl, 1% SDS, 10 mg/ml proteinase K] and extracted with 
phenol:chloroform (1:1). A forward primer specific for SdhB exon one (LJM-2784: 
AGCTGAC2AGACA2GAGTCACAG2TGAT2GACAGA) and a reverse primer specific for the 
β-Geo marker (LJM-2787: AGTATCG2C2TCAG2A2GATCGCACTC2AGC2AGC) were used to 
amplify the region of the gene trap vector integration by PCR (Epicentre, Failsafe kit). The 
PCR product was purified and sequenced across the β-Geo marker to verify the exact SdhB:β-
Geo junction. 
2.6 Generation and husbandry of mice 
Following genetic characterization, SdhB +/- ES cells were injected into C57/BL6 blastocysts 
and used to generate chimeric animals as described (Hofker & van Deursen, 2002). Animals 
were caged in groups of five, segregated by genotype and gender. Standard animal 
husbandry methods were used under IACUC protocol A29505 in the Mayo Clinic non-
barrier mouse facility. 
2.7 DNA extraction 
DNA extraction from tail clippings was performed after overnight digestion in 
lysis/precipitation buffer [50 mM Tris-HCl (pH 8.0), 100 mM EDTA (pH 8.0), 100 mM NaCl, 
1% SDS, 10 mg/ml proteinase K] at 55°C. DNA was precipitated with isopropanol, washed 
once in 80% ethanol and resuspended in sterile water. 
2.8 Genotyping 
To distinguish SdhB +/+ and SdhB +/- animals, genomic DNA was analyzed by PCR 
(Epicentre, Failsafe kit) with a common forward primer LJM-2826 (5’-
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GTGTAGC3TG2CTGTC2TG2A2CT2GCTC) and differential reverse primers, LJM-2828 (5’-
G2CA3C3A4G3TCT3GAGCAC2AG) and LJM-2830 (5’-GTG3AC2TGCGTGACA3GT 
GCATG2AG), specific for β-Geo and intron one, respectively. Bub1 Genotyping used 
standard PCR methods employing the Failsafe kit (Epicentre). The Bub1 WT locus was 
amplified with a forward primer in exon eight (LJM-3169: CTG2C2TG2A2CT2GCTATGTC) 
and a reverse primer in intron eight (LJM-3171: CG2T3CTCTGTATAGC3TG2C). The Bub1 
knockout allele was amplified with a forward primer in the neomycin cassette (LJM-3178: 
GCAGT2CAT2CAG3CAC2G2AC) and the reverse primer LJM-3171. The Bub1 hypomorphic 
allele was amplified with a primer set in the hygromycin cassette (forward primer, LJM-
3172: CG2A2GTGCT2GACAT2G2; reverse primer, LJM-3173: GTAT2GAC2GA-T2C2T2GCG). 
2.9 Histology 
Tissue samples for histology were dissected and fixed in neutral-buffered 10% formalin 
(Sigma) for 24 h. Tissues were dehydrated, embedded in paraffin, and 10-µm slices were 
prepared with a microtome and mounted. Standard hematoxylin and eosin staining was 
used for initial histopathology. Bifurcations containing carotid bodies were dissected and 
xed in formalin (Sigma) at 4°C for 16 h. Tissues were dehydrated and parafn embedded, 
and 10-µm slices were obtained by using an RM2125 microtome (Leica Microsystems). 
Immunohistochemistry was performed according to standard procedures. For detection of 
glomus cells, tissues were immunostained with a rabbit polyclonal antityrosine hydroxylase 
(TH) antibody (Pel-Freez). After immunodetection with peroxidase-conjugated secondary 
antibody, tissue samples were counterstained with hematoxylin. 
2.10 Quantitative RNA analysis by RT-PCR 
RNA from liver or kidney tissue was harvested with the RNeasy Plus Mini kit (Qiagen), 
quantitated with a RiboGreen assay (Invitrogen) and reverse transcribed by random 
nonamers (Epicentre). cDNA was amplified by PCR (BioRad IQ SuperMix) with a forward 
primer (LJM-3115: ATGA2CATCA2CG2AG2CA2TAC) and a reverse primer (LJM-3116: 
GAG3TAGAT4G2AGACT3GC) located downstream of the βGEO insertion site in exon four. 
Probe 5’-6-FAM/CACACGCAG2ATCGACACG2AC2T/3BHQ-1 specific for exon four was 
used to monitor target amplification of either cDNA or an 82-bp synthetic DNA amplicon 
used to produce a standard curve in a BioRad iCycler.  
2.11 Enzyme assays 
SDH activity was assayed in kidney and liver extracts from juvenile mice of each genotype 
euthanized by cervical dislocation. SDH activity was measured as PMS-mediated reduction 
of the 2,6-dichloroindophenol dye in the presence of antimycin A, rotenone and cyanide, 
monitored at 600 nm as described (Kramer et al., 2005).  
2.12 Metabolite analysis 
Levels of TCA cycle metabolites were determined by acidification of urine and extraction of 
free acids into ethyl acetate. 2-keto acids (e.g. 2-KG) were first protected by oximation with 
hydroxylamine hydrate. After evaporation, the dry residue was silyated with N,O-bis-
(trimethylysilyl)trifluoroacetamide and trimethylchlorosilane to produce volatile 
derivatives, and analyzed by capillary gas chromatography/mass spectrometry on an HP 
ChemStation instrument equipped with an HP-5 25 m column (ID 0.2 mm) using 
pentadecanoic acid as an internal standard. Metabolite levels were normalized to creatine. 
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3.1 Generation of SdhB +/- mice 
Two approaches were initially taken to generate an SdhB +/- mouse strain (Fig. 3). The first 
strategy involved the creation of a DNA targeting vector that would specifically replace part 
of exon three through part of intron four by homologous recombination with a neomycin 
resistance marker on a single SdhB allele (Fig. 3A). The targeting vector carried two arms of 
homology to SdhB (Scrambler A and Scrambler B) and two selectable markers – NEO 
(neomycin phosphotransferase) and TK (thymidine kinase) genes. These genes allow for 
selection of integrants and counterselection against non-homologous insertions, 
respectively. This construct was intended to exchange the selectable NEO marker for a 
segment of SdhB extending from part of exon 3 through part of intron 4. This strategy would 
create an SdhB mRNA with only a short reading frame, followed by nonsense codons. The 
resulting truncated polypeptide is analogous to loss-of-function products seen in human 
SdhB mutations causing PGL (Benn et al., 2006).  
The targeting vector was constructed and verified with diagnostic restriction digests that 
confirmed the successful insertion and orientation of both SdhB homology regions into the 
targeting vector. Its size (13.6 kb) was confirmed by linearization with NotI, Scrambler A 
insertion was confirmed by a HindIII/XhoI digest, and Scrambler B insertion was confirmed 
by a SacII digest. Molecular junctions were sequenced to confirm expected features of the 
targeting vector. 
Mouse ES cells were electroporated with the linearized SdhB targeting vector, and 
NEO+ TK- colonies were selected and screened for targeted inactivation of one copy of 
SdhB. DNA was harvested from over 400 potential clones and analyzed by Southern 
blot. None of the clones showed evidence of homologous recombination at SdhB. 
Similar results were obtained even when the Scrambler B SdhB homology segment was 
increased in length. 
We therefore adopted a second strategy (Fig. 3B). We obtained an SdhB +/- embryonic 
stem (ES) cell line that had been created by high throughput random gene trap integration 
by the Sanger Center gene trap consortium (Nord et al., 2006). Sequencing of an RT-PCR 
product derived from the integrated β-Geo marker gene revealed integration of the gene 
trap cassette in intron 1 of the mouse SdhB gene. The strong cleavage and poly(A) signals 
of the gene trap fragment should truncate SdhB mRNA after the short exon 1, resulting in 
a completely non-functional SdhB mRNA, analogous to that produced by disease-
associated truncating alleles in humans. We confirmed the presence of the gene trap by 
PCR from random-primed cDNA prepared from the ES cells. PCR of genomic DNA from 
the ES cell line allowed us to map the precise location of the gene trap, and sequencing of 
PCR products showed the exact position of the trap reporter gene downstream of the exon 
1/intron 1 junction (Fig. 4A).  
The SdhB +/- ES cells were injected into blastocyts that were then implanted in 
pseudopregnant females. Multiple chimeric offspring were obtained, four of which 
transmitted the mutant SdhB allele in their germ lines. These founders were mated with 
C57BL/6 strain females. A PCR screening procedure was developed (Fig. 4B) to allow 
genotyping of (129SV/E x C57BL/6)F1 offspring generated from SdhB +/+ x chimeric SdhB 
+/- matings. This approach proved successful for generating the desired SdhB +/- mouse 
strain used to develop a colony of 55 SdhB +/+ and 55 SdhB +/- mice. 
 




Fig. 3. SdhB knockout strategies. A. Targeted knockout approach. A targeting vector with 
homology regions encompassing intron two through part of exon three (shaded A) and 
encompassing part of intron four through intron seven (shaded B) flanking a neomycin 
cassette was used to target the WT SdhB locus and generate a disrupted SdhB locus. 
Numbers indicate position in SdhB locus from transcription start site. B. Gene trap vector 
approach. Gene trap vector contains a splice acceptor (SA) site upstream of the βGEO 
cassette (encodes β-galactosidase−neomycin phosphotransferase fusion protein) followed by 
a strong polyadenylation (pA) site inserted into intron one of SdhB. The SA site of the βGEO 
cassette will replace the SA site of exon two and will be spliced with the splice donor site of 
exon one.  
 
Fig. 4. SdhB genotyping PCR design. A. Schematic diagram showing the SdhB locus with or 
without a βGEO insertion in intron one. Primer set A/C amplifies the 912 bp WT locus and 
primer set A/B amplifies 439 bp from the disrupted locus. Numbers indicate position from 
the transcription start site in the wild type SdhB locus. B. PCR genotyping agarose gel 
showing SdhB +/+ vs. SdhB +/- amplification products from genomic DNA. 
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3.2 Characterization of SdhB +/- mice 
We determined the viability of SdhB -/- mice. We hypothesized that the SdhB -/- condition 
would not support mammalian development due to lack of TCA cycle function. To test this 
hypothesis we crossed SdhB +/- heterozygotes and examined the genotypes of progeny. In 
the absence of SdhB -/- offspring, the prediction from Mendelian genetics is tbat 1/3 of 
progeny will be SdhB +/+ WT and 2/3 will be SdhB +/- heterozygotes. Breeding to test this 
hypothesis was performed until 107 offspring were genotyped. These offspring included 35 
SdhB +/+ mice, 72 SdhB +/- mice with no SdhB(-/-) mice observed. This result implies that 
the SdhB -/- condition has an embryonic lethal phenotype. Indeed, it was previously 
reported that SdhD -/- mice die at 6.5 to 7.5 days post conception (Piruat et al., 2004). 
Evidence suggests that SdhB -/- mice also die around the time of organogenesis. 
SdhB +/- mouse tissues were then characterized in terms of SdhB gene expression and SDH 
enzyme activity (Fig. 5).  
 
 
Fig. 5. Characterization of SdhB +/+ and SdhB +/- mice. A. SdhB expression levels (n=5). B. 
SDH activity (n=5). C. TCA metabolite levels in urine (n=3). 1, succinate; 2, fumarate; 3, 
malate; 4, citrate; 5, aconitate. Error basis indicates SEM. D. Results of 24-h urine 
normetanephrine screening in WT and SdhB +/- mice.  
It was previously reported that SdhD +/- mice have a 50% decrease in SdhD expression and 
SDH activity (Piruat et al., 2004). We characterized SdhB expression and SDH activity in the 
liver and kidneys of SdhB +/- mice relative to SdhB +/+ mice. These organs have high 
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metabolic activity and are easily homogenized for assays. We found that SdhB gene 
expression was decreased by 50% (based on quantitative RT-PCR analysis; Fig. 5A). In 
contrast, no difference in SDH enzyme activity was detected in these tissues (Fig. 5B), 
suggesting translational compensation or other homeostatic mechanisms. Furthermore, TCA 
cycle metabolites (He et al., 2004) in tissue (Fig. 5C) and metanephrines in urine (Fig. 5D) 
were not different between mice with SdhB+/+ and SdhB+/- genotypes. 
 
 
Fig. 6. Weight analysis for SdhB +/+ and SdhB +/- mice, by gender: A. Females. B. Males. 
The box represents the middle 50% of the weights (25-75%) and the horizontal bar 
represents the median weight for each group. The dashed lines encompass the remainder of 
the data, excluding outliers represented by circles. 
Animals in the experimental colony were monitored by abdominal palpation and weight 
measurement. No abnormalities were detected in SdhB +/- animals. No significant 
differences were observed for weights of SdhB +/+ and SdhB +/- mice (Fig. 6). After one 
year, six SdhB +/+ and six SdhB +/- mice were euthanized and reviewed for gross and 
microscopic pathology of adrenal glands, heart, liver, lung, and kidneys. A detailed 
pathological analysis of carotid bodies investigated the possibility of neuroendocrine cell 
hypertrophy as has been suggested for SdhD +/- heterozygotes (Piruat et al., 2004). The 
results are shown in Fig. 7. Although there was a trend towards smaller carotid body size in 
SdhB +/- heterozygotes (Fig. 7A), the trend was not statistically significant (p values > 0.05 
by t-test). This trend came mainly from male mice. Neuroendocrine cells of the carotid 
 
Pheochromocytoma – A New View of the Old Problem 
 
34
3.2 Characterization of SdhB +/- mice 
We determined the viability of SdhB -/- mice. We hypothesized that the SdhB -/- condition 
would not support mammalian development due to lack of TCA cycle function. To test this 
hypothesis we crossed SdhB +/- heterozygotes and examined the genotypes of progeny. In 
the absence of SdhB -/- offspring, the prediction from Mendelian genetics is tbat 1/3 of 
progeny will be SdhB +/+ WT and 2/3 will be SdhB +/- heterozygotes. Breeding to test this 
hypothesis was performed until 107 offspring were genotyped. These offspring included 35 
SdhB +/+ mice, 72 SdhB +/- mice with no SdhB(-/-) mice observed. This result implies that 
the SdhB -/- condition has an embryonic lethal phenotype. Indeed, it was previously 
reported that SdhD -/- mice die at 6.5 to 7.5 days post conception (Piruat et al., 2004). 
Evidence suggests that SdhB -/- mice also die around the time of organogenesis. 
SdhB +/- mouse tissues were then characterized in terms of SdhB gene expression and SDH 
enzyme activity (Fig. 5).  
 
 
Fig. 5. Characterization of SdhB +/+ and SdhB +/- mice. A. SdhB expression levels (n=5). B. 
SDH activity (n=5). C. TCA metabolite levels in urine (n=3). 1, succinate; 2, fumarate; 3, 
malate; 4, citrate; 5, aconitate. Error basis indicates SEM. D. Results of 24-h urine 
normetanephrine screening in WT and SdhB +/- mice.  
It was previously reported that SdhD +/- mice have a 50% decrease in SdhD expression and 
SDH activity (Piruat et al., 2004). We characterized SdhB expression and SDH activity in the 
liver and kidneys of SdhB +/- mice relative to SdhB +/+ mice. These organs have high 
 
Mouse Models of Human Familial Paraganglioma 
 
35 
metabolic activity and are easily homogenized for assays. We found that SdhB gene 
expression was decreased by 50% (based on quantitative RT-PCR analysis; Fig. 5A). In 
contrast, no difference in SDH enzyme activity was detected in these tissues (Fig. 5B), 
suggesting translational compensation or other homeostatic mechanisms. Furthermore, TCA 
cycle metabolites (He et al., 2004) in tissue (Fig. 5C) and metanephrines in urine (Fig. 5D) 
were not different between mice with SdhB+/+ and SdhB+/- genotypes. 
 
 
Fig. 6. Weight analysis for SdhB +/+ and SdhB +/- mice, by gender: A. Females. B. Males. 
The box represents the middle 50% of the weights (25-75%) and the horizontal bar 
represents the median weight for each group. The dashed lines encompass the remainder of 
the data, excluding outliers represented by circles. 
Animals in the experimental colony were monitored by abdominal palpation and weight 
measurement. No abnormalities were detected in SdhB +/- animals. No significant 
differences were observed for weights of SdhB +/+ and SdhB +/- mice (Fig. 6). After one 
year, six SdhB +/+ and six SdhB +/- mice were euthanized and reviewed for gross and 
microscopic pathology of adrenal glands, heart, liver, lung, and kidneys. A detailed 
pathological analysis of carotid bodies investigated the possibility of neuroendocrine cell 
hypertrophy as has been suggested for SdhD +/- heterozygotes (Piruat et al., 2004). The 
results are shown in Fig. 7. Although there was a trend towards smaller carotid body size in 
SdhB +/- heterozygotes (Fig. 7A), the trend was not statistically significant (p values > 0.05 
by t-test). This trend came mainly from male mice. Neuroendocrine cells of the carotid 
 
Pheochromocytoma – A New View of the Old Problem 
 
36
bodies of males were detected by tyrosine hydroxylase (TH) staining. Again, a trend toward 
a reduced number of type I (TH+) cells was observed in the SdhB +/- carotid bodies (Fig. 
7B). Again, this difference was not statistically significant. There was no carotid body 
hypertrophy or any sign of hyperproliferation (Fig. 7C). No PGL or PHEO tumors were 
observed in any mice, even in compound SdhB +/- SdhD +/- heterozygotes. 
 
 
Fig. 7. Mouse carotid body pathology. A. Observed trend toward smaller carotid body size 
in SdhB +/- mice, not reaching statistic significance by t-test. The contribution to this trend 
comes mainly from males. B. Analysis of tyrosine hydroxylase positive (TH+) cells in carotid 
bodies from males. The trend toward a reduced number of TH+ cells in SdhB +/- male mice 
does not reach statistical significance. C. Examples of carotid body pathology. There is no 
evidence of carorid body hypertrophy or hyperproliferation in SdhB +/- mice. 
3.3 Generation of SdhB +/- Bub1 H/- mice 
We hypothesized that the absence of PGL in SdhB +/- mice was due to the low rate of SdhB 
LOH. We therefore sought genetic methods to enhance this rate. Aneuploidy (abnormal 
chromosome content) is a hallmark of most solid tumors and cancer cell lines (Heim & 
Mitelman, 1995; Lengauer et al., 1997; Lengauer et al., 1997). Over 100 years ago Theodor 
Boveri postulated that chromosome instability (CIN) drives tumorigenesis. CIN is believed 
to be frequently responsible for TSG LOH (Bignold et al., 2006; Kops et al., 2005). More than 
100 CIN genes have been identified in yeast (Kolodner et al., 2002; Nasmyth, 2002; Shonn et 
al., 2000). A novel mammalian gene of this type is Bub1 (mouse chromosome 2), which plays 
a key role in the mitotic checkpoint.  
Mitotic checkpoint proteins survey proper kinetichore attachment during mitosis. When the 
mitotic spindle is correctly attached to all kinetochores, Cdc20 activates the anaphase 
promoting complex (APC) to degrade securin, allowing release of separase to “unbind” 
sister chromatids and promote the transition from metaphase to anaphase (Kops et al., 
2005). Mitotic checkpoint proteins produce a “stop anaphase” signal when kinetochores are 
not properly attached to the mitotic spindle during prometaphase. An APC inhibitory 
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complex is involved (Kops et al., 2005; Shah & Cleveland, 2000; Wang et al., 2001). The BUB1 
protein has three putative molecular functions in this mitotic checkpoint (Acampora et al., 
1999) as illustrated in Fig. 8. 
 
 
Fig. 8. Putative functions of Bub1 in mitosis. 1. Bub1 mediates Mad1/Mad2 binding to 
kinetochores, which allows for efficient formation of APC inhibitory complexes consisting of 
Mad2, BubR1, and Bub3. The APC inhibitory complex functions by sequestration of Cdc20. 
2. Bub1 phosphorylates Cdc20, thereby preventing APC activation. 3. Bub1 is required for 
stability and centromeric localization of centromeric cohesin. 
Loss of Bub1 expression was predicted to result in aneuploidy and increased tumorigenesis. 
In support of this hypothesis, Bub1 mutations were detected in 2/19 colorectal cancer cell 
lines with CIN (Cahill et al., 1998) and epigenetic silencing of Bub1 is a frequent event in 
human colorectal carcinomas, with 30% exhibiting at least two-fold reduction in Bub1 
expression (Shichiri et al., 2002). In addition, Bub1 mutations have been correlated with lung, 
pancreatic and rectal cancers (Gemma et al., 2000; Hempen et al., 2003; Imai et al., 1999).  
The van Deursen laboratory has developed a series of mouse strains in which expression of 
Bub1 protein is reduced in a graded fashion by different combinations of wild type, 
knockout, and hypomorphic alleles (Jeganathan et al., 2007). The Bub1 hypomorphic allele 
[Bub1(H)] results from intron 9 insertion of the hygromycin B phosphotransferase gene 
(Hyg), resulting in a high level of premature transcription termination (van Deursen et al., 
1994). Standard procedures and breeding yielded Bub1 +/H, Bub1 H/H, and Bub1 H/- 
viable offspring. Western blotting showed graded reduction of Bub1 levels across these 
strains in mouse embryonic fibroblasts.  
Of the mice in the Bub1 genotype series, the Bub1 H/- strain shows the most dramatic 
phenotype. Bub1 H/- mice display increased aneuploidy and tumorigenesis relative to the 
other Bub1 genotypes. Analysis of 150 mitotic figures from Bub1 H/- splenocytes showed 
39% aneuploidy, compared to only 1% aneuploidy in Bub1 +/+ animals (Jeganathan et al., 
2007). Bub1 H/- animals also suffer more tumors (52% tumor incidence in 530 days) than 
Bub1 +/+ animals (33% tumor incidence in 772 days). Lymphoma and sarcoma incidence 
was higher and hepatocellular carcinoma incidence lower for Bub1 H/- animals than for 
wild type animals. 
Mutations in CIN genes can increase the rate of loss of entire chromosomes or chromosome 
segments during cell division, thereby accelerating LOH of tumor suppressor genes (Cahill 
et al., 1999; Cahill et al., 1998; Jallepalli & Lengauer, 2001). Indeed, it was shown in a cohort 
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of 30 Bub1 H/- p53 +/- animals monitored for 100 days that 5 mice developed tumors. In 
contrast, 0/30 age-matched p53 +/- mice developed tumors during the same time period 
(Jeganathan et al., 2007). All tumors in Bub1 H/- p53 +/- mice were thymic lymphomas, the 
most common tumor form in p53(-/-) mice (Donehower et al., 1992; Donehower et al., 1995; 
Jacks et al., 1994). Accelerated tumorigenesis resulted from p53 LOH as shown by PCR 
analysis of DNA from Bub1 H/- p53 +/- lymphomas (Jeganathan et al., 2007; Jacks et al., 
1994). 
A two-part breeding program created a colony of 55 SdhB +/- Bub1 H/- compound 
heterozygote mice (Fig. 9). In part 1, SdhB +/– females were crossed with Bub1 H/- males to 
generate offspring of four genotypes (Fig. 9A). In part 2, offspring of these matings were 
crossed to generate the desired SdhB +/-Bub1 H/- animals at the indicated expected 
frequencies (Fig. 9B). Multiplex PCR genotyping was developed to distinguish Bub1 +, H 
and – alleles (Fig. 9C). The colony of SdhB +/- Bub1 H/- compound heterozygote mice was 
monitored for PGL tumorigenesis. Age-dependent survival of this and related strains is 
shown in Fig. 10. As had been observed for SdhB +/- mice, no PGL tumors were observed in 
SdhB +/- Bub1 H/- animals. 
 
 
Fig. 9. SdhB +/- Bub1 H/- breeding scheme. A. Initial cross providing offspring for brother-
sister matings. B. Brother-sister mating scheme from (A), indicating expected frequencies of 
the desired SdhB +/- Bub1 H/- genotype among offspring. Allele abbreviations: SdhB WT: 
D; SdhB gene trap disruption: d; Bub1 WT: B; Bub1 hypomorph, H; Bub1 disruption: (-). C. 
Bub1 Genotyping PCR design. Schematic diagram showing the Bub1 locus with or without a 
hygromycin (hypomorphic allele) or neomycin (knockout allele) insertion. Primers used to 
amplify the alleles are designated by arrowheads. 
 




Fig. 10. Kaplan-Meier plot of mouse survival data. 
4. Discussion  
Spontaneous PGL is rare in mice (Jacks et al., 1994; Jacks et al., 1994). In a mouse model of 
human neurofibromatosis type 1, a dominant disease caused by inheritance of a mutant 
allele of NF1, a modest incidence of PHEO was observed (Jacks et al., 1994), but this genetic 
pathway to PGL appears unrelated to tumor suppression by Sdh genes. 
We hypothesized that SdhB +/- mice would be predisposed to familial PGL. This hypothesis 
was based on the prevailing evidence that the SdhB +/- genotype predisposes humans to 
PGL, with high penetrance. We therefore developed a strain of SdhB +/- mice using mouse 
stem cells carrying a gene trap insertion in intron 1 of SdhB. Using these animals we showed 
that, as anticipated, the SdhB -/- genotype is not viable. Although we found that there is a 
significant reduction of SdhB expression in tissues of SdhB +/- mice relative to SdhB +/+ 
mice, there was no difference in SDH activity between the two groups in either liver or 
kidney. These results suggest that there is no phenotypic difference between SdhB +/- and 
SdhB +/+ mice, consistent with the absence of phenotype for humans heterozygous for Sdh 
germline mutations. However, unlike humans where there is high penetrance of PGL in 
SdhB +/- individuals, no PGL tumors were detected in SdhB +/- mice. 
LOH of a TSG can be the rate-limiting step in tumor development (Lasko et al., 1991; Luo et 
al., 2000). The mechanism for LOH is not completely understood but involves chromosome 
loss, deletion and/or homologous interchromosomal mitotic recombination events (Henson 
et al., 1991; Shao et al., 2000; Stark & Jasin, 2003). Mitotic recombination refers to the 
reciprocal exchange of genetic material between nonsister chromatids in mitotic cells. 
Mitotic recombination occurs at a high frequency in humans and mice (Gupta et al., 1997; 
Holt et al., 1999; Shao et al., 1999). It has been suggested that mitotic recombination is the 
predominant pathway to LOH (Gupta et al., 1997; Luo et al., 2000; Shao et al., 1999; Shao et 
al., 2000).  
Because mitotic recombination requires high nucleotide sequence homology, chromosomal 
divergence suppresses mitotic recombination and may modify cancer development by 
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lowering the rate of LOH (Shao et al., 2001). The use of inbred strains in this study (C57BL/6 
x 129SVE)F1 should promote mitotic recombination. It has also been found that the 
spontaneous frequency of mitotic recombination increases with age (Grist et al., 1992). The 
penetrance of SdhB mutations in familial PGL is estimated to be 50% at age 30 and 
approaches 100% after 60 years of age (Neumann et al., 2004).  
To address the possible limitation of LOH in converting somatic neuroendocrine cells from 
SdhB +/- to SdhB -/-, we developed a mouse colony of SdhB +/- mice bred onto the Bub1 
H/- genetic background previously shown to enhance aneuploidy. PGL tumorigenesis was 
not observed in this strain. 
There are at least three possible explanations for these results. First, it is possible that the 
rate of somatic LOH at SdhB in neuroendocrine cells remains insufficient to drive PGL 
tumorigenesis within the lifespan of mice. Second, it is possible that PGL tumorigenesis 
takes place in SdhB +/- mice, but the subsequent rate of tumor growth is too slow to permit 
tumor detection within the mouse lifespan. Finally, it is possible that SdhB is not a tumor 
suppressor in murine PGL. 
If either of the first two explanations are correct, it might be possible to enhance the rate of 
PGL tumorigenesis by developing a conditional knockout mouse strain where both copies of 
the Sdh gene for one SDH subunit are replaced by a knock-in construct that can be 
recombinationally inactived upon expression of a recombinase. Unlike standard conditional 
knock-out designs, it would be important to delete the Sdh subunit gene only at very low 
frequency, since most affected tissues would presumably be damaged by loss of the TCA 
cycle. Rather, an inefficient recombination that eliminated SDH in perhaps 1% of cells might 
be appropriate. This might be achieved either by low levels of neuroendocrine-specific 
expression of recombinase (e.g. from the tyrosine hydroxylase promoter), or by low levels of 
global recombinase expression. Unfortunately, mouse strains are not yet available for tissue-
specific CRE expression in neuroendocrine cells.  
Either low-efficiency conditional knockout strategy offers the prospect of dramatically 
increasing the early generation of neuroendocrine cells lacking SDH activity. Such a model 
would be hypothesized to increase the frequency of tumorigenesis, and allow a longer 
period for tumor growth. 
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lowering the rate of LOH (Shao et al., 2001). The use of inbred strains in this study (C57BL/6 
x 129SVE)F1 should promote mitotic recombination. It has also been found that the 
spontaneous frequency of mitotic recombination increases with age (Grist et al., 1992). The 
penetrance of SdhB mutations in familial PGL is estimated to be 50% at age 30 and 
approaches 100% after 60 years of age (Neumann et al., 2004).  
To address the possible limitation of LOH in converting somatic neuroendocrine cells from 
SdhB +/- to SdhB -/-, we developed a mouse colony of SdhB +/- mice bred onto the Bub1 
H/- genetic background previously shown to enhance aneuploidy. PGL tumorigenesis was 
not observed in this strain. 
There are at least three possible explanations for these results. First, it is possible that the 
rate of somatic LOH at SdhB in neuroendocrine cells remains insufficient to drive PGL 
tumorigenesis within the lifespan of mice. Second, it is possible that PGL tumorigenesis 
takes place in SdhB +/- mice, but the subsequent rate of tumor growth is too slow to permit 
tumor detection within the mouse lifespan. Finally, it is possible that SdhB is not a tumor 
suppressor in murine PGL. 
If either of the first two explanations are correct, it might be possible to enhance the rate of 
PGL tumorigenesis by developing a conditional knockout mouse strain where both copies of 
the Sdh gene for one SDH subunit are replaced by a knock-in construct that can be 
recombinationally inactived upon expression of a recombinase. Unlike standard conditional 
knock-out designs, it would be important to delete the Sdh subunit gene only at very low 
frequency, since most affected tissues would presumably be damaged by loss of the TCA 
cycle. Rather, an inefficient recombination that eliminated SDH in perhaps 1% of cells might 
be appropriate. This might be achieved either by low levels of neuroendocrine-specific 
expression of recombinase (e.g. from the tyrosine hydroxylase promoter), or by low levels of 
global recombinase expression. Unfortunately, mouse strains are not yet available for tissue-
specific CRE expression in neuroendocrine cells.  
Either low-efficiency conditional knockout strategy offers the prospect of dramatically 
increasing the early generation of neuroendocrine cells lacking SDH activity. Such a model 
would be hypothesized to increase the frequency of tumorigenesis, and allow a longer 
period for tumor growth. 
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1. Introduction  
The stem cell differentiation is greatly dependent on the living environment i.e., the cell 
differentiation determined by timing, amplitude, amount and etc. of stimulation from 
outside of cells (Lanza & Rosenthal, 2004). If living environment of cell can be controlled 
artificially by using micro device, we will be able to guide the cell having specific function 
from stem cells. The micromachining technology allows integration of various mechanical, 
electrical, and chemical elements, and has produced micro devices that can manipulate 
chemical solution, small mechanical parts, cells and etc. (Meyer et al., 2000; Takeuchi & 
Shimoyama, 1999; Nakashima et al., 2010; Nakashima & Yasuda, 2009; Chen et al., 2007; Taff 
& Voldman, 2005; Choi & Park, 2005; Doh & Cho, 2005). Our purpose is to fabricate micro 
devices which can control cell differentiation and axon elongation by extracellular 
stimulation. The cell differentiation induction on the micro devices will be applied to a 
technique for restoring impaired or lost biological function and controlling differentiation of 
a stem cell to a specific cell. This paper presents two micro devices intended to control the 
induction of cell differentiation dynamically by chemical stimulation and mechanical 
stimulation. First, we present a chemical stimulation device consisting of a microvalve, a 
nano-holes array, and a chamber, which are placed very close to one another. The amount of 
chemical solution released from the nano-hole array can be controlled very precisely by 
opening and closing the microvalve. Also, we show the behavior of cells stimulated using 
the fabricated chemical stimulation device, i.e., differentiation guidance of cells using release 
control of nerve growth factor (NGF) which is a protein that enhances axonal outgrowth 
from a cell body. Next, we present a mechanical stimulation device consisting of a chamber 
for cell culture and a microlinkage mechanism for applying uniaxial stretching to the 
microchamber. Then we show the fluorescence observation of behavior of a cell that receives 
stimulation by fabricated mechanical stimulation device.  
2. Chemical stimulation device 
2.1 Design of the chemical stimulation device 
The microdevice we designed for chemical stimulation consists of a nano-hole array for 
NGF release, a hydrophobic passive microvalve for controlling NGF release, a microchannel 
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stimulation by fabricated mechanical stimulation device.  
2. Chemical stimulation device 
2.1 Design of the chemical stimulation device 
The microdevice we designed for chemical stimulation consists of a nano-hole array for 
NGF release, a hydrophobic passive microvalve for controlling NGF release, a microchannel 
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for carrying NGF and a chamber for cell culture as shown in Fig. 1(a, b) (Nakashima & 
Yasuda, 2005; Nakashima & Yasuda, 2009). The device is microfabricated from a SOI (Silicon 
on Insulator) wafer as detailed below. A chamber for cultivating a cell was fabricated on one 
side of the wafer, and a microchannel was fabricated on the other side. The nano-hole array 
was fabricated in a SiO2 membrane of 0.5 m in thickness. The inside diameter of the nano-
holes must be less than 0.5 m because the typical diameter of an axon terminal is 0.5 – 4 
m. The etching technique using FIB (Focused Ion Beam, Seiko Instruments Inc., JFIB-2300) 
satisfies the need for the fabrication of such small holes. Nerve cells are cultured on a SiO2 
diaphragm including the nano-hole array. 
 
 
Fig. 1. Schematic of a fabricated chemical stimulation micro device. 
Figure 1(c) shows the schematic of liquid switching principle of a microvalve using different 
liquid surface tensions on hydrophilic and hydrophobic channels. Liquids injected into the 
hydrophilic channels stop at the boundary between the hydrophilic and hydrophobic 
channels. The air that was initially in the hydrophobic channel separates the two liquids. 
When pressure is applied from the inlet, the inlet liquid will break into the hydrophobic 
channel and merge with the outlet liquid. If the inlet liquid includes NGF, it will diffuse into 
the outlet liquid. This is a hydrophobic passive microvalve which has very simple structure 
without any mechanically movable parts and which can be driven by low pressure (Yun et 
al, 2002; Lee et al, 2002). 
Figure 2 shows the SEM photograph which was taken from the channel side of the 
device. The microchannel measures 60 m in width and 8 m in depth. 100 nano-holes 
with a square side of about 500 nm in length were opened in the SiO2 membrane inside 
the channel. The microvalve was constructed at the T-shaped crossing of the 
microchannel. 
 




Fig. 2. SEM photographs of the fabricated device. The microchannels including a 
hydrophobic passive microvalve and nano-hole array. 
2.2 Device fabrication 
Figure 3 shows the fabrication process of the chemical stimulation device. SiO2 films were 
created by thermal oxidation on both sides of a SOI wafer that consists of 350 m thick 
handle Si layer, 500 nm thick SiO2 layer, and 8 m thick Si layer (Fig. 3(a)). The SOI wafer 
was spin-coated with photoresist ZPN-1150 (ZEON Corp.) on the front side, and the SiO2 
film was patterned by photolithography and wet etching. In order to fabricate the culture 
chamber, the thick Si layer was etched anisotropically (Fig. 3(b)). Next, the microchannel 
was fabricated by anisotropically etching the backside of Si layer (Fig. 3(c)). Then, the 
microvalve was fabricated by lift-off method of Au deposition and by creating hydrophobic 
SAM (self assembled monolayer), 1-octadecanethiol on the Au surface (Fig. 3(d)). The nano-
holes were fabricated in a SiO2 membrane by FIB (Fig. 3(e)). Finally, the culture chamber 
was coated by collagen, and the microchannels were covered with the PDMS sheet. 
 
 
Fig. 3. Fabrication process of the chemical stimulation device. 
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Fig. 4. Photograph of liquid switching test using the fabricated microvalve. (a) The initial 
state. (b) Inlet pressure was applied. (c) The valve opened. (d) The valve closed after 
eliminating inlet pressure. 
2.3 Switching test of the microvalve and chemical release tests 
Figure 4 shows the photograph of the test result using deionized water as the test liquid. 
When water was injected into the channel, it was infiltrated into the hydrophilic channel by 
the capillary force and stopped at the edge of the hydrophobic channel. Inlet water was 
initially separated from outlet water (Fig. 4(a)). When inlet pressure was applied, inlet water 
began to flow through the hydrophobic channel (Fig. 4(b)) and eventually merged with 
outlet water (Fig. 4(c)). When inlet pressure was eliminated, water stopped flowing and 
separated into two fluids. At the inlet, water flowed backwards (Fig. 4(d)) and returned to 
the original state (Fig. 4(a)). This enabled us to open and close the microvalve with inlet 
pressure. Also, we confirmed that when culture medium is used as a working fluid having 
higher viscosity than water, the fabricated microvalve could open and close. 
2.4 Chemical release tests 
Chemical release tests were conducted using the fabricated microfluidic device. We 
observed diffusion of the fluorescent dye (Rhodamine B, Molecular Probes, Inc., R-648) 
released through the nano-hole array under the inverted microscope (Nikon Co., TE2000). 
Figure 5 shows experimental setup for chemical release testing. When pressure was applied 
from the liquid inlet, a hydrophobic microvalve will open and the fluorescent dye oozed 
from the nano-hole array and spread out into the deionized water that filled the chamber of 
the device. 
Figure 6 shows that the fluorescent dye was oozing from the nano-hole array and spreading 
out into the deionized water by diffusion. The fluorescence intensity was measured at 
several positions (see Figure 6(b)) at 60 sec after the diffusion began. The dye concentration 
decreased by 56 % at the position of 50 m away from the nano-hole array as shown in 
Figure 7.  
 




Fig. 5. Experimental setup. The fabricated microfluidic device was covered with PDMS film. 
Diffusion of the fluorescent dye through the nano-hole array was observed under the 
inverted microscope. 
The variation in the fluorescence intensity synchronized with opening and closing of the 
microvalve as shown in Fig.8. The fluorescence intensity rose immediately after the valve 
opened, and decreased immediately when the valve was closed. Additionally, the 
fluorescence intensity changed according to the switching interval, the smaller the 
fluorescence intensity change. This result means that the fabricated device can control 
release of chemical solution by opening and closing of the valve. 
 
 
Fig. 6. Diffusion of fluorescent dye through a nano-hole array. Light gray indicates high 
concentration of fluorescent dye. 
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Fig. 7. Relationship between the fluorescence intensity and distance from the nano-hole at 60 
sec after the diffusion began. 
 
 
Fig. 8. Variation in the fluorescence intensity after the microvalve is opened and closed 
repeatedly. 
2.5 Cell differentiation induction test by chemical stimulation 
PC 12 (adrenal pheochromocytoma) cells were used in the experiments and prepared as 
follows. The cells were maintained in culture medium (RPMI1640, SIGMA-ALDRICH 
Corp.) supplemented with 10 % fetal bovine serum and 100 ng/ml nerve growth factor 
(NGF). The cells were cultured in 5 % CO2 at 37 °C for 3 days to start their differentiation 
and make them sensitive to NGF stimulation. Then, these cells were collected by pipetting, 
and cultivated without NGF on the cell culture chamber of the fabricated device in 5 % CO2 
at 37 °C for 30 min. Finally, the cells were stimulated chemically by releasing NGF through 
the nano-hole array on the device. 
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We confirmed whether cell differentiation can be controlled on the device or not. Figure 9 
shows experimental procedure for cell differentiation induction. Growth of cells stimulated 
by NGF is observed under a microscope from the chamber side. The inlet culture medium 
containing NGF and the culture medium in the cell culture chamber are initially separated 
by a closed hydrophobic microvalve. When pressure is applied from the inlet, the inlet 
liquid and the chamber liquid are connected by opening the microvalve. After that, NGF 
diffused into the chamber liquid and is released into the chamber through the nano-hole 
array. Thus, the cells in the chamber are stimulated by NGF. 
We conducted the experiment that was NGF stimulation controlled by periodic switching of 
the microvalve using the fabricated microdevice. We observed the growth of cultured cells 
while the microvalve was switched at 1Hz under the inverted microscope. As shown in 
Fig.10, the lower left cell that adhered to the device surface elongated the axon toward nano-
holes as time passed. On the other hand, because the right side cell did not adhere to the 
device surface at first, it could not begin to differentiate. However, after it succeeded in 
adhering to the device surface 2 hours after the original stimulus was applied, the right side 
cell also demonstrated our intended movement manner, i.e. it elongated the axon toward the 
nano-holes as time passed. From this result, we conclude that we can guide the cell 







Fig. 9. Experimental procedure for cell differentiation induction using fabricated 
microdevice. 
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Fig. 10. Cell differentiation guidance on the fabricated microfluidic device. The axons 
elongated toward the nano-holes according to NGF stimulation from the nano-holes. 
3. Mechanical stimulation device 
3.1 Design of the mechanical stimulation device 
The mechanical stimulation device developed in the present study is fabricated on a glass 
coverslip and 6 devices are fabricated on one coverslip. This coverslip with the microdevice 
is bonded to the bottom of a = 35 mm culture dish with a 14 mm hole and used in the 
experiment. With this device, an inverted microscope and an oil-immersion objective lens 
can be used for the observation. The schematic of a mechanical stimulation device is shown 
in Fig. 11. The size of each device is 2 mm square. This device consists of one microchamber 
made of PDMS, one pair of stretching arms by which the microchamber is uniaxially 
stretched, the journal bearings that support the stretching arms, and the slider that drives 
the stretching arms (Sato et al., 2010). The slider is pushed by a microneedle connected to the 
micromanipulator that drives the pair of stretching arms. Finally, sliding movement is 
converted into rotation movement via the journal bearing, and the microchamber is 
stretched from each side. 
Figure 12 shows the SEM photograph of the fabricated device. A micro three-dimensional 
structure was fabricated by multiple exposures to SU-8. The dimension error in the link 
mechanism was measured as approximately 5 m. The clearance in the journal bearing and 
slider was designed to be 10 m to allow the dimension error arise in the fabrication process, 
therefore, the journal bearing, the most important element in the link mechanism, was 
successfully fabricated. It was also confirmed that the slider was successfully fabricated and 
that all of the link mechanisms were movable structures. The chamber has a thin film 
stretching part (stretching substrate) in the center of the chamber. The size of the stretching 
substrate is 400 x 100 m and the thickness is 10 m. The stretching substrate is supported 
by the surrounding support frame with the size of 50 m width and 50 m thickness. The 
microchamber also has a binding part with stretching arms at both the ends of the support 
frame. In the fabrication process, six microchambers are molded on one glass coverslip at 
once. The excess part is cut and removed to obtain the chamber shape. 
 




Fig. 11. Schematic of a fabricated mechanical stimulation micro device. 
 
 
Fig. 12. SEM photograph of the fabricated mechanical stimulation micro device. 
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3.2 Device fabrication 
The fabrication process of the device consists of two processes. One is the micromolding of 
silicone elastomer (PDMS) to fabricate the microchamber. The other is the patterning of 
thick photoresist to fabricate the link mechanism. The microchamber is made of transparent 
PDMS enable the observation using the inverted microscope. Although PDMS is generally 
used in the experiment of applying stretching deformation as a mechanical stimulus to cells 
(Costa et al., 2002), its chemical stability makes it difficult to shape by a microfabrication 
technique such as etching. Therefore, we adopted micromolding to fabricate the 
microchamber.  
The fabrication process is shown in Fig. 13, and an outline of the process is described below. 
In the first step of the fabrication process of the microchamber, an original model of the 
microchamber for molding is prepared. The photoresist (SU-8, Kayaku MicroChem Co., Ltd) 
is spin-coated to 10 m thickness (Fig. 13(a, b)), exposed and developed to pattern the 
stretching substrate (Fig. 13(c)). A second layer of SU-8 with 50 m thickness is spin-coated 
onto the first layer (Fig. 13(d)), exposed and developed to pattern the support frame (Fig. 
13(e)). By these two steps, an original model of the microchamber is obtained. In the next 
step, following the fabrication of the original model, the fluorine polymer is sprayed onto 
the original model to form very thin layer as mold-releasing agents (Fig. 13(f)). PDMS (KE-
106, Shin-etsu Silicone) is casted on the original model to obtain a mold transcribed with the 
shape of the original model (Fig. 13(g)). The obtained mold is again sprayed with fluorine 
polymer, and punched to form the gate for molding (Fig. 13(h, i)). Finally, the microchamber 
made of PDMS is molded by using the obtained mold. The link mechanism is fabricated by 
the multilayer SU-8-based MEMS process (Foulds, I.G. & Parameswaran, M, 2006). This 






Fig. 13. Fabrication process of the original model and the micromold for the fabricated 
microchamber. 
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The fabrication process chart is shown in Fig. 14, and an outline of the process is described 
below. First, Ge is sputtered onto the glass coverslip and patterned as the sacrificial layer by 
which the microchamber (Fig. 14(j)), stretching arms and slider part are rendered movable. 
The PDMS microchamber is molded on the Ge-patterned coverslip (Fig. 14(l-n)). The first 
layer of SU-8 is spin-coated to 100 m thickness (Fig. 14(o)), and exposed using the 
photomask of the link mechanism pattern (Fig. 14(p). In addition, without development, the 
second layer of SU-8 is spin-coated to 50 m thickness on the first layer (Fig. 14(q)). The 
second exposure is applied to pattern the axis of the journal bearing (Fig. 14(r)). Finally, the 
surface exposure technique is applied to fabricate the stopper of the journal bearing (Fig. 
14(s)). After the curing and the development of the entire device structure (Fig. 14(t)), the Ge 
sacrificial layer is removed and the link mechanism is completed (Fig. 14(u)). 
 
 
Fig. 14. Fabrication process of the microlink mechanism for mechanical stimulation device. 
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3.3 Operation test of mechanical stimulation device 
The fabricated device on the glass coverslip was immersed in DI (deionized) water and 
tested. Figure 15 shows the image during the operation test using an inverted phase-contrast 
microscope (Olympus Co., CKX-41). Figure 15(a) shows the initial state of the device. Figure 
15(b) shows the state after the slider was pushed by tweezers and the microchamber was 
stretched from both ends in the directions to the right and lift in the figure. It was shown 




Fig. 15. Operating image of mechanical stimulation device. (a) The initial state. (b) The 
stretched state. 
3.4 Cell stretching test by the mechanical stimulation device 
We carried out the biocompatibility test by cell culture on the fabricated mechanical 
stimulation device. The cells were incubated using D-MEM with 10 % FBS (Fetal Bovine 
Serum), and in 37 °C, humidified 95 % air-5 % CO2 atmosphere. In the preparation for the 
test, cultured cells were seeded into the dish with the built-in cell-stretching microdevices, 
and incubated for 8h. After the preincubation, fluorescent indictor dye Fluo 3 was loaded to 
the cell as the observation marker by incubating the cell in the opti-MEM containing 12 M 
Fluo 3-AM (Dojindo) for 30 min. After loading the indicator dye, the cells were rinsed twice 
with PBS (phosphate buffered saline), and used for the test in normal culture medium. The 
epifluorescent inverted microscope was used for observation with a x 60 oil immersion 
objective lens. 
Figure 16 shows the time lapse image of the stimulated single cell cultured on the chamber. 
For the sequential stretching operation, Fig. 16(b) shows an image immediately before the 
operation where we define t = 0.0 s. Cells are located slightly above the center in the figure. 
Two particles slightly below the center are dust particles of fluorescence dye. Figure 16(c) 
shows an image immediately after the stretching operation, t = 0.1 s. Stretching operation 
was continued to t = 0.7 s (Fig. 16(f)) and the amount of maximum nominal tensile strain in 
stretching axis was roughly estimated as 13 % by measuring the displacement of dust 
 
 













Fig. 16. Sequential time lapse images of a single cell uniaxially stretched using mechanical 
stimulation micro device. Dark gray indicates higher fluorescent intensity. 
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stretched from both ends in the directions to the right and lift in the figure. It was shown 




Fig. 15. Operating image of mechanical stimulation device. (a) The initial state. (b) The 
stretched state. 
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and incubated for 8h. After the preincubation, fluorescent indictor dye Fluo 3 was loaded to 
the cell as the observation marker by incubating the cell in the opti-MEM containing 12 M 
Fluo 3-AM (Dojindo) for 30 min. After loading the indicator dye, the cells were rinsed twice 
with PBS (phosphate buffered saline), and used for the test in normal culture medium. The 
epifluorescent inverted microscope was used for observation with a x 60 oil immersion 
objective lens. 
Figure 16 shows the time lapse image of the stimulated single cell cultured on the chamber. 
For the sequential stretching operation, Fig. 16(b) shows an image immediately before the 
operation where we define t = 0.0 s. Cells are located slightly above the center in the figure. 
Two particles slightly below the center are dust particles of fluorescence dye. Figure 16(c) 
shows an image immediately after the stretching operation, t = 0.1 s. Stretching operation 
was continued to t = 0.7 s (Fig. 16(f)) and the amount of maximum nominal tensile strain in 
stretching axis was roughly estimated as 13 % by measuring the displacement of dust 
 
 













Fig. 16. Sequential time lapse images of a single cell uniaxially stretched using mechanical 
stimulation micro device. Dark gray indicates higher fluorescent intensity. 
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particles. Immediately after the maximum stretching, the stretching operation was stopped, 
and the microchamber returned to the initial state at t = 1.7 s (Fig. 16(h)). As a result, the cell 
successfully adhered to the stretched substrate and received the stretching stimulation in the 
microchamber. This result indicates that the fabricated mechanical stimulation device is 
biocompatible and able to apply dynamic mechanical stimulus to a cell. Also, the observed 
cell stayed in the field of view, indicating that this device can reduce the rigid displacement 
of the cell during the stretching operation. Therefore, this device can be used in the 
observation experiments of reaction to a mechanical stimulus of a cell such as the alteration 
of cellular morphology and cell differentiation induction. 
4. Conclusions 
This paper demonstrated that two micro devices for dynamic cell differentiation induction. 
First, we demonstrated that a chemical stimulation micro device consisting of nano-hole 
array for chemical release and a hydrophobic passive microvalve for its release control is 
effective in controlling NGF concentration that is required to control stimulation to a cell. 
Release of chemical solution such as culture medium could be controlled precisely by 
opening and closing the microvalve because the microvalve was placed very close to the 
nano-hole array. Furthermore, we succeeded in cell differentiation guidance by controlling 
NGF release from nano-hole array. 
On the other hand, we evaluated the performance of the mechanical stimulation micro 
device consisting of the culture chamber, the stretching arms, the journal bearings and the 
slider. Mechanical stimulation to a cell can be controlled by regulating of the chamber 
contraction with the slider operation. We succeeded in observation of the single cell reaction 
behavior stimulated by stretching. This result indicated this device can induce the cell 
differentiation by stimulation control based on cellular reaction. 
These devices are able to evaluate the response and morphology transformation of 
pheochromocytoma based on the chemical/mechanical stimulation. Also, these results 
suggest that the fabricated two devices can dynamically induce the stem cell differentiation 
by controlling chemical and mechanical stimulation. 
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1. Introduction 
Phospholipases A2 (PLA2s) (phosphatidylcholine 2-acylhydrolases, EC 3.1.1.4) are 
ubiquitous lipolytic enzymes. PLA2s are widely spread in nature; they have been found in 
many organisms including mammals, reptiles, invertebrates, plants, fungi, ameba, bacteria, 
and viruses as well as in snake and bee venom. The PLA2s include five distinct types of 
enzymes: the secreted PLA2s (sPLA2), the cytosolic PLA2s, the Ca2+ independent PLA2s, the 
platelet-activating factor acetylhydrolases, and the lysosomal PLA2s (Schaloske  & Dennis 
2006); a new type, so-called adipose-specific PLA2, has been described recently (Duncan et 
al., 2008). PLA2s form a numerous protein superfamily, which is divided into 15 groups and 
many subgroups basing on their amino acid sequences, molecular masses, origin, number of 
disulphide bonds, Ca2+-dependence and so on. 
“Conventional” sPLA2s belonging to groups I/II/V/X are closely related, 13–19-kDa 
secreted enzymes with a highly conserved Ca2+-binding loop, a catalytic site with a His–Asp 
dyad, six absolutely conserved disulfide bonds and up to two additional unique disulfide 
bonds, which contribute to the high degree of stability of these enzymes (Murakami et al., 
2011). They require calcium at a level of extracellular environment for the lipolytic activity. 
For examples, PLA2s of group I are monomers of 13-15 kDa with 7 disulfide bridges. 
Among these, there are PLA2s of group IA found in Elapidae snake venom and those of 
group IB found mostly in mammalian pancreas. Group II of PLA2s comprises 6 sub-groups: 
sub-groups IIA and IIB are typical for Viperidae snake venom whereas sub-groups IIC-IIF 
are typical for mammalian tissues. Group III comprises sPLA2s from mammals, lizards, and 
bee venom (Schaloske  & Dennis 2006). 
Cytosolic PLA2s have no apparent homology to sPLA2s and differ from the latter in 
molecular mass, which is in the range from 60 to 115 kDa, stability to thiol reagents and 
requirement in calcium at a cytosolic level which, in contrast to the sPLA2s, is required 
rather for translocation of the enzyme to intracellular membranes than for catalysis. 
Cytosolic PLA2s utilize the Asp-Ser catalytic dyad; phosphorylation of the Ser residue 
enhances lipolytic activity (Schaloske  & Dennis 2006). These PLA2s are found only in 
vertebrates (Murakami et al., 2011). 
Ca2+-independent PLA2s are referred to so-called patatin-like phospholipase domain-
containing lipases (Murakami et al., 2011). Like cytosolic PLA2, they utilize a serine for 
catalysis (Schaloske  & Dennis 2006). 
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The main effect of PLA2 is the hydrolysis of the sn-2 position of glycerophospholipids to 
release fatty acid (as a rule, unsaturated one, especially arachidonic acid, 20:4 n–6) and 2-
lysophospholipids. The down-stream enzymes of arachidonate methabolism are 
cyclooxygenases and lipoxygenases (COXs and LOXs). Arachidonic acid is a key precursor 
of various eicosanoids including prostaglandins, thromboxanes and leukotrienes with their 
own biological activities. In addition to (or along with) lipolytic activity, PLA2s may exert a 
broad spectrum of biological effects. So, they may impact different cell functions as well as 
display pro-inflammatory, platelet-activating, cytotoxic and other stress response-inducing 
properties (see reviews (Boyanovsky & Webb, 2009; Lambeau & Gelb, 2008)) and even anti-
bacterial action (mainly of group IIA, (Buckland & Wilton, 2000; Nevalainen et al., ,2008)). 
sPLA2s from venoms may also possess anticoagulant activity, presynaptic neurotoxicity, 
myo- and cytotoxicity. The main biological activities of PLA2s from different groups along 
with their effects on PC12 cells are summarized in table 1. Some of these diverse effects 
depend on the enzymatic activity while others do not. In certain cases, e.g., affecting blood 
coagulation, some of sPLA2s need to hydrolyze phospholipids to gain an anti-coagulant 
effect while others show the anti-coagulant activity per se, without such hydrolysis (Kini, 
2005). The non-enzymatic effects may involve different mechanisms, for example, protein-
protein interactions (Hanasaki, 2004; Lambeau & Lazdunsky, 1999; Valentin & Lambeau, 
2000), which will be discussed below. 
None of known PLA2s exerts all variety of the above biological effects. To explain snake 
venom sPLA2 functional specificity, Kini and Evans (Kini, 2005; Kini & Evans, 1989) have 
proposed a so-called “target model”. According to this model, surface of a target cell or 
tissue have a “target site” (“target protein”) which is recognized by a complementary 
“pharmacological site” in the PLA2 molecule. The affinity between PLA2s and target 
proteins lies in the nanomolar range, whereas the affinity between PLA2s and 
phospholipids covers the micromolar range. Such a difference may explain why the 
interaction of venom PLA2 with target protein governs the pharmacological specificity 
(Kini, 2005). The “pharmacological site” is independent of, but sometimes overlapping with, 
the active enzymatic site. Of course, neighboring phospholipids may also contribute to the 
interaction (Kini, 2005). 
A variety of membrane and soluble proteins strongly bind sPLA2s, suggesting that the 
sPLA2 enzymes could also function as high affinity ligands (Hanasaki, 2004; Valentin & 
Lambeau, 2000). Most of the binding data have been accumulated with venom sPLA2s and 
group IB and IIA mammalian sPLA2s. In general, venom sPLA2s have been shown to bind to 
membrane and soluble mammalian proteins of the C-type lectin superfamily (M-type sPLA2 
receptor and lung surfactant proteins), to N-type receptors, to pentraxin and reticulocalbin 
proteins, and to factor Xa (see review (Valentin & Lambeau, 2000)). M-type PLA2 receptor 
has been found in muscle first (therefore – M) and then identified in other organs; the PLA2 
binding to this receptor is calcium-insensitive. N-type PLA2 receptor has been found in 
brain (N – neuronal); more recently N-type-like PLA2 receptors have been found in other 
organs. The PLA2 binding to this receptor is calcium-dependent. These receptors selectively 
bind certain sPLA2s with picomolar affinity. So, bee venom PLA2 binds to N-type and M-
type receptors with IC50 of 80 pM and >0.3 M, respectively. The affinity of OS1, a PLA2 
from taipan snake venom, for these two receptors is quite different: 34 pM for M-type and 
1.5 M for N-type, while OS2 from taipan binds these receptors with almost equal affinity (6 
and 10 pM for M- and N-type, respectively) (Lambeau & Lazdunski, 1999). Hence, some 
additional mechanism(s) besides phospholipide hydrolysis should be considered in 
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PLA2 group  Distribution Main activity(s) Effect(s) on PC12 
IA Elapidae snake venom 







lung, liver, spleen, kidney, 
brain  
Digestion of dietary PLs; 
antibacterial; eicosanoid 




Elapidae snake venom  Differentiation 
IIA 
Acute phase serum, 
intestinal mucosa, lacrimal 
gland cells, prostatic 
epithelial cells 
Inflammation, acute phase 
protein; antibacterial; atherogenic; 
anti-tumor or pro-tumorigenic; 
cell proliferation, migration, 





Viperidae snake venom 







release (blockage at 
internal application). 
III 

























atherogenic, pro-tumorigenic. Differentiation. 
XIII Bacteria/fungi Modulation of host inflammatory response. Differentiation. 
Cytosolic 
PLA2s 
Kidney, brain, heart, 
spleen, thyroid 
Inflammation, anaphylaxis; 
ulceration; acute lung injury, 
brain injury; parturition; 
nociception; junction proteins 
through or from the Golgi. 
Apoptosis, hypoxic or 
ischemic cell death; 




Different cell types 
Cell activation, proliferation, 
migration, or apoptosis, pro-
tumorigenic; secretion; control of 
energy metabolism in adipocytes.
Apoptosis, hypoxic or 
ischemic cell death; 
regulation of exocytosis. 
Table 1. The main biological activities of PLA2s and their effects on PC12 cells. The table 
includes only those PLA2 groups that have been shown to act on/in PC12 cells. The data 
have been compiled mainly from (Boyanovsky & Webb, 2009; Farooqui, 2009; Murakami et 
al., 2011; Nakashima et al., 2003; Schaloske & Dennis 2006). 
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PLA2 group  Distribution Main activity(s) Effect(s) on PC12 
IA Elapidae snake venom 







lung, liver, spleen, kidney, 
brain  
Digestion of dietary PLs; 
antibacterial; eicosanoid 




Elapidae snake venom  Differentiation 
IIA 
Acute phase serum, 
intestinal mucosa, lacrimal 
gland cells, prostatic 
epithelial cells 
Inflammation, acute phase 
protein; antibacterial; atherogenic; 
anti-tumor or pro-tumorigenic; 
cell proliferation, migration, 





Viperidae snake venom 







release (blockage at 
internal application). 
III 

























atherogenic, pro-tumorigenic. Differentiation. 
XIII Bacteria/fungi Modulation of host inflammatory response. Differentiation. 
Cytosolic 
PLA2s 
Kidney, brain, heart, 
spleen, thyroid 
Inflammation, anaphylaxis; 
ulceration; acute lung injury, 
brain injury; parturition; 
nociception; junction proteins 
through or from the Golgi. 
Apoptosis, hypoxic or 
ischemic cell death; 




Different cell types 
Cell activation, proliferation, 
migration, or apoptosis, pro-
tumorigenic; secretion; control of 
energy metabolism in adipocytes.
Apoptosis, hypoxic or 
ischemic cell death; 
regulation of exocytosis. 
Table 1. The main biological activities of PLA2s and their effects on PC12 cells. The table 
includes only those PLA2 groups that have been shown to act on/in PC12 cells. The data 
have been compiled mainly from (Boyanovsky & Webb, 2009; Farooqui, 2009; Murakami et 
al., 2011; Nakashima et al., 2003; Schaloske & Dennis 2006). 
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signaling pathways in which PLA2s take part. For example, it has been suggested that 
“neuronal” effects of sPLA2s derived from animal venoms may be mediated by their 
specific binding to N-type receptor on neuronal membranes (Hanasaki, 2004). It should be 
noted, that to date there is no direct evidence on presence of a sPLA2 receptor in PC12 cells 
(neither of C-lectin-like nor of any other type). 
There is a lot of data that PLA2s may display neurotoxic properties. They may affect also 
some important neuronal functions, such as neurotransmitter release and neuronal survival 
as well as neuritogenesis. Thus, there is no coincidence that PLA2s are found in nerve 
growth cones in PC12 cells. We do not intend to discuss here all the effects of PLA2 on 
various types of neuronal cells as it has already done in overall by others (for instance, see 
respective chapters in (Farooqui, 2009) and other reviews). In accordance with the topic of 
the present book, we shall consider in details the PLA2 effects mainly on PC12 cell line.  
2. PLA2 and neurite outgrowth in PC12 cells 
PC12 cell line has been derived from rat pheochromocytoma which is a tumor of neuronal 
origin. This cell line serves sometimes as a convenient model for studying some “neuronal” 
effects of different compounds. It is known for many years that PC12 cells are also capable 
to exhibit neurite outgrowth upon appropriate external stimulation. This process may be 
evoked by application of different biochemical agents: polypeptides (e.g., neurotrophins: 
nerve growth factor (NGF) or fibroblast growth factors, and some neuropeptides of secretin 
superfamily (e.g., PACAP) (Ravni et al., 2006; Vaudry et al., 2002)), cAMP, which seems to 
be a messenger of the latters (Gerdin & Eiden, 2007),  and its certain derivatives (Gunning et 
al., 1981), sialoglycosides (Ledden et al., 1990) and sialic acid precursors (Kontou et al., 
2009), lectins (Wu et al., 2004), some phospholipide metabolites (discussed below), calcium 
ions (by membrane depolarization), etc. Biochemical pathways converting signals from such 
diverse molecules to the neurite outgrowth may be either very different or almost identical, 
may overlap, or supplement, or amplify each other. For example, the differentiation 
pathways in PC12 are summarized in (Eiden et al., 2011). In all cases, the neurite outgrowth 
in PC12 is accompanied by shifting from a chromaffin cell-like phenotype to a neurite-
bearing sympathetic neuron-like phenotype and results in termination of proliferation. The 
sum of these events is considered as an indicator of cell differentiation (Nakashima et al., 
2004), the process opposed to malignant growth. Thus, PC12 is an excellent model to study 
at a cellular level the neuronal differentiation and antiproliferative effects of different 
compounds. In this paper we undertake the first attempt to systematize the data about 
effects of PLA2s on PC12 and to consider the possible mechanism(s) involved in these 
processes. However, we should say that PC12 cells in non-differentiated and differentiated 
forms have been documented to display at certain circumstances their own endogenous 
secretory, cytosolic, and calcium-independent PLA2 activity.  
There is a number of papers discussing a role of activation of intracellular phospoholipase C 
or phospholipase D in NGF-induced PC12 differentiation (as well as in some other cellular 
events). The effects of these enzymes will not be considered in details in the present paper. 
At the same time, increased activity of endogenous PLA2 has been found in nerve growth 
cones in differentiating PC12 and much of this PLA2 activity has been shown to be calcium-
independent and secretory rather than cytosolic (Martin, 1998) or solely secretory (Ferrini et 
al., 2010). One cannot assert, however, that the activation of endogenous PLA2 is indeed an 
initial cause of neuritogenesis. 
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Along with the above mentioned substances, exogenous sPLA2s derived from different 
sources have been also found to induce the neurite outgrowth as well as produce some other 
effects in PC12 cells. Such a “neuritogenic” property has been already reported for sPLA2s 
of groups IA and IB from cobra venom (Makarova et al., 2006; Osipov et al., 2010), IIA from 
viper venom (Makarova et al., 2006), III from bee venom (Nakashima et al., 2003) and from 
human neuronal cells (Masuda et al., 2008), V from mouse (Nakashima et al., 2003), X from 
mouse (Nakashima et al., 2003) and human (Ikeno et al., 2005; Masuda et al., 2005), as well 
as XIII from bacteria and fungi (Nakashima et al., 2003). According to the early report 
(Hanada et al., 1996), fungal PLA2 p15 promotes only NGF-induced neuritogenesis but itself 
alone fails to induce neurite outgrowth in PC12; however, under some conditions p15 can 
displays neuritogenic properties (Wakatsuki et al, 1999). The concentrations at which 
sPLA2s begin to exert the neuritogenic effect are quite different. So, sPLA2 from bee venom 
being the most active among studied sPLA2s induces neurite outgrowth at concentration as 
low as 0.1 nM. sPLA2 of group XIII is effective starting from 1 nM (Nakashima et al., 2003), 
and snake venom sPLA2s of groups IA, IB, and IIA are effective at concentrations of 1-10 
M (Makarova et al., 2006; Osipov et al., 2010). Not all of sPLA2s can induce neuritogenesis: 
for example, mammalian sPLA2s of groups I and II are unable to produce this effect 
(Nakashima et al., 2003), while PLA2s of these groups from snake venom and mammalian 
PLA2s of groups V and X are effective in inducing neurite outgrowth . 
It is assumed now that neurite outgrowth stimulated by PLA2s in PC12 cells is induced by 
the products of phospholipids hydrolysis and/or by their metabolites. Numerous data 
argue for this assumption. For instance, lysophosphatidylcholine (LPC) but not other 
lysophospholipids or arachidonic acid has been shown to promote the neurite outgrowth 
(Ikeno et al., 2005; Masuda et al., 2008). Overproduction or suppression of G2A, a G-protein-
coupled receptor involved in LPC signaling, results in the enhancement or reduction, 
respectively, of neuritogenesis induced by sPLA2 treatment (Ikeno et al., 2005). LPC (either 
exogenously added or generated in situ by sPLA2-catalysed phosphatidyl choline 
hydrolysis) acts through an L-type Ca2+ channel-dependent mechanism. No synergistic 
enhancement of both sPLA2-promoted and LPC-induced neuritogenesis is produced by the 
co-addition of 100 μM arachidonic acid (Nakashima et al., 2003). Another way for LPC 
signaling is an activation of cytosolic phospholipase D2 which is involved in the regulation 
of depolarization-induced PC12 cell differentiation through activation of tyrosine kinases 
Pyk2(Y881) and ERK (extracellular signal-regulated kinase). However, action of different 
phospholipid products on PC12 is multilateral and dependent on certain extra factors. For 
example, similarly to PLA2 docosahexaenoic acid (22:6 n–3) is present in neurite growth 
cones. This acid decreases time-course activity of cytosolic PLA2 (Martin, 1998) and 
attenuates (Kim et al., 2001) or accelerates (Schonfeld et al., 2007) apoptotic death in PC12 
cells. On the other hand arachidonic acid suppresses neurite outgrowth induced by nerve 
growth factor (Ikemoto et al., 1997) and also may be both anti-apoptotic (Kim et al., 2001) 
and pro-apoptotic at deprivation of NGF and serum (Atsumi et al., 1997) in PC12 (see also 
section 4). The above mentioned phospholipase D2 hydrolyzes the lysophospholipids with 
the formation of lysophosphatidic acid, which enhances cell proliferation. In differentiated 
PC12 cells lysophosphatidic acid provokes a rapid withdrawal of neurites (Moolenaar et al., 
2004). 
The direct relationship between the PLA2 enzymatic and differentiating activities may not 
be always evident. A number of papers (Ikeno et al., 2005; Nakashima et al., 2003; 
Nakashima et al., 2004) argues that anti-proliferative activity of PLA2s in PC12 is directly 
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related to enzymatic activity. It has been suggested (Ikeno et al., 2005) that the binding of 
bee venom sPLA2 to the putative neuronal N-type receptor (see above) unlikely to be 
involved in PLA2-induced neurite outgrowth in PC12 cells. However, the data of 
(Nakashima et al., 2003) are contradictory to these conclusions: it has been shown that in 
PC12 cells catalytically inactive mutants of sPLA2s from groups V and X in which the active 
site His has been replaced by Ala exhibit neuritogenic activity that is only two times smaller 
than that of the native forms. Therefore, the His residue in the active site only promotes but 
does not determine the neuritogenic activity of sPLA2s in PC12. Another example showing 
that phospholipid hydrolysis is not the single requirement for the neuritogenic activity is a 
sPLA2 from Egyptian cobra venom: it possesses very weak enzymatic activity but induces 
neurite outgrowth in PC12 even more efficiently than cobra venom sPLA2 with strong 
enzymatic activity (Osipov et al., 2010). 
Tumor cells of definite types can change their shape and stop proliferation being separated 
from a substrate. In whole, this is true for PC12 cells too. The possible role of extracellular 
matrix in the PLA2-induced neuritogenesis becomes evident from the following data. When 
PC12 cells are grown on polyethyleneimine used as a plate coat, fungal PLA2 p15 is unable 
to induce neurites but can only enhance the effect of NGF (Hanada et al., 1996). On the other 
hand it is known that collagen is the most effective purified extracellular matrix component 
supporting PC12 cell adhesion and NGF-induced neurite outgrowth. If the PC12 cells are 
grown on collagen-coated surface, p15 alone induces neurite outgrowth at concentration as 
low as 1 nM and does not require the addition of NGF for this effect (Wakatsuki et al, 1999). 
Moreover, the effect of p15 is faster than that of NGF: small neurites appear after 6 h of p15 
treatment versus 24 h in the case of NGF (Wakatsuki et al, 1999). 
3. Interdependent action of PLA2 and other agents 
PC12 cells express sodium, potassium, and calcium ion channels and receptors for a lot of 
different ligands (grouth factors, neurotransmitters, adenosine and so on); effects of all these 
membrane proteins are in strong interdependence. At the first place, there are receptors for 
growth factors. There are two classes of receptors for NGF on cell surface: high affinity 
TrkA, a receptor tyrosine kinase which is highly specific for NGF, and a low affinity p75 
neurotrophin receptor which binds all members of the neurotrophin family with a similar 
affinity (Skaper, 2008). Activation of p75 results in apoptosis of PC12 cells while activation 
of TrkA results in their differentiation. There is one intriguing and so far unexplained 
observation that NGF and several other agents are mitogens for normal chromaffin cells, but 
are anti-proliferative agents and induce neuronal differentiation of PC12 cells (Tischler et al., 
2004). It should be mentioned that NGF induces an activation of the Na+, K+-pump in PC12 
cells and increases sodium influx. Moreover, some researchers have seen small changes in 
cAMP level and in calcium currents evoked by NGF while others have not. 
In PC12 cells NGF increases mRNA level for cytosolic PLA2 after treatment for 4h and 
cytosolic PLA2 protein level at 24h after beginning of treatment via the ERK1/2, p38 MAPK 
and PKC pathways (Akiyama et al, 2004). The following data support synergism in PLA2 
and NGF action (Masuda et al., 2008). Adenoviral expression of human sPLA2 of group III 
(PLA2-III) in PC12 cells or dorsal root ganglion explants facilitates neurite outgrowth, 
whereas expression of a catalytically inactive PLA2-III mutant or use of PLA2-III-directed 
small interfering RNA (siRNA) reduces NGF-induced neuritogenesis. The results of the 
experiment with siRNA suggest that endogenous sPLA2-III profoundly affects 
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neuritogenesis of PC12 cells. PLA2-III also suppresses neuronal death induced by NGF 
deprivation. In principle, this work (Masuda et al., 2008) demonstrates that the effects of 
NGF and PLA2 are different, however they complement each other. Thus, the 
overexpression of PLA2 replaces NGF, while NGF is not effective if PLA2 is switch off. 
The data on blockage of PC12 differentiation evoked either by NGF or by PLA2 indicate that 
different pathways are involved in effects of these two agents. Thus, tyrosine kinase 
inhibitor K-252a blocks differentiation induced by NGF. Unlike NGF, neuritogenesis 
induced by sPLA2s is insensitive to K-252a. In contrary, inhibition of L-type calcium channel 
or depletion of extracellular calcium, which are ineffective in blocking NGF-induced 
neuritogenesis, may inhibit sPLA2-induced neurite outgrowth (Wakatsuki et al., 1999). 
On the other hand, NGF activates not only tyrosine kinase cascade but also phospholipases 
C and A2 which in turn results in enhance of arachidonate release from the cell lipids 
(Tsukada et al., 1994). Phosphorylation in vitro and in vivo of cytosolic PLA2 by mitogen-
activated protein kinase at Ser505 increases its intrinsic enzyme activity several fold (Lin et 
al., 1993). After NGF treatment, the PLA2 activity in the PC12 cell lysate increases 4-fold on 
the third day (Ferrini et al., 2010) and during 7 days increases approximately 1.5-fold 
(Matsuzawa et al., 1996) i.e., effects of NGF and PLA2 on PC12 cells are mediated by 
different but somehow related mechanism(s). NGF changes the subcellular localization of 
group IIa endogenous sPLA2 in PC12 cells. In untreated cells, this PLA2 is mainly cytosolic 
and mitochondrial in localization. As soon as 6 h after NGF stimulation, it is no longer 
associated with mitochondria being found diffusely in the cytoplasm and associated with 
the plasma membrane as well as in growth cones at specific membrane domains. After 24 h, 
IIA PLA2 is detected within neurites and, at longer periods, the enzyme is mostly localized 
at neurite tips of neuron-like differentiated cells, as determined by confocal laser 
immunofluorescence microscopy analysis using anti-rat group IIA PLA2 monoclonal 
antibody (Ferrini et al., 2010). After treatment with NGF under identical conditions, group V 
PLA2 retains its cytoplasmic and nuclear localization and is scarcely present within neurites 
and neurite tips. 
PC12 cells themselves comprise enzymes for synthesis of both catecholamines and 
acetylcholine. At the same time they bear acetylcholine receptors of both nicotinic and 
muscarinic types; stimulation of the formers results in the release of catecholamines while 
stimulation of the latter results in calcium influx and phosphoinositide hydrolysis (Fujita et 
al., 1989). 
Calcium ion influx through voltage-gated channels triggers a variety of cellular events 
leading to neurite outgrowth via the concerted action of various calcium-binding proteins. 
Calcium influx mediates induction of gene expression in response to membrane 
depolarization. In PC12 cells, L-type channels are the primary carrier of voltage-sensitive 
calcium currents and have been shown to be required for sPLA2-induced neuritogenesis 
(Nakashima et al., 2003). The calcium signal transduction pathway promoting neurite 
outgrowth causes the rapid activation of protein tyrosine kinases, which include MEK1 and 
Src. They, in turn, further activate Ras (small guanine nucleotide-binding protein) and MAP 
kinase. A set of stimuli evokes the calcium influx; simultaneously cytosolic PLA2s are 
activated which results in release of arachidonic acid and other products of phospholipid 
hydrolysis. Interestingly, such a calcium-dependent activation of the cytosolic PLA2 does 
not need the extracellular calcium, and calcium from intracellular stores would be enough. 
Activation of an exogenous sPLA2 (either applied externally or expressed in PC12 cells) 
requires an influx of extracellular calcium. Thus, sub-millimolar and sub-micromolar Ca2+ 
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neuritogenesis of PC12 cells. PLA2-III also suppresses neuronal death induced by NGF 
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at neurite tips of neuron-like differentiated cells, as determined by confocal laser 
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(Nakashima et al., 2003). The calcium signal transduction pathway promoting neurite 
outgrowth causes the rapid activation of protein tyrosine kinases, which include MEK1 and 
Src. They, in turn, further activate Ras (small guanine nucleotide-binding protein) and MAP 
kinase. A set of stimuli evokes the calcium influx; simultaneously cytosolic PLA2s are 
activated which results in release of arachidonic acid and other products of phospholipid 
hydrolysis. Interestingly, such a calcium-dependent activation of the cytosolic PLA2 does 
not need the extracellular calcium, and calcium from intracellular stores would be enough. 
Activation of an exogenous sPLA2 (either applied externally or expressed in PC12 cells) 
requires an influx of extracellular calcium. Thus, sub-millimolar and sub-micromolar Ca2+ 
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concentrations are necessary for activation of secretory and cytosolic PLA2s, respectively 
(Matsuzawa et al., 1996). Similarly to calcium as well as NGF pathways (Rusanescu et al., 
1995; Vaudry et al., 2002), the sPLA2-induced neuritogenesis in PC12 involves the activation 
of Src and Ras proteins and is accompanied by the activation of MAPK cascade (Wakatsuki 
et al., 1999). The existing data indicate that PLA2, NGF, and calcium ions can act 
independently but synergistically in PC12 cells. However, as all of them activate the 
Ras/MAPK cascade, it is reasonable to suggest that their signaling pathways partially 
overlap. 
Endogenous PLA2s in PC12 can be activated by different damaging agents (cyanides, 
reactive oxygen species, some cytolysins, etc.) that results in release arachidonic acid and its 
metabolites. Arachidonic acid being released by diacylglycerol hydrolysis promotes the 
opening of L- and/or N-type calcium channels that may lead to neurite outgrowth. 
Furthermore, the direct addition of arachidonic acid to the culture medium stimulates 
neurite outgrowth when PC12 cells grow on a fibroblast monolayer. However, arachidonic 
acid does not increase the steady-state calcium levels in neuronal growth cones (Nakashima 
et al., 2003, as cited in Walsh & Doherty, 1997). From existing data it is still not obvious, 
whether one of the activation pathway induced by either PLA2 or calcium channels begins 
first and then evokes other one. 
Besides NGF receptor, PC12 express also two classes of epidermal growth factor receptors 
(activation of which in contrast to NGF receptor results in enhancement of PC12 
proliferation, (Vaudry et al., 2002)) and receptors for fibroblast growth factor. To our 
knowledge, there are no data published on any cross-interaction of these receptors and 
PLA2. 
Thus, PLA2s induce different cellular responses via very complex biochemical pathways in 
which PLA2s themselves or products of their enzymatic activity interact with various 
substances. These interactions are shown in a simplified form in Fig.1. 
4. PLA2 in apoptosis and cytotoxicity 
There are a lot of reports on the cytotoxic property of sPLA2s. This property is mostly 
attributable to PLA2s from animal venom. Concerning cytotoxicity of PLA2 in respect to 
PC12, it should be mentioned that sPLA2s from bee venom at concentrations higher than 10 
nM (Nakashima et al., 2003), and from cobra and viper venoms at concentrations 10 M and 
higher (Makarova et al., 2006) are toxic for these cells (i.e., induce the necrotic changes). 
Thus, cytotoxicity of many venom PLA2s attenuates strongly their “therapeutic” potential 
for differentiating action (section 2). However, non-cytotoxic sPLA2s (e.g., mammalian 
sPLA2s of groups V, X, and fungal/bacterial XIII (Nakashima et al., 2003), as well as a non-
cytotoxic variant of venom sPLA2 (Osipov et al., 2010)) still preserve this potential and can 
be regarded antiproliferative agents.  
Some toxic agents (for examples, reactive oxygen species produced by cyanides 
(Kanthasamy et al., 1997), by hydrogen peroxide (Akiyama et al., 2005), and so on) require 
cytosolic PLA2 activity for their damaging action. 
A mechanism of endogenous sPLA2 cytotoxicity remains unknown yet. Sometimes, 
researchers assign it to enzymatic activity and to released arachidonate. In several cases 
such correlation may be traced, indeed. For instances, arachidonic acid itself being added to 
PC12 in concentrations above 10 M kills the cells within 1-2 hours and does not require 
extracellular Ca2+ for the toxic effect. The removal of extracellular Ca2+ dramatically 
 







































































Fig. 1. Scheme of PLA2 interactions with the various substances mentioned in the text. The 
key players are in the ellipses; the processes considered are italicized. Inhibiting effects are 
indicated by minus, stimulating effects – by plus. DAG is diacylglycerol, PL is a phospho-
lipide, lyso-PA is lyso-phosphatidic acid, and PLC and PLD are phospholipases C and D, 
respectively. 
accelerates the acute cell death (Doroshenko & Doroshenko, 2004). Cytolysins impair ionic 
permeability of cell membrane, leading to cell death. Several different cytolysins have been 
tested on PC12 cells and found to enhance PLA2 activity as well as levels both of 
arachidonic acid and certain its metabolites (Raya et al., 1993). Peroxynitrite-dependent 
release of arachidonate by sPLA2 is supposed to be casually linked to peroxynitrite-
dependent induction of DNA cleavage and toxicity (Guidarelli et al., 2000). However, there 
are enough reports (including cited in this paper) on PLA2s which possess high enzymatic 
activity and devoid of apparent cytotoxicity. Moreover, several papers describe the role of 
arachidonate in programmed cell death (apoptosis) but not in acute cytotoxicity. 
PC12 may undergo apoptotic cell death under some stimuli (for example, under NGF 
deprivation or by activating p75 NGF receptor). PLA2s have been shown to take part in this 
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PC12 may undergo apoptotic cell death under some stimuli (for example, under NGF 
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process and extracellular Ca2+-dependent release of arachidonic acid by sPLA2 is considered 
to mediate their action (Atsumi et al., 1997). Association of sPLA2 with cell surface 
proteoglycan, which has been shown to be a prerequisite for endogenous sPLA2-dependent 
arachidonic acid release from the plasma membranes of live cells, is not essential for sPLA2-
mediated hydrolysis of apoptotic cell membranes. The authors give evidences that the 
apoptotic cell membrane is a potential target for extracellular type II sPLA2 (Atsumi et al., 
1997). Arachidonic acid, a signaling lipid potentially associated with tumor necrosis factor 
receptor-I signal cascade, induces apoptosis in PC12 cells through inhibition of both protein 
kinase C zeta and nuclear factor kappaB activity. Apoptosis induced by arachidonate cannot 
be prevented by NGF (Macdonald et al., 1999). 
Controversially, arachidonic acid has been reported to prevent neuronal apoptosis during 
serum starvation and COX and LOX do not participate in this process (Kim et al., 2001). 
Another research group has reported that arachidonic acid shows normal survival of NGF-
differentiated PC12 whereas stearic acid and palmitic acid induce apoptotic cell death 
(Ulloth et al., 2003). 
Several compounds have been reported to induce apoptosis in PC12 cells and in many cases 
PLA2 activity appears to be essential. For examples, short- and long-chain sphingosines are 
mediators of many cellular events including apoptosis in both naïve and NGF-differentiated 
PC12 (Posse de Chaves, 2006). C2-Ceramide (N-acetyl-D-erythro-sphingosine) alone 
stimulates arachidonic acid release and enhances the ionomycin-induced release. In 
contract, some sphingosines show an opposite effect and directly inhibite cytosolic 
phospholipase A2alpha activity (Nakamura et al., 2004). Nitric oxide can induce apoptosis. 
Nitric oxide is involved in the regulation of cytosolic PLA2, its phosphorylation and activity, 
arachidonic acid release and as consequence in up-regulation of expression and activity of 
COXs and LOXs; blockage of their activity may rescue cell death (Pytlowany et al., 2008). In 
neuronal PC12 cells, TNF-alpha induces moderate apoptosis. Application of TNF-alpha to 
the PC12 cells results in p38 MAPK phosphorylation and activation. Phosphorylation of p38 
MAPK is regulated by cytosolic PLA2, which produces arachidonic acid. The results present 
one possible mechanism for enhancing the neuronal cell death by arachidonate through the 
regulation of p38 MAPK. However, how arachidonate attenuates the phosphorylation of 
p38 MAPK is unknown (Park et al., 2002).  
Ortho-substituted polychlorinated biphenyls induce apoptosis in PC12. These compounds 
evoke PLA2-mediated Ca2+ influx. However, in the presence of extracellular Ca2+, PLA2 
activation is inhibited by neither an extracellular nor an intracellular Ca2+ chelator but is 
depressed by inhibitors of calcium-independent PLA2 (Shin et al., 2002). 
Along apoptosis, PC12 cells may undergo hypoxic or ischemic caspase-independent cell 
death characterized by nuclear shrinkage (pyknosis). This process comes with participation 
of calcium-independent PLA2 and, to a lesser extension, cytosolic PLA2. Interestingly, bee 
venom PLA2 and porcine pancreatic sPLA2 also can cause nuclear shrinkage in another cell 
type. Neither arachidonate nor other fatty acids (stearic, linoleic, palmitic, and oleic acids) 
induces the shrinkage suggesting that PLA2 induces nuclear shrinkage itself and that its 
metabolites are ineffective (Shinzawa & Tsujimoto, 2003). 
Thus, calcium-independent PLA2 seems to play an important role in programmed cell death 
in PC12 that is consistent with the data on participation of group VIA calcium-independent 
PLA2 in apoptosis in cell types other than PC12 (Balsinde et al., 2006; Lei et al., 2010). 
Cytosolic PLA2 also seems to participate in apoptosis. 
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Nevertheless, it is not quite understood yet why a PLA2 activity in PC12 results in cell 
necrosis in several cases, in apoptosis in some cases, and in differentiation in other.  
5. Exocytosis and secretion in PC12 cells and PLA2 
As PC12 cells are tumor scions of neuroendocrine chromaffin cells, it is relevant to mention 
the PLA2 action on catecholamine secretion in the chromaffin cells. Pre-synaptic neurotoxic 
snake venom sPLA2, taipoxin, enhances exocytosis in bovine chromaffin cells in response to 
depolarizing stimuli. It entries into the cytosol, that is already detectable after 5 min and is 
independent on extracellular calcium, i.e., the toxin does not use calcium-dependent 
endocytosis to reach the chromaffin cell cytoplasm. After 1 h, a large portion of the toxin has 
redistributed to the plasma membrane and fragmentation of the F-actin cytoskeleton is 
observed; an increased number of events of granule fusion takes place during the initial 
phase of secretion with an enhancement of the initial rate of release, and after 1 day, cell 
death becomes evident (Neco et al., 2003). Authors (Giner et al., 2007) propose mechanism 
according to which, in neuroendocrine chromaffin cells, neurotoxic sPLA2s bind to surface 
membrane receptors and hydrolyze phospholipids that results in release of 
lysophosphatidic acid among other products. This product activates intracellular pathways 
involving the glycogen synthase kinase 3 (GSK-3), an important modulator of many 
physiological processes, such as neurodevelopment, the cell cycle, apoptosis and 
oncogenesis (either as a suppressor or as a promoter) (Mishra, 2010), causing cytoskeleton 
alterations with neurite retraction. Alterations in actin cytoskeleton result in the loosening of 
the peripheral cortex barrier thus facilitating the access of secretory granules to the release 
sites of the plasmalemma (Giner et al., 2007). 
There is a lot of indications on the participation of PLA2s in exocytosis in PC12. On the one 
hand, PLA2 may participate in regulation of cell secretion; on the other hand, sPLA2 itself 
may be released by exocytosis. sPLA2 of group II is involved in the regulation of 
neurotransmitter secretion by PC12 cells. The neurotransmitters released from PC12 cells by 
PLA2 are catecholamines and acetylcholine. PLA2 seems to be involved also in the 
degranulation process in neuronal cells and itself may influence exocytosis in PC12 cells. 
External application of group IIA sPLA2 (purified crotoxin subunit B from snake venom or 
purified human synovial sPLA2) causes an immediate increase in exocytosis and 
neurotransmitter release in PC12 cells, detected by carbon fiber electrodes placed near the 
cells, or by changes in membrane capacitance of the cells. There is an indication that the 
effect of sPLA2 is dependent on calcium and sPLA2 enzymatic activity (Wei et al., 2003). 
When type II sPLA2 purified from rat platelets is added to NGF-treated PC12 cells, there is a 
dose-dependent release of both noradrenaline and dopamine, reaching a maximum release 
of ~10% at 20-40 g/ml sPLA2 after 10-30 min of incubation. Release of dopamine by 
exogenous sPLA2 is dependent on extracellular calcium. Interestingly, thielocin A1, a type II 
sPLA2-specific inhibitor, or neutralizing antibody against type II sPLA2 suppress 
noradrenaline release in a dose-dependent manner. These results indicate that endogenous 
sPLA2 may be involved in catecholamine secretion from PC12 cells. The concentration of 
exogenous type II sPLA2 required for catecholamine secretion from PC12 cells is higher than 
that which can be released from activated PC12 cells (Matsuzawa et al., 1996). Secretion of 
dopamine from PC12 cells that is stimulated by glutamate is suppressed by type II sPLA2 
inhibitors. Exogenous type II sPLA2 added alone directly elicites release of dopamine from 
PC12 cells (Kudo et al., 1996). Because the antibody could not pass through the plasma 
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membrane without permeabilization, it is likely that sPLA2 might act from outside the cells, 
becoming accessible to the antibody after cell activation. This is supported by the fact that 
exogenously added sPLA2 directly elicites dopamine release from PC12 cells in an 
extracellular Ca2+-dependent manner (Matsuzawa et al., 1996). 
In contrast to external application, internal application of sPLA2 to PC12 cells produces 
blockade of neurotransmitter release (Wei et al., 2003). 
It was suggested (Matsuzawa et al., 1996) that arachidonic acid metabolism elicited by 
neurotransmitters or by depolarization, which mobilizes intracellular Ca2+, is more likely to 
be regulated by cytosolic PLA2. However, the authors do not rule out the possibility for 
hydrolysis of membrane phospholipids by sPLA2 to liberate arachidonic acid, which leads 
to catecholamine secretion. Arachidonic acid may be released from PC12 cells in response to 
different stimuli. Thus, it is released from undifferentiated PC12 under NGF action 
(Tsukada et al., 1994). PLA2 also promotes release of arachidonate from NGF-differentiated 
PC12 cells which are stimulated, for examples, by staphylococcal alpha-toxin at subcytotoxic 
concentrations (Fink et al., 1989), peroxynitrite (by activation of endogenous sPLA2) 
(Guidarelli et al., 2000), high K+ or via direct stimulation of phospholipide hydrolysis by 
mastoparan, a tetradecapeptide PLA2 activator from bee venom (Ray et al., 1999). Several 
other compounds including orthovanadate, phenylarsine oxide, pardaxin, anandamide and 
capsaicin have been reported to induce the arachidonate releasing by PLA2 from PC12 
treated with NGF, with subsequent prostaglandin F2alpha formation. Orthovanadate 
activates cytosolic PLA2 to release arachidonate, stimulates tyrosine phosphorylation in 
proteins and enhances Ca2+-induced noradrenaline release (Mori et al., 2001). Phenylarsine 
oxide acts probably via activation of endogenous secretory PLA2; it may act synergistically 
with exogenous sPLA2 from bee venom (Ohsawa et al., 2002). Pardaxin, an -helical 
cytolysin from the fish Pardachirus marmoratus, aggregates in the plasma membrane to form 
ionic channels, followed by calcium influx. By this way it activates calcium-dependent 
PLA2, but it also can activate calcium-independent PLA2 in PC12 (Abu-Raya et al., 1998). 
Anandamide and capsaicin stimulate arachidonic acid release even in the absence of 
extracellular calcium. The effects of anandamide and capsaicin are inhibited by PLA2 
inhibitors, but not by an antagonist for vanilloid VR1 receptor (Someya et al., 2002). 
Exocytosis in PC12 may be evoked also by lysophosphatidylinositol, another product of 
phospholipid hydrolysis by sPLA2 (Ma et al., 2010). 
Arachidonate release is associated with acetylcholine release in NGF-differentiated PC12 
cells. Botulinum neurotoxin type A (BoTx) inhibits this process. K+-stimulated acetylcholine 
release is also totally inhibited by pretreatment of cells with BoTx (2 nM). Inclusion of 
exogenous arachidonate, or the PLA2 activator melittin, or bee venom sPLA2 itself prevents 
the effect of BoTx (Ray et al., 1993). Treatment of differentiated PC12 cells with mastoparan 
and high (80 mM) K+ induces acetylcholine exocytosis. The acetylcholine release depends 
upon Ca2+ influx via the N-type voltage-sensitive Ca2+ channels. The release is followed by a 
rise in intracellular free Ca2+ concentration; the increased Ca2+ activates PLA2 and, thereby, 
increases the arachidonate level (Ray et al., 1999). BoTx cleaves SNAP-25, a conserved 
synaptosomal protein essential for vesicle fusion and docking during neuroexocytosis. 
Blockage of SNAP-25 function by the antisense oligonucleotides has shown that the 
neuroexocytosis involving PLA2 activity proceeds without participation of this protein. 
Moreover, mastoparan prevents the neurotoxic effect of BoTx through induction PLA2 
activity that seems not to involve SNAP-25 pathway (Ray et al., 1999). 
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Differentiated PC12 cells, being stimulated with carbamylcholine, potassium, or glutamate, 
release sPLA2 into the medium. Thus, sPLA2 of group II is released in response to 
stimulation by neurotransmitters or depolarization. sPLA2 is released from neuronally 
differentiated PC12 cells upon stimulation by carbamylcholine via acetylcholine receptors or 
by high K+ via voltage-dependent Ca2+ channels through membrane depolarization 
(Matsuzawa et al., 1996). When NGF-treated PC12 cells are activated with glutamate, 
approximately 40% of their group II sPLA2 is released into the extracellular medium. 
Glutamate-stimulated secretion of dopamine from PC12 cells is PLA2-dependent, as it is 
suppressed by group II sPLA2 inhibitors (Kudo et al., 1996). 
As after activation of PC12 cells by carbamylcholine, the time courses of  noradrenaline and 
sPLA2 release are not parallel (the release of noradrenaline reaches a plateau at 10 min and 
that of sPLA2 at 15 min), sPLA2 and catecholamine may be stored in different secretory 
granules (Matsuzawa et al., 1996). 
A recent report has appeared concerning a role of calcium independent PLA2 in exocytosis 
and mitochondrial function in PC12: inhibition of this type of PLA2 results in excessive 
exocytosis through increased oxidative damage (or failure to repair such damage) and 
defects in mitochondrial function (Ma et al., 2011). 
It is still unclear, however, whether the relation between neurotransmitter signaling/release 
and the effects of PLA2 plays a significant role in other discussed processes including the 
PC12 differentiation. 
6. Conclusion 
In general, PLA2s are involved in different signaling pathways in PC12 cells. Various types of 
PLA2s and even groups within types may exert diverse effects on the cells. Most of them in 
one or another way are now associated with phospholipid products. One should note, 
however, that it would not be correct to attribute such diversity of effects to enzymatic activity 
of PLA2 only. Understanding the mechanisms involved in PC12 differentiation induced by 
PLA2s may results in development of new drugs inhibiting tumor cell proliferation.  
As it has been discussed in this paper, PLA2 enzymes manifest a number of very diverse 
biological properties. At the same time, PC12 cell line is a valuable model for study of 
different signaling mechanisms. The effects of PLA2s on PC12 cells are quite complex and 
multifaceted. Several striking findings have already been made upon investigation of these 
effects and one can expect further exciting findings in this area. 
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1. Introduction 
The endocrine system is a network of endocrine glands and nerves throughout the body. 
Endocrine glands produce and release hormones that circulate around the body in the 
blood. Hormones keep an even balance of chemicals and fluid within the body, and help us 
respond to changes in the environment. The endocrine system is made up of several glands, 
including the adrenal glands. 
1.1 The adrenal medulla and its hormones 
There are two adrenal glands in our body that produce a number of vital hormones essential 
for survival. The adrenal glands, located at the superior poles of the two kidneys, are 
composed of two distinct layers, the adrenal cortex and the adrenal medulla. The outer 
adrenal cortex, which develops from the abdominal mesothelium, surrounding the medulla 
during embryogenesis, synthesizes and secretes the adrenocortical hormones, the 
mineralocorticoids and glucocorticoids, as well as the adrenogenic (sexual) hormones.  
The adrenal medulla, which comprises the central 20% of the gland, originates from the 
neural crest, and does not become distinct and compact until the adrenal cortex atrophies 
during the first few weeks postnatally. The adrenal medulla is a modified sympathetic 
ganglion which secretes in the bloodstream the catecholamines epinephrine (adrenaline) 
and norepinephrine (noradrenaline) in response to sympathetic neural stimulation to the 
medullae. Depending on the physiological conditions, this secretion averages 80% 
epinephrine to 20% norepinephrine. Although dopamine is present in the adrenal and 
serves as a precursor for norepinephrine and epinephrine, minimal dopamine secretion 
occurs and the role of adrenal dopamine is not well understood.  
Cells of the medulla are known as pheochromocytes or chromaffin cells, referring to the 
dark color produced by the polymerization of oxidized catecholamines when these cells are 
exposed to chromium salts. The early medulla also contains neuroblasts and developing 
sympathetic ganglion cells, but these populations decrease with proliferation and 
maturation of the chromaffin cell population during the first years of life in the human. The 
pheochromocytes are arranged in nests and cords and contain abundant membrane-bound 
dense granules, in which the catecholamines are stored. On stimulation, these granules are 
transported to the cell surface via the microtubular system, and the neurotransmitter 
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contents of the vesicles released by exocytosis. Although circulating epinephrine is derived 
entirely from the adrenal medulla, only about 30% of the circulating norepinephrine comes 
from the medulla. The rest is released from nerve terminals and hence the adrenal medulla 
is not essential for life. 
1.2 Functions of medullary catecholamines 
The physiologic effects of epinephrine and norepinephrine are initiated by their binding to 
adrenergic receptors on the surface of target cells. These receptors are prototypical examples 
of seven-pass transmembrane proteins that are coupled to G proteins which stimulate or 
inhibit intracellular signaling pathways. Complex physiologic responses result from adrenal 
medullary stimulation because there are multiple receptor types which are differentially 
expressed in different tissues and cells. The alpha and beta adrenergic receptors and their 
subtypes were originally defined by differential binding of various agonists/antagonists 
and by analysis of molecular clones.  
In general, circulating epinephrine and norepinephrine released from the adrenal medulla 
have the same effects on target organs as direct stimulation by sympathetic nerves, except 
the effects last five to ten times as long because these neurotransmitter hormones are 
removed too slowly from peripheral circulation. Additionally, of course, circulating 
hormones can cause effects in cells and tissues that are not directly innervated. The 
physiologic consequences of medullary catecholamine release are justifiably framed as 
responses which aid in dealing with stress. These effects are important in helping the body 
to react to emergency situations, thus norepinephrine and epinephrine are sometimes called 
the hormones of “fight or flight”. A listing of some major effects mediated by medullary 
catecholamine are: increased rate and force of contraction of the heart muscle; constriction of 
blood vessels (this causes widespread vasoconstriction, resulting in increased resistance and 
hence arterial blood pressure); dilation of bronchioles (assists in pulmonary ventilation); 
stimulation of lipolysis in fat cells (this provides fatty acids for energy production in many 
tissues and aids in conservation of dwindling reserves of blood glucose); increased 
metabolic rate (oxygen consumption and heat production increase throughout the body as 
well as the breakdown of glycogen in skeletal muscle which provides glucose for energy 
production); dilation of the pupils; inhibition of certain "non-essential" processes: an 
example is inhibition of gastrointestinal secretion and motor activity. Common stimuli for 
secretion of adrenomedullary hormones include exercise, hypoglycemia, hemorrhage and 
emotional distress.  
1.3 Tumours of the adrenal medulla: pheochromocytomas 
A tumour cell is part of a tissue that is abnormally growing. It may be either malignant or 
benign in nature. “Tumour” originally meant “swelling” because, with unchecked cellular 
reproduction, the tissue affected swells to sometimes grotesque proportions. Tumour cells 
that are malignant are generally referred to as cancer cells, and have the ability to 
metastasize, or spread to neighboring tissues and grow tumours there. Benign tumour cells 
do not invade neighboring tissues, but may grow to great size and cause other problems: 
breathing, mobility, circulatory. While a malignant tumour might not be eradicated by 
surgically removing it, a benign tumour generally is. 
Tumours of the adrenal gland can develop in either the cortex or the medulla. Benign 
tumours of the cortex are called adrenal cortical adenomas. Malignant tumours are called 
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adrenal cortical carcinomas. The World Health Organization reserves the term 
pheochromocytoma for tumours arising from chromaffin cells in the adrenal medulla. A 
small number of phaeochromocytomas start outside the medulla part of the adrenal gland 
and are known as extra-adrenal phaeochromocytomas or paragangliomas. A 
pheochromocytoma is an intra-adrenal sympathetic paraganglioma. This arbitrary 
nomenclature emphasizes important distinctive properties of intra-adrenal tumours, 
including an often adrenergic phenotype, relatively low rate of malignancy, and 
predilection to occur in particular hereditary syndromes. Although pheochromocytomas are 
extremely rare in humans, with an annual incidence of less than 1 per million, occult 
germline mutations characteristic of familial syndromes are now found in more than 20% of 
patients with apparently sporadic tumours, bringing the percentage of tumours with a 
known genetic basis close to 30% (Karagiannis et al., 2007). In addition, tumour location and 
risk of malignancy vary with the underlying genetic defect.  
Pheochromocytoma develops as a single tumour or as more than one growth. Only one 
adrenal gland is usually affected. Rarely, tumours affect both adrenal glands; these are 
known as bilateral adrenal tumours. The tumours may occur at any age, but they are most 
common from early to mid-adulthood. In patients with pheochromocytomas, there is a 
release of excessive amounts of catecholamines. If the diagnosis of a pheochromocytoma is 
overlooked, the consequences could be disastrous, even fatal; however, if a 
pheochromocytoma is found, it is potentially curable. Most pheochromocytomas are benign 
(noncancerous), and 90% of cases can be successfully treated by surgery (Petri et al., 2009).  
Many cardiac manifestations are associated with pheochromocytomas. Hypertension is the 
most common complication. Cardiac arrhythmias, such as atrial and ventricular fibrillation, 
may occur because of excessive plasma catecholamine levels. Other complications include 
myocarditis, signs and symptoms of myocardial infarction, dilated cardiomyopathy, and 
pulmonary edema, either of cardiac or noncardiac origin. Different neurologic complications 
may also occur. A pheochromocytoma-induced hypertensive crisis may precipitate 
hypertensive encephalopathy, which is characterized by altered mental status, focal 
neurologic signs and symptoms, or seizures. Other neurologic complications include stroke 
due to cerebral infarction or an embolic event secondary to a mural thrombus from a dilated 
cardiomyopathy. Moreover, intracerebral hemorrhage may origine because of uncontrolled 
hypertension. 
2. Pheochromocytoma cell lines 
Pheochromocytoma cells rapidly cease proliferating in primary culture. In most instances, 
proliferation of neoplastic chromaffin cells ceases with two weeks and does not resume, 
although the cells persist in cultures maintained for many months (Tischler et al., 2004). In 
addition, variable proportions of the tumour cell populations undergo spontaneous 
neuronal differentiation. Propensity for neuronal differentiation may in part reflect 
underlying genetic abnormalities. Establishment of pheochromocytoma cell lines is 
therefore a challenging task. Routinely, different immunocytochemical staining provide a 
means for distinguishing neoplastic chromaffin cells from other cell types in primary 
cultures and for rapidly assessing the success of attempts to establish cell lines (Powers et 
al., 2000).  
The development of experimental applications of animal models of pheochromocytoma has, 
to a large extent, been initially driven by intriguing observations made with human tumour 
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tissue. Individual animal models have subsequently found their own applications, while at 
the same time contributing, in different ways and varying degrees, to understanding of 
human pathology. The rarity of pheochromocytomas is notable across species, with the 
exception of the rat. In some strains of laboratory rats, upwards of 30% of males 
spontaneously develop pheochromocytomas. In contrast, the lifetime frequency of the 
tumours is typically around 1% in wildtype laboratory mice, but much higher in several 
genetically engineered mouse models (Ohta et al., 2006; Tischler et al., 2004). Similarities and 
differences between the rat and mouse models suggest both parallel and unique 
applications for each and also raise questions of which model is more relevant to various 
aspects of human tumour biology. Advantages of the murine models include genetic 
resemblances to human pheochromocytomas (Eaton & Duplan, 2004; Molatore et al., 2010). 
Disadvantages include an apparently less stable phenotype. 
At present, a variety of continuous adrenal medullary cell lines have been established (Eaton 
& Duplan, 2004). Initially, continuous chromaffin cell lines were derived from spontaneous 
pheochromocytoma tumours of the medulla, either from murine (i.e., rat PC12 cells) or 
human sources. In particular, the first continuous cell line derived from a sporadic benign 
human adrenal pheochomocytoma is the KNA cell line (Pfragner et al., 1998) although 
earlier attempts by these same researchers resulted in four similar human cell lines with 
finite lifespans of up to one year in culture. However, there is a heterogeneity among KNA 
subclones. In addition, KNA cells detach early from the tissue culture dish and grow as 
large multicellular spheroids with loose cell-cell adhesion. A similar medullary adrenal cell 
line derived from a human pheochromocytoma is the KAT45 cell line (Venihaki et al., 1998). 
Such cell lines have revealed both the unique characteristics of oncogenic adrenal medullary 
tumours, as well as similarities in catecholamine regulation to normal chromaffin adrenal 
tissue. However, both human cell lines have only provided in vitro data and it is generally 
accepted that there are currently no adequately documented human pheochromocytoma cell 
lines, despite the attempts to establish them.  
Over the last few decades, more sophisticated molecular methods have allowed for induced 
tumourigenesis and targeted oncogenesis in vivo, where isolation of specific populations of 
mouse cell lines of endocrine origin have resulted in model cells to examine a variety of 
regulatory pathways in the chromaffin phenotype (Eaton & Duplan, 2004; Tischler et al., 
2004). Although these cells are attractive experimental models by virtue of their genetic and 
functional similarities to human pheochromocytomas, a drawback compared to other 
models is a greater tendency to phenotype drift. This may in part be due to the same factors 
that cause mouse pheochromocytomas to appear polymorphous in histologic sections or it 
may reflect cell culture artefact. Finally, conditional immortalization with retroviral 
infection of chromaffin precursors has provided homogeneous and expandable chromaffin 
cells in animal models. This same strategy of immortalization with conditionally expressed 
oncogenes has been expanded to create the first disimmortalizable chromaffin cells (Eaton & 
Duplan, 2004). However, these promising lines have not been extensively studied, yet. 
Although the available cell models have already been used for several additional novel 
applications, they are best regarded as complementary systems of human 
pheochromocytomas. Data indicates that caution is warranted in drawing general 
conclusions from any single cell line, but also suggest that understanding of factors that 
permit pheochromocytoma cells to proliferate might itself provide important insights for 
tumour biology. 
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2.1 PC12 cells 
Among chromaffin cell lines, the earliest example is PC12 rat cell line. It was first established 
from a representative rat pheochromocytoma in 1976 (Greene & Tischler, 1976) and has 
become an important workhorse in many disciplines. PC12 cells arose from animals that had 
been irradiated postnatally, probably with resultant genetic damage that permitted the lines 
to be established. The phenotype of the PC12 line has been remarkably stable during almost 
35 years of propagation. However, a somewhat variability of different desired traits has 
occurred in some laboratories, emphasizing the importance of freezing and storing early 
passages of any cell line. The characteristics of the cells have also been affected by culture 
conditions, most notably a switch made in some laboratories early in the history of the cell 
line from RPMI 1640 medium to Dulbecco’s modified Eagle’s medium, which increases cell 
flattening and cell-substratum adhesion.  
The popularity of PC12 cells is mainly because of their extreme versatility for 
pharmacological manipulation, their ease of culture and the large amount of background 
knowledge on their proliferation and differentiation. Like adrenal chromaffin cells, PC12 
cells synthesize and store dopamine and sometimes noradrenaline, which are released upon 
depolarization in a Ca2+-dependent way. A common application of PC12 cells concerns the 
study of the cellular and molecular aspects of cell death, involving normal and neoplastic 
conditions. Also, a notable characteristic of PC12 cells is that they can readily be induced to 
differentiate in culture with the NGF, whereby cells cease to multiply, assume a neurite-
bearing phenotype that resemble mature sympathetic neurons and exhibit firm attachment 
to the substratum.  
3. Apoptosis in pheochromocytoma PC12 cells 
The fate of a cell is determined by a balance of survival or promoting signals. While survival 
signals mediate cell maintenance, promoting signals induce cells to proliferate, differentiate, 
transform or apoptose. The natural occurrence of cell death has long been appreciated and 
was widely studied by nineteenth century biologists. While multiple modes of cell death 
have been described, undoubtedly the most renowned process is the programmed form of 
cell death known as apoptosis. In many diseases, aberrant regulation of apoptosis is the 
central abnormality. For example, resistance of cells to apoptosis is thought to be responsible 
for many types of cancer, while on the other hand in many neurological disorders an 
excessive neuronal death is a central feature.  
As NGF can readily induce PC12 transition from a naïve, actively proliferating to a 
quiescent, differentiated phenotype, the responsiveness to NGF by PC12 cells has allowed 
them to be used for a great variety of studies concerning not only PC12 cells as a purported 
model of adrenal medullary cells, but as a model of neuronal differentiation and 
pluripotency. These features are possessed by primitive progenitors from the medulla which 
can differentiate into either chromaffin cells or sympathetic neurons, depending on the local 
microenvironment.  
A search of the PubMed database in June 2011 yields almost 1800 papers published from 
1990 describing apoptosis in PC12 cells. Indeed, PC12 is considered a suitable and reliable 
model to study (neuro)apoptotic mechanisms as well as for predicting (neuro)cytotoxicity of 
experimental drugs and natural compounds. Although caution is warranted in drawing 
general conclusions from any single cell line, understanding of factors that modulate PC12 
cell proliferation/death might itself provide important insights in cell biology.  
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2.1 PC12 cells 
Among chromaffin cell lines, the earliest example is PC12 rat cell line. It was first established 
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been irradiated postnatally, probably with resultant genetic damage that permitted the lines 
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line from RPMI 1640 medium to Dulbecco’s modified Eagle’s medium, which increases cell 
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for many types of cancer, while on the other hand in many neurological disorders an 
excessive neuronal death is a central feature.  
As NGF can readily induce PC12 transition from a naïve, actively proliferating to a 
quiescent, differentiated phenotype, the responsiveness to NGF by PC12 cells has allowed 
them to be used for a great variety of studies concerning not only PC12 cells as a purported 
model of adrenal medullary cells, but as a model of neuronal differentiation and 
pluripotency. These features are possessed by primitive progenitors from the medulla which 
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In this section, we will concentrate on the programmed cell death mechanisms in PC12 cells, 
considering primarily the recent insights achieved in the last years. We will also consider 
these mechanisms under a pharmacological point of view, as for instance in the context of 
(neuro)cytotoxicological studies and/or the developing of promising compounds with 
potential therapeutic applications. 
3.1 Cellular machinery  
Apoptosis, also known as programmed cell death, is characterized by distinctive 
stereotyped morphological and biochemical alterations, such as exposure of 
phosphatidylserine on the outer leaflet of the plasma membrane and blebbing, cell 
shrinkage, chromatin condensation, and DNA fragmentation. This process leads to the 
formation of apoptotic bodies that are subsequently eliminated by phagocytosis. Key event 
in the apoptotic process is the activation of caspases, a family of cysteinyl aspartate-specific 
proteases. They are constitutively expressed in almost all cell types as inactive proenzymes 
(zymogens) that became processed and activated in response to a variety of pro-apoptotic 
stimuli. Evidence for the sequential activation of caspases has lead to the concept of a 
caspase cascade: during apoptosis, apoptogenic stimuli induce the autocatalitically 
activation of initiator caspases; subsequentely they cleave and thereby activate downstream 
effector caspases that carry on the cleavage of specific proteins in order to “dismantle” the 
cell. 
The induction of apoptosis can be mediated by two pathways: the death receptor-dependent 
or the mitochondria-dependent pathways, also known as the extrinsic and intrinsic 
apoptotic pathways, respectively (Jin & El-Deiry, 2005). The extrinsic apoptotic pathway 
begins at the cell surface where death receptors bind their ligands, such TNF family 
members, including FasL (or CD95L). Ligand binding to the death receptor triggers the 
oligomerization of the death receptor and the aggregation of the characteristic intracellular 
motif, known as “death domain” able to recruit adaptor proteins containing death domains, 
such as FADD. These adaptor proteins function to activate initiator caspase-8 and/or 
caspase-10, resulting in the formation of the death-inducing signaling complex. Activated 
initiator caspases in turn process and activate the downstream executioner caspases, 
including caspase-3, -6, and -7, which execute the destruction of the cell (Degterev et al., 
2003). The study of death receptors-induced apoptosis in PC12 cells has been particularly 
important in understanding the pathogenesis of neurodegenerative diseases. For instance, it 
is of interest to note that amyloid β peptide toxicity (a model of Alzheimer disease in vitro, 
see also below) may involve the CD95 pathway while TNF is strictly linked with excitotoxic 
mechanisms. The intrinsic apoptotic pathway involves the mitochondria in response to 
diverse cellular stress such as UV and gamma irradiation, heat and the activation of some 
oncogenic factors. The critical event in the mitochondria-mediated apoptotic pathway is the 
mitochondrial outer membrane permeabilization, that prompts the release of various 
proteins of the mitochondrial intermembrane space into the cytosol. In addition, the 
mitochondrial proteins of Bcl2 family (i.e., Bcl2 and Bax) play a fundamental role as negative 
or positive modulators. Of importance, cytochrome c, released from mitochondria, binds to 
Apaf-1 to form a complex, the “apoptosome,” that recruits procaspase-9 and facilitates its 
oligomerization and activation. Activated caspase-9, in turn, processes and activates the 
executioner caspases-3, -6, and -7, which drive the execution of the cell.  
The homeostasis of healthy tissues is maintained by the survival signaling pathways 
responsible for the control of cell proliferation. In this respect, one of the best-studied 
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mechanism responsible for apoptosis in PC12-derived neurons is the serum or growth factor 
withdrawal leading to the classical apoptosis. In contrast, the best-characterized survival 
pathway in PC12 cells is that involving NGF. NGF belongs to a family of structurally related 
neurotrophin proteins, including BDNF, NT-3, and NT-4/5 that function to support the 
growth and survival of many populations of neurons. NGF binds the TrkA neurotrophin 
receptor, whereas BDNF and NT-4/5 bind the TrkB neurotrophin receptor, and NT-3 
primarily binds the TrkC neurotrophin receptor. These Trk neurotrophin receptors are able 
to protect neuronal cells from apoptosis, and they can stimulate neuronal regeneration in 
different model systems. NGF activates a variety of signaling cascades, including the protein 
kinases ERK1/2 and PI3K-Akt pathways, that are dynamically linked to the apoptotic 
machinery in a complex cellular signaling network. Their activation by survival signals 
serves to block apoptotic signaling. The proto-oncogene protein kinase Raf-MEK-ERK1/2 
pathway is the better characterized Ras (a GTPase) effector pathway that plays a key role in 
PC12 cell proliferation. Once activated, ERK phosphorylates and thereby regulates the 
activities of a number of substrates, including multiple transcription factors inducing 
alteration in gene expression directly linked with the extracellular signal from the cell 
surface receptors and thus preventing apoptosis. It is very recent the discovery that, among 
all the targets of NGF-activated ERK in PC12 cells the two microRNA 221 and 222 are 
involved in NGF-dependent neuronal survival. (Terasawa et al., 2009). In PC12 cells, the 
PI3K-Akt pathway, the other downstream mediator of NGF, includes, among its several 
targets, the FoxO family of transcription factors which play a particularly important role in 
the regulation of cell death, proliferation, and survival through modulation of the 
expression of cell-cycle inhibitory genes and pro-apoptotic genes. The kinase Akt also 
controls the activity of mTORC1, another key mediator of cell growth, proliferation, and 
survival that can function to inhibit PC12 cell apoptosis. 
Another intriguing issue, recently demonstrated in several models including PC12, is that 
cell cycle activation often precedes neuronal death , indicating that neurons attempt to 
divide before dying (Bianco et al., 2011). Multiple pathways and stimuli, including NGF 
deprivation, have been demonstrated to participate in the regulation of cell cycle events 
during death of differentiated PC12. These aspects may have a significant clinical interest. 
Indeed, different papers have reported the re-expression of proteins of the cell cycle in 
neurons from patients with Alzheimer disease, Parkinson’s disease, ataxia telangiectasia, 
stroke, and other neurodegenerative conditions. 
On the other hand, controversial is the use of PC12 as model of apoptotis induced by the 
release of the excitatory neurotransmitter glutamate. For many years PC12 cells have been 
used to investigate NMDA receptor mediated excitotoxicity and potential neuroprotective 
mechanisms (Lee et al., 2006). In a key paper, Casado and coll. (Casado et al., 1996) 
demonstrated an increase in NR1 protein (a NMDA channel subunit) expression levels in 
PC12 cells in response to NGF, and their ability to evoke NMDA and glutamate induced 
currents. However, other studies are not entirely consistent with these results. Among them, 
Edwards and coll. (Edwards et al., 2007) demonstrated the absence of functional NMDA 
receptors in PC12 cells thus suggesting that the mechanism by which NMDA or glutamate 
induces excitotoxicity in PC12 cells cannot be assumed to occurr by direct actions on NMDA 
receptors but, instead, non-NMDA receptor mechanisms, including oxidative stress, may 
drive cytotoxic response to high glutamate concentrations.  
PC12 cells have been also shown to be useful models to characterize the molecular 
mechanisms that determine cellular commitment to cell death following oxygen-derived 
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Fig. 1. Scheme of some apoptotic mechanisms achieved in PC12 cells (GF: Growth factors; 
GFR: GF receptors; Shc/Grb2/Sos: classical protein complex involved in Ras activation). 
free radicals including superoxide, peroxynitrite, peroxyl radicals, and the hydroxyl radical. 
The toxicity of oxygen-derived free radicals arises from the presence of one or more 
unpaired electrons that extract electrons from macromolecules, ultimately inactivating them. 
At high level reactive oxygene species induce the oxidation of protein, lipid and 
DNA/RNA, increase the leakage of lactate dehydrogenase and reduce the intracellular 
glutathione level. In neuron and in neuronal cell lines (e.g., PC12) accumulation of H2O2 can 
activate the stress sensor JNK/p38 MAPK pathway (Cho et al., 2008) and eventually the 
tumour suppressor gene p53 (Reuter et al., 2010). A source of the hydroxyl radical is also the 
nitrogen-derived radical, nitric oxide, which can combine with superoxide to produce 
peroxynitrite. Peroxynitrite is capable of directly damaging proteins, lipids, and nucleic 
acids and can generate hydroxyl radicals and NO2 in PC12 cells (Pytlowany et al., 2008; 
Shacka et al., 2006). 
In the last decade increasing attention has been focused on alternative signaling pathways 
leading to cell death, as for instance autophagy and parthanatos. In PC12 cells serum or 
growth factors withdrawal can lead to autophagy instead of apoptosis. Autophagy is an 
evolutionarily conserved lysosomal pathway involved in the turnover of long-lived proteins 
and organelles. Functions of autophagy include: remodeling during development and 
differentiation and elimination of unwanted or damaged organelles and molecules. These 
functions are important for maintenance of cytoplasmic homeostasis. Autophagy can be 
 
Programmed Cell Death Mechanisms and Pheocromocytomas: Recent Advances in PC12 Cells 
 
93 
stimulated in response to different situations of stress, such as starvation, changes in cell 
volume, oxidative stress, accumulation of misfolded proteins, hormonal signaling, 
irradiation, xenobiotic or the pro-apoptotic ligand TRAIL treatment. Following the 
induction of autophagy, autophagic vesicles or autophagosomes are formed through the 
assembly and expansion of double-layered, membrane-bound structures of endoplasmic 
reticulum around whole organelles and isolated proteins. The autophagosome encapsulates 
the cytosolic materials, then docks and fuses with lysosomes or other vacuoles, causing 
degradation of the autophagosomal contents. At the molecular level, the signaling pathway 
that leads to autophagy seem to involve the activities of PI3K and mTOR. In PC12 cells, two 
key autophagy genes, ATG7 and beclin 1, have been recently reported to be involved in this 
non-apoptotic death pathway.  
In traumatic brain injury, excitotoxicity, ischemia, and, in many neurodegenerative 
disorders, PARP-1 activation is an early biochemical cell death event. PARP-1 activation 
leads to a unique form of cell death that is in large part mediated via accumulation of PAR 
and nuclear translocation of AIF from mitochondria that induces large-scale DNA 
fragmentation, chromatin condensation, and cell death. PARP-1-dependent cell death is 
caspase independent as caspase inhibitors are ineffective in limiting it and is termed 
parthanatos. In several neuronal model including PC12, parthanatos has been recently 
studied together with its players (Kondo et al., 2010). The intriguing aspect emerging from 
parthanatos is that the nuclear–mitochondrial cross talk with PAR is important player for 
cell death initiation. Indeed, PAR is generated mainly in the nucleus and localizes to cytosol 
and interacts with mitochondria to induce cell death. Parthanatos is a unique form of cell 
death that occurs across organ systems, which is primarily mediated by toxic accumulation 
of PAR in cytosol from overactivation of PARP-1. Although the mechanism of parthanatos 
includes PAR as a signaling molecule to induce AIF release from mitochondria, the 
mechanistic aspects of the AIF-releasing capacity of PAR remain unclear.  
Although programmed cell death is well accepted as a common homeostatic property of all 
tissues, its frequency is underestimated. Dying cells are rarely observed in normal tissues, 
thus illustrating the effectiveness of the clearance process. Indeed, a key event in the 
apoptosis programme is the swift clearance and phagocytosis of dying cells by wandering or 
resident scavengers and neighbouring phagocytes (Gregory & Pound, 2011). However, the 
vast majority of research on apoptosis has focused on the stages leading up to the clearance 
phase, or indeed has been carried out under artificial conditions lacking the clearance phase 
such as in model populations of non-phagocytic cells in vitro. In normal or pathological 
tissues, apoptotic cells are invariably found in association with macrophages and 
neighbouring cells of various lineages which actively engage in the apoptotic cell clearance 
process. In the developing brain, multipotential cells phagocytose their dying neighbours 
prior to the appearance of the specialist phagocytes of the nervous system, the microglia. 
Furthermore, in tumours, clearance of apoptotic cells is mediated by macrophages, non-
macrophage stromal cells, and tumour cells themselves. These features need to be taken into 
account in elucidating the finer mechanisms of apoptotic cell death, as for instance those 
underlying the interactions of the apoptotic cell with its environment. 
3.2 Factors and compounds involved in apoptosis regulation  
Much current work with in vitro systems for (neuro)cytotoxicity/(neuro)cytoprotection 
testing lies in maximizing their potential for yelding valid mechanistic response. Among the 
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advantages of in vitro models, i.e., PC12 cells, are the option to study a single cell type of 
interest in the absence of other cell types, ease of direct observation and measurement of 
cellular responses to chemicals, a defined extracellular environment, and direct interactions 
of the chemical with test cells. Until recently, it was thought that cytotoxic/cytoprotective 
drugs affected target cells directly by interfering with some life-maintaining function. 
However, of late, it has been shown that exposure to several drugs with disparate 
mechanisms of action modulates apoptosis in both pathological and normal cells. 
Among ubiquitous toxic environmental contaminants, cadmium, manganese, copper (an 
essential trace element contained in common foods), methylmercury, and bisphenol A may 
induce apoptosis in PC12 cells. Recently, it has been demonstrated that melamine, which has 
been used in milk powder as an additive to raise the measured protein content, and 
monocrotophos, a widely used organophosphate pesticide, also displayed apoptotic effects. 
In contrast, the phenol tert-butylhydroquinone, a synthetic food grade antioxidant, that is 
used to stabilize foods, fats and vegetable oils aganist oxidative damage, prevents apoptosis 
in differentiated PC12 cells. Similar effects are achieved by pyrroloquinoline quinone, a 
novel redox cofactor which exists in various foods. 
Current evidence in the literature supports a cytoprotective role of NGF in PC12 cells (see 
also above) such as against apoptosis induced by TNFα. The transition of cells from a 
proliferative to a differentiated, quiescent stage is associated with acquisition of a highly 
reduced intracellular environment, which confers cytoprotection against oxidative 
challenge. The reason as to why PC12 cells acquire a reduced intracellular status during 
differentiation is probably due to the fact that neuronal cells are highly oxidative, which 
could render cells vulnerable to reactive oxygene species-induced injury. Therefore, 
adaptation of differentiated neuron-like PC12 cells to a reduced environment and a higher 
expression of redox enzymes would permit cells to function optimally under oxidizing 
conditions, and increase the likelihood for survival against oxidative challenges. 
Oxidative stress has been widely believed to be an important pathogenetic mechanism of 
neuronal apoptosis, occurring in different brain diseases, as for instance Alzheimer disease 
and Parkinson’s disease. It is thus not surprising that neuron-like PC12 cells are extensively 
used in the study of brain disorders. In this respect, amyloid β peptide, dopamine, 6-
hydroxydopamine, and MPP+ are shown to induce apoptosis in PC12 cells. Amyloid β 
peptide toxicity is a well-established pathway of neuronal cell death which play a role in 
Alzheimer’s disease. In addition, 6-hydroxydopamine is a neurotoxin used by scientists to 
selectively kill dopaminergic and noradrenergic neurons. The main use for 6-
hydroxydopamine in scientific research is to induce Parkinsonism, as well as the neurotoxin 
1-methyl-4-phenylpyridinium. Similarly, dieldrin, which may selectively destroy 
dopaminergic neurons, induces apoptosis in PC12 cells. It is a chlorinated hydrocarbon 
originally produced as an insecticide and has been reported to be one of the environmental 
factors correlated with Parkinson’s disease. The effects of some of these substances can be 
reverted by different anti-apoptotic compounds. Among them, some novel substituted 
bisphenol A derivatives, bone morphogenetic protein 7, and galantamine have protective 
effects against amyloid β peptide-induced PC12 apoptosis. Galantamine is an 
acetylcholinesterase inhibitor widely used for patients with Alzheimer’s disease. In 
addition, granulocyte-macrophage colony-stimulating factor, a hematopoietic cytokine that 
has the potential for clinical application, significantly reduces 1-methyl-4-
phenylpyridinium-induced PC12 apoptosis. Some interesting results may also account from 
gene therapy strategies. For instance, the anti-apoptotic herpes simplex virus type 2 gene 
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ICP10PK has been reported to protect neuronally differentiated PC12 cells from apoptosis 
death caused by MPP+. Finally, other substances which display somewhat activity in brain 
have been shown to modulate apoptosis in PC12 cells: the opioid morphine induces 
apoptosis, while lithium chloride, the antipsychotics citalopram and trifluoperazine, and 
serotonin exert opposite effects. 
 
name description source effect 
hydroxyecdysone ecdysteroid hormone different plant sources anti-apoptotic 
apocynum leaf flavonoid extract Apocynum venetum anti-apoptotic 
aucubin iridoid glycoside Aucuba japonica and other plant sources anti-apoptotic 
camptothecin alkaloid Camptotheca accuminata apoptotic 
cEppt  cinnamon extract anti-apoptotic 
decursin coumarin Angelica gigas anti-apoptotic 
euplotin C sesquiterpenoid ciliate protist Euplotes crassus apoptotic 
gomesin peptide tarantula Acanthoscurria gomesiana apoptotic 
ginsenoside Rb1 steroid glycoside ginseng (Panax) anti-apoptotic 
icariin flavonoid Epimedium brevicornum anti-apoptotic 
isochaihulactone lignan compound Bupleurum scorzonerifolium anti-apoptotic 
isoflavones poliphenolic compounds Fabaceae anti-apoptotic 
kaempferol flavonoid different plant sources anti-apoptotic 
lactacystin cyclic amide bacteria Streptomyces apoptotic 
MAM naphthoquinone Polygonum cuspidatum anti-apoptotic 
olive leaf  olive tree (Olea europaea) anti-apoptotic 
paclitaxel/docetaxel taxanes Taxus brevifolia, baccata apoptotic 
paeoniflorin monoterpene glycoside Paeonia albiflora anti-apoptotic 
puerarin isoflavone C-glycoside Pueraria lobota anti-apoptotic 
quercetin flavonoid Quercum and other plant sources anti-apoptotic 
salidroside phenylpropanoid glycoside Rhodiola rosea anti-apoptotic 
schisandrin B/C lignans Schisandra chinensis anti-apoptotic 
SG-168 acetal skeleton Dendrobium nobile anti-apoptotic 
silibinin flavonolignan milk thistle (Silybum arianum) anti-apoptotic 
tetrahydroxystilbene 
glucoside monomer of stilbene Polygonum multiflorum anti-apoptotic 
trans resveratrol phenol grapes anti-apoptotic 
vincristine/vinblastine vinca alkaloids Catharanthus roseus apoptotic 
xyloketals  mangrove fungus Xylaria anti-apoptotic 
Table 1. Examples of natural products identified as modulators of PC12 cell apoptosis 
Many commercialized drugs have been obtained by the synthesis of new compounds. On 
the other hand, an alternative source of drugs is natural products (and the structural 
modification of natural products), which frequently seem to be more effective and/or less 
toxic. A natural product is a chemical compound or substance produced by a living 
organism - found in nature that usually has a pharmacological or biological activity. Nature 
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advantages of in vitro models, i.e., PC12 cells, are the option to study a single cell type of 
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is an attractive source of new therapeutic candidate compounds (da Rocha et al., 2001) as a 
tremendous chemical diversity is found in millions of species of plants, animals, marine 
organisms and microorganisms. For many living organisms, this chemical diversity reflects 
the impact of evolution in the selection and conservation of self-defense mechanisms that 
represent the strategies employed to repel or destroy predators. However, the development 
of novel agents from natural sources presents obstacles that are not usually met when one 
deals with synthetic compounds. For instance, there may be difficulties in accessing the 
source of the samples, obtaining appropriate amounts of the sample, identification and 
isolation of the active compound in the sample, and problems in synthesizing the necessary 
amounts of the compound of interest. These problems became evident when the tubulin-
interacting agent taxol was introduced in clinical use. Antitumour activity was observed in 
various in vitro systems, including PC12 cells, and in vivo tumours. It took some years to 
develop a semi-synthetic analog which is derived from a renewable source. Currently, total 
synthesis has been achieved drug supply is no longer a problem. Among their various 
biological activities, natural products can modulate apoptosis signaling pathways (Fulda, 
2010). In PC12 cells, many scientific papers report pro-apoptotic and anti-apoptotic activity 
of different natural products, isolated mostly from plant sources, others from microbes, 
fungi and different marine organisms. Table 1 shows some examples of agents derived from 
natural sources which have been studied in 2010-2011 as modulators of PC12 cell apoptosis. 
Some “classical” apoptotic modulators have been also indicated.  
In many studies, PC12 cell models to study apoptotic mechanisms/modulations have been 
obtained with the use of lipopolysaccharide, the major component of the outer membrane of 
Gram-negative bacteria, or ethanol. Apoptosis can be also induced by depletion of serum 
and NGF from the culture medium. Other factors may include glucose deprivation, a high 
oxygen atmosphere or oxidative agents as for instance hydrogen peroxide, peroxynitrite, the 
lipid peroxidation product 4-hydroxynonenal, and 7-ketocholesterol, the major oxidation 
product of cholesterol found in human atherosclerotic plaque. Moreover, many other 
organic/endogenous compounds, like parathyroid hormone(1-34), corticosterone, and 
ceramide exert pro-apoptotic effects in PC12 cells. Interestingly, taurine, a free amino acid 
with antioxidant activity present in high concentrations in a variety of organs of 
mammalians, protects cells from apoptosis induced by hydrogen peroxide. In addition, 
heparin-binding epidermal growth factor-like growth factor is a member of the epidermal 
growth factor family that is expressed in many cell types. In PC12 cells, its protective effects 
against apoptosis induced by oxygen and glucose deprivation has been reported. Recently, 
different synthetic compounds have been shown to display cytoprotective behaviours 
against oxidative stress, among them folacin C60, the isothiocyanates 3H-1, 2-dithiole-3-
thione, fasudil mesylate, the new 1,2,4-triazine, , 3-butyl-6-bromo-1(3H)-isobenzofuranon 
and a new synthetic 1,2-diaryl oxazine derivative, 2-ethoxy-4,5-diphenyl-1,3-oxazine-6-one. 
In this line, the soluble guanylyl cyclase activator YC-1, which inhibits the hypoxia-
inducible factor 1, and edaravone, a potent free radical scavenger in clinical use, 
significantly antagonize the PC12 apoptosis induced by glutamate or prion protein peptides, 
respectively. 
The ability to induce apoptosis in many tumoural systems, including PC12 cells, has been 
reported as key property for different chemotherapeutic drugs or substances with potential 
therapeutic activity. For instance, the chemotherapeutic drugs fluorouracil, paclitaxel, and 
enediynes are potent inducers of apoptosis in PC12 cells. Also, therapeutic concentrations of 
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cisplatin may cause a hybrid type of cell death characterized by concurrent apoptosis and 
necrosis in the same individual cells. Interestingly, I-387, a novel synthetic compound that 
inhibits tubulin action and exhibits potent antitumour activity in various preclinical models, 
has been shown to display apoptotic activity in different systems, including PC12 cells, 
suggesting that it may represent a new antimitotic agent for management of various 
malignancies. It is also of interest the fact that human pheochromocytomas express high 
levels of the receptor subtype 2 for the neuropeptide somatostatin. Recently, it has been 
demonstrated that somatostatin agonists as well as somatostatin cytotoxic compounds may 
induce PC12 cell apoptosis, although no data are available on pheochromocytomas in vivo 
(Ziegler et al., 2009). Generally, the implications of such apoptotic studies in oncology are 
puzzling. Indeed, often forgotten in the biology of tumours, cell loss in malignant disease is 
a very significant component of tumour dynamics. One may assume that enhanced 
apoptosis will retard tumour growth and hence indicate a favourable prognosis compared 
with tumours showing a low apoptotic activity. However, also the opposite seems to be 
true: apoptosis is a common process in high-grade malignancy, with high apoptosis indices 
generally reflecting poor prognosis. Clearly, the balance between cell birth and cell death 
must favour the former in order for a tumour to grow but, given the properties of apoptotic 
cells and their capacity to affect their microenvironments and host immune systems, it 
seems likely that the cell-death programme also provides oncogenic drive (Gregory & 
Pound, 2011). In this respect, the implications that the homeostatic properties of apoptosis 
can be hijacked as a sinister, facilitatory mechanism for malignant disease development and 
progression are clear and the programme may be regarded as ‘altruistic’ in this context: loss 
of a fraction of the growing population for the greater good of the whole (but detriment of 
the host). 
4. Conclusion 
From a general point of view, dysregulation of apoptosis is associated with many 
pathologic conditions and may even be central in the pathogenesis of many diseases 
(Zangemeister-Wittke & Simon, 2001). Apoptosis research is rapidly proceeding making 
it difficult to keep track of the constant stream of newly identified proteins and 
molecular interactions involved in cell death regulation. However, there is a general 
agreement that the suppression, overexpression or mutation of a number of factors 
which orchestrate the apoptotic process are associated with disease. As outlined above, 
the study of apoptosis mechanisms in PC12 cells represent one application currently of 
great potential interest.  
In pheochromocytomas as well as in the majority of malignancy there is a need of novel 
compounds which may act as potent and selective apoptotic modulators. In the clinical 
practice of benign pheochromocytoma, the most common treatment is surgical removal of 
the entire affected adrenal gland. On the other hand, there is currently no effective 
treatment for malignant pheochromocytoma. Radiotherapy provides benefit in some 
patients with malignant pheochromocytoma. Chemotherapy with cyclophosphamide, 
vincristine, and dacarbazine may produce partial remission, but again is not curative. In 
this respect, much work is still to do in order to exploit new chemical space for drug-like 
molecules.  
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AIF, apoptosis inducing factor; Apaf-1, apoptosis protease-activating factor 1; BDNF, brain-
derived neurotrophic factor; ERK, extracellular-regulated kinases; FADD, Fas-associated 
death domain; FasL, Fas Ligand; FoxO, forkhead box O; GTP, guanosine triphosphate; JNK, 
Jun N-terminal Kinase; MAPK, mitogen-activated protein kinases; MEK, MAPK kinases; 
MPP+, 1-methyl-4-phenylpyridinium; mTOR, mammalian target of rapamycin; mTORC1, 
mTOR complex 1; NGF, Nerve Growth Factor; NMDA, N-Methyl-D-aspartic acid; NT, 
neurotrophin; PARP-1, poly (ADP-ribose) polymerase-1; PI3K, phosphatidylinositol 3-
kinases; TNF, Tumour Necrosis Factor; Trk, transmembrane tyrosine kinase proteins. 
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1. Introduction 
Two motives have combined to make me write a paper on headache in patients with 
pheochromocytoma. First, I would like to contribute to the clinical practices of both 
endocrinological clinicians who are working with patients with pheochromocytoma and 
neurologists who are performing headache consultations by elucidating the clinical 
characteristics of headache in patients with pheochromocytoma. Second, I will discuss the 
stereotypy of current diagnostic criteria provided by “The international classification of 
headache disorders,” 2nd edition (ICHDII)(1) by reviewing the literature concerning the 
mechanism of headache attributed to pheochromocytoma. 
Pheochromocytoma is a rare tumor arising from the chromaffin tissue. Although it is well-
known to produce catecholamine , the tumor is frequently disclosed incidentally by autopsy 
or adrenal imaging.(2)-(3) The representative clinical features are characterized by the 
pentad of symptoms known as the “5Hs”, that is headache, hypertension, hyperglycemia, 
hypermetabolism, and hyperhydrosis. Among these symptoms, which are attributed to the 
overproduction of catecholamine by the tumor, headache is important for four reasons. 
First, it is one of the most frequent symptoms.(4)(5)(6)(7) Second, it is frequently the 
presenting symptom.(8) Third, it may be the only symptom.(9)(10) Fourth, it may be the 
presenting symptom of a life-threatening disease with a histopathologically confirmed 
tumor.(11)(7) 
2. Clinical characteristics of headache attributed to pheochromocytoma 
Paroxysmal headache occurs in 51-80% of patients with pheochromocytoma. The most 
characteristic feature of the headache is its rapid onset. It nearly always seems to reach its 
peak within minutes, sometimes within one minute (thunderclap headache).(10)(12-14) It 
usually occurs spontaneously, but recurrent severe headaches may occur after voiding in 
patients with bladder pheochromocytoma.(13, 15) 
An important feature of the paroxysmal headache is its short duration. In 50% of patients it 
lasts for less than 15 minutes, and in 70% its duration is less than one hour.(4) However, in 
patients with migraine, it may last longer.(8) 
The headache was nearly always bilateral, (8) affecting any part of the head. The occipital, 
nuchal-occipital, and frontal-occipital regions are the predominant locations.(4) The 
headache is generally described as throbbing, pulsating, or bursting in quality, and is 
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moderately to very severe in intensity.(8) As in the other patients with pheochromocytoma, 
headaches are frequently associated with palpitation and perspiration. Other features 
include apprehension and/or anxiety, often with a sense of impending death, tremor, visual 
disturbances, abdominal or chest pain, nausea, vomiting, and occasionally paraesthesia. The 
face can blanch or flush during attack. 
The headaches are sometimes worse when lying down and sometimes made worse by 
moving.(8) Stress maneuvers such as coughing, sneezing, bending, and straining commonly 
aggravate the pain.(4) Measurement of blood pressure before and after onset of the 
headache revealed a sudden increase in both systolic and diastolic blood pressure.(8) 
3. Diagnosis of headache attributed to pheochromocytoma 
Diagnostic cues are usually provided by additional symptoms attributed to sympathetic 
activation, such as diaphoresis, palpitation, apprehension, and/or anxiety. The diagnosis is 
established by the demonstration of increased excretion of catecholamines or catecholamine 
metabolites, and can usually be verified by analysis of a single 24-hour urine sample 
collected when the patient is hypertensive or symptomatic. 
4. Differential diagnosis 
The typical case with the full-blown syndrome (5Hs) is not difficult to diagnose, but in some 
cases of pheochromocytoma, the symptoms are very subtle or absent except for severe 
headache. The most important point is to include pheochromocytoma in the differential 
diagnosis of a case with episodic headache. Further, careful history taking with close 
attention to sympathetic autonomic features will guide physicians to the right path. 
Development of radiology enables us to exclude most secondary headache disorders easily, 
but in all primary headaches and some secondary headaches, brain imaging studies reveal 
no changes. In the case of pheochromocytoma,  normal brain imaging is not the end but the 
starting point for the differential diagnosis. 
4.1 Cluster headache and other trigeminal autonomic cephalalgia 
Among the primary headaches, cluster headache is most similar to pheochromocytoma 
headache. An episodic pattern of occurrence, sudden onset, rapid evolution, short duration, 
and severity characterize both headaches. However, cluster headache is strictly unilateral 
and has parasympathetic autonomic system features, while pheochromocytoma headache is 
usually bilateral and has sympathetic autonomic system features. In addition to the 
difference in autonomic features, its unilaterality is also characteristic of cluster headache. 
Pain is usually more localized to the orbital area in patients with cluster headache. If these 
two diseases are confounded, highly critical outcomes may follow. In one reported cases, for 
example, dihydroergotamine, an agent sometimes used to treat cluster headache, was 
administered errorneously to a patient with pheochromocytoma, causing a hypertensive 
crisis and posterior reversible encephalopathy syndrome.(16) 
4.2 Migraine 
Because migraine is one of the commonest headache disorders, it is always included in the 
differential diagnosis of headache disorders. Classical migraine with aura will be no 
diagnostic problem, but a bilateral episodic headache without aura, should be differentiated 
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from other disorders, including pheochromocytoma. Particularly, if the history of headaches 
is short and their duration is brief, it will be a diagnostic challenge. Nausea is usually 
associated with both types of headache. Magnetic resonance imaging of the brain is useless 
in the differential diagnosis of these two. Careful history taking with particular attention to 
additional features, including scotoma, photophobia, and sympathetic autonomic symptoms 
reveals the correct diagnosis. 
4.3 Thunderclap headache (TCH) 
Thunderclap headache (TCH) is defined as a severe head pain with sudden onset, reaching 
its maximum intensity in less than 1 minute and lasting from 1 hour to 10 days. 
Subarachnoid hemorrhage is by far the most common   and most dangerous cause of 
thunderclap headache, but numerous other diseases involving the vasculature of the central 
nervous system, such as ischemic stroke, cerebral venous thrombosis, cervical arterial 
dissection, acute hypertensive crisis, retroclival hematoma, pituitary apoplexy, and the non-
vascular structures of the central nervous system, such as spontaneous intracranial 
hypotension, third ventricle colloid cyst, and intracranial infection are found on the list of 
the diseases to be excluded in the differential diagnosis. Therefore, TCH is a particularly 
important symptom in differential diagnosis by cranial imaging. However, it is also 
important to bear in mind that many other diseases associated with TCHs, such as 
pheochromocytoma(10, 12-14) and myocardial infarction, cannot be detected by cranial 
imaging and may have serious outcomes. 
4.4 Tension-type headache (TTH) 
Tension-type headache (TTH) is the most common type of primary headache, and its 
lifetime prevalence in the general population is estimated to be from 30% to 78%. TTH is 
subdivided into episodic and chronic subtypes. Episodic TTH is further subdivided into 
frequent and infrequent subtypes. Frequent episodic TTH may be a candidate for the 
diagnosis of pheochromocytoma. It is usually bilateral and non-throbbing in nature. The 
intensity of the headache is mild to moderate, and it is not aggravated by routine physical 
activity. It lacks nausea, vomiting, arterial hypertension, or other sympathetic autonomic 
features (palpitation, perspiration, pallor, tremor, or anxiety).  
4.5 Headache attributed to arterial hypertension 
Mild (140-159/90-99 mmHg) or moderate (160-179/100-109 mmHg) chronic arterial 
hypertension does not cause headache.(17) Ambulatory blood pressure monitoring in 
patients with mild to moderate hypertension has shown no convincing relationship between 
blood pressure fluctuations over a 24-hour period and the presence or absence of 
headache.(18) However, paroxysmal hypertension may cause headache. “Headache 
attributed to hypertensive crisis without hypertensive encephalopathy” is defined as a 
bilateral pulsating headache that may be precipitated by physical activity and associated 
with a hypertensive crisis. A hypertensive crisis is defined as a paroxysmal rise in systolic 
(to ≧180 mmHg) and/or diastolic (to ≧120 mmHg) blood pressure but without clinical 
features of hypertensive encephalopathy. Further, headache that develops during a 
hypertensive crisis should resolve within one hour after normalization of blood pressure.(1) 
The mechanism of this type of headache is not fully understood. Failure of baroreceptor 
reflexes (after carotid endarterectomy or subsequent to irradiation of the neck) is thought to 
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be a one of the mechanisms. Although it shows no sympathetic autonomic features, the rest 
of the characterisics of this headache are quite similar to pheochromocytoma headache. 
Again, it is important to ask the patient about their present and past history of sympathetic 
autonomic symptoms (palpitation, perspiration, pallor, tremor, or anxiety) and neck 
surgery. 
4.6 Intracranial pheochromocytoma 
Brain metastases of pheochromocytoma are extremely rare, and intracranial lesions are the 
only sites of metastasis in patients with adrenal pheochromocytoma. Mercuri et al. reported 
a primary meningeal pheochromocytoma that presented with headache, vomitting, and 
arterial hypertension.(19) Laboratory studies revealed high plasma catecholamines 
(norepinephrine and epinephrine). The tumor was resected, and histopathological 
examination confirmed the diagnosis. Six years follow-up after surgery showed that the 
patient was neurologically intact with normalized blood pressure and catecholamine values. 
This case is a very rare exception in which cranial imaging study provided the crucial 
information to make a diagnosis of headache attributed to pheochromocytoma. 
4.7 Spontaneous intracranial hemorrhage due to pheochromocytoma 
Park et al. reported an 18-year-old man who presented with a sudden onset of headaches, 
followed by left hemianopsia.(20) He had experienced palpitations and chest discomfort 
during physical exertion for two years prior to admission. A brain CT scan showed 
intracerebral hemorrhage in the left frontoparietal area. Hypertension in the form of 
paroxysmal attacks led the authors to suspect pheochromocytoma. Evaluation of a 24-h 
urine specimen showed elevated vanillylmandelic acid and metanephrine levels. 
Abdominal CT demonstrated a para-aortic mass, and 131I-metaiodobenzylguanidine (MIBG) 
scintigraphy showed high uptake in the same area. This case typically showed that cranial 
imaging is useless to make a correct diagnosis of headache caused by pheochromocytoma. 
4.8 Pheochromocytoma crisis induced by glucocorticoids 
Pheochromocytoma crisis (PC) is a rare life-threatening endocrineological emergency that 
may present spontaneously or can be elicited by triggers, including certain medications that 
trigger the release of catecholamines by tumors. Acute and rapidly progressive 
hemodynamic disturbances result from the actions of high quantities of catecholamines 
secreted by the tumor. Hypertensive crisis, cardiac ischemia, cardiogenic shock, and end-
organ failure may occur. Some patients show headache concomitant with hypertension. 
Many drugs can cause adverse reactions in patients with pheochromocytoma, but we also 
have to keep in mind that a high-dose dexamethasone suppression test (DST) may 
precipitate PC in cases with incidental adrenal masses.(21) 
5. Headache and hypertension 
Recording of blood pressure before and after the onset of the headache revealed a sudden 
increase in both systolic and diastolic blood pressure.(8) Probably because of this single sign, 
the diagnostic criteria proposed in “The international classification of headache disorders, 
2nd edition (ICHD-II)” included concomitant hypertension as a mandatory item for the 
diagnosis of headache attributed to pheochromocytoma.(1) However, in some patients, very 
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high blood pressures were observed without concomitant headache.(8) In addition, 
observation of normal or low blood pressure in pheochromocytoma cases is not particularly 
rare,(22) and it is known that catecholamine concentrations in circulating blood are not well 
correlated with blood pressure. There were other cases in which hypertension was not 
observed despite confirmation of urinary cathecholamine metabolite elevation.(23) 
6. Mechanism of headache in patients with pheochromocytoma 
The mechanism of headache associated with pheochromocytoma is not fully understood. 
According to the International Classification of Headache Disorders; 2nd Edition (ICHDII), 
the diagnosis of headache attributed to pheochromocytoma is established by fulfillment of 
the following two conditions. First, headache develops concomitantly with an abrupt rise in 
blood pressure. Second, headache resolves or markedly improves within 1 hour of 
normalization of blood pressure. However, not a small number of patients who were 
demonstrated to have pheochromocytoma by biochemical or radiological examination 
and/or histopathological findings of their surgical specimens showed typical headache 
without hypertension.(14, 23) Therefore, hypertension is not the only factor in headache 
pathogenesis.(24)  
6.1 Catecholamines and headache 
The human cerebral circulation is innervated by sympathetic nerves. The sympathetic 
system contains the transmitters noradrenaline, neuropeptide Y (NPY), and possibly 
adenosinetriphosphate (ATP) and is a vasoconstrictor pathway.(25) The cranial vessels are 
also innervated by the trigeminal nerve. This system is marked by the presence of calcitonin 
gene-related peptide (CGRP), substance P, and neurokinin A. It is a vasodilator pathway(26) 
via antidromic release upon activation as well as having a primary involvement in sensory 
function.(27) 
It is hardly possible to connect throbbing headache with the direct action of the strong 
vasopressor, noradrenalin, which usually causes hypertension in patients with 
pheochromocytoma. Lance et al. studied the relationship between the main subtype of 
catecholamine produced by the pheochromocytoma and clinical symptoms of patients. They 
concluded that the presence or absence of headache or quality of the headache did not bear 
any relationship to the ratio of norepinephrine to epinephrine secreted.(8) Intravenous 
infusion of norepinephrine into a patient susceptible to migraine at a sufficient 
concentration to raise the systolic blood pressure 10 to 40 mmHg is not sufficient to produce 
headache. Wolff et al. administered such infusions on 116 occasions to 35 patients with 
vascular headaches of the migraine type, with abolition or reduction in intensity of 
headache in 93 instances. In these cases, the diameter of the temporal artery and the 
amplitude of its pulse wave were observed to diminish as the headache abated.  
6.2 Neuropeptides and headache 
It seems quite plausible that strong vasodilator peptides produced by pheochromocytoma, 
such as adrenomedullin(28) and  CGRP(23) can cause episodic vascular headaches 
characterized by throbbing in patients with pheochromocytoma. The headache-inducing 
property of CGRP has been studied in one double-blind controlled trial.(29) The headache 
was pulsating in quality and resolved within 1 hour after ingestion of CGRP. In addition, a 
 
Pheochromocytoma – A New View of the Old Problem 
 
106 
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recent study showed that a CGRP antagonist is effective in the acute treatment of 
migraine.(30) To elucidate a possible role of CGRP in the pathological mechanism of 
pheochromocytoma headache, a trial using a CGRP antagonist in patients with 
pheochromocytoma headache should be performed. 
7. Conclusion 
It is very important to understand the characteristics of the headache attributed to 
pheochromocytoma because it is one of the most frequent symptoms of a disease that is 
frequently neglected clinically. It is also important to consider during headache consultation 
because both neurological and radiological examinations of the brain will provide little 
information for the correct diagnosis. 
The mechanism of the headache in patients with pheochromocytoma is not fully 
understood. In addition to the arterial hypertension, vasodilator peptides produced by the 
tumor may play important roles. 
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Pheochromocytomas are catecholamine-producing neuroendocrine tumors arise from 
primitive neural crest cells. About 90% of these tumors occur as solitary benign tumors of 
the adrenal medulla, where majority of chromaffin cells are concentrated. Only ten percent 
originates from extra-adrenal sites with the organ of Zukerkandal (paraganglia along 
abdominal aorta) being the most common. Chromaffin cells can also be found in the wall of 
blood vessels, along the aorta, prostate, urinary bladder and ovaries. Primary cardiac 
pheochromocytomas are extremely rare, occurring in only 0.001% to 0.03% of several 
reported autopsy series. Most of these tumors are found in the left atrium, possibly 
explained by close proximity of paraganglionic cell nest to the left atrium. Primary cardiac 
pheochromocytoms produce large amount of catecholamine, primarily norepinephrine and 
less frequently epinephrine. 
2. Pathophysiology and pathology 
Cardiac pheochromocytomas occur at any age, but mostly in the fourth and fifth decades of 
live. They are extremely vascular, their blood supply exclusively derived from coronary 
circulation. These tumors are usually functional, producing excessive amount of 
catecholamines, primarily secrete norepinephrine, which is a potent vasoconstrictor and 
raises the peripheral vascular resistance. Therefore, systolic blood pressure rises, but 
diastolic blood pressure may fall.  It has very minimal, if any, direct effect on the heart, 
actually, cardiac output may fall reflexly as a result of an increase in the blood pressure. 
Cardiac pheochromcytoma arise from branchiomeric (coronary, pulmonary or 
aortopulmonary) paraganglia or visceral autonomic (atrium or interatrial septum) 
paraganglia. Often, they are dark red-brownish, soft, fleshy and highly vascular non 
encapsulated tumors that found under the aorta and pulmonary artery in association with 
left atrium (Figure 1). They can extend into the atrio-ventricular groove and the coronary 
arteries. Malignant changes are present in 10% of catecholamine-secreting tumors as defined 
by presence of metastasis or local tissue invasion. Cardiac pheochromocytomas appear more 
invasive and difficult to “shell out”, unlike benign adrenal pheochromocytomas.  
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Fig. 1. Resected cardiac pheochromocytoma. 
3. Clinical manifestations 
The clinical manifestation of cardiac pheochromocytoma can be related to catecholamine 
secretion, size of the tumor and competition for blood supply with normal myocardium. 
Headache, excess sweating, flushing and palpitation are the usual symptoms of cardiac 
pheochromocytomas. Sustained, labile, or paroxysmal hypertension is typically present in 
almost all patients with cardiac pheochromocytomas as a result of excess circulating 
catecholamines. These tumors can cause angina chest pain as it competes with normal 
myocardium for coronary blood supply. Occasionally seizures occur and very rarely intense 
mesenteric artery vasoconstriction may cause ischemic enterocolitis with severe abdominal 
pain. However clinical manifestations of cardiac pheochromocytomas are less dramatic 
compared to adrenal pheochromocytoma. We reported a case presenting with angina chest 
pain and the tumor received dual blood supply from both right and left coronary arteries 
and had undergone complete surgical excision utilizing cardiopulmonary bypass  
(Figure 3, 4).  
 




Clinical suspicion is raised in cases of resistant hypertension particularly in patients with 
family history of pheochromocytoma. Quantification of the plasma or urinary catecholamine 
metabolite metanephrine is the most sensitive test for the diagnosis (sensitivity 99%, 
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Fig. 3. Coronary angiogram: showing right coronary artery tumor blush.   
 
 
Fig. 4. Coronary angiogram: showing left circumflex coronary arteries tumor blush. 
 




Complete Surgical resection with adequate disease-free margins and reconstruction with 
pericardial or synthetic patch is the gold standard treatment for primary cardiac 
pheochromocytomas, but this can be technically difficult and is complicated by the 
position and extension of the tumor. These include pheochromocytoma extension into 
atrioventricular groove, direct coronary artery involvement and extension into the left 
ventricle. In these patients, resection with adequate margin carries high mortality and 
morbidity as a result of fatal hemorrhage and myocardial infarction. In this group of 
patients cardiac transplantation is the best treatment option provided distant metastasis 
has been excluded. Adequate preoperative preparation with alpha and beta adrenergic 
blockers and total cardiopulmonary bypass with cardioplegic arrest should be instituted 
to isolate the heart from systemic circulation before manipulation of the tumor. However, 
in all patients, life-long surveillance for recurrence should be performed with regular 
follow-up employing biochemical testing for fractionated metanephrines and imaging 
techniques such as 123-iodine-iodobenzylguanidine (MIBG) and computed tomography 
scans when appropriate.   
6. Conclusion 
Primary cardiac pheochromocytomas are very rare tumor of the heart. The multimodality 
imaging studies in assessing cardiac tumor are important in planning surgical strategy. 
Complete resection of cardiac pheochromocytoma with adequate disease free margin is the 
standard treatment which safely performed using cardiopulmonary bypass. Long-term 
surveillance is warranted for tumor recurrence. 
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1. Introduction  
Pheochromocytomas and paragangliomas are rare catechomine-producing tumors. 
Pheochromocytoma is a chromaffin tumor originating in the adrenal medulla and 
paraganglioma is originating in the sympathetic and parasympathetic portions of the 
autonomic nervous system paraganglia. The patients’ symptoms are variable according the 
tumor secretion of norepinephrine (NE), epinephrine (E) or dopamine into the circulation. 
Patients with tumors predominantly secrete norepinephrine present with severe and 
refractory hypertension to conventional treatment. Patients with predominantly epinephrine 
and dopamine-secreting tumors present with episodic symptoms such as tachycardia with 
palpitations, panic attacks and feelings of doom.  
1.1 Multiple Endocrine Neoplasia syndromes (MEN) 
MEN 1 is a rare autosomal dominant disease that consists of tumors of the parathyroid 
glands, pancreatic islets (insulinomas) and anterior pituitary. Pheochromocytoma is not a 
feature in this syndrome. 
MEN 2 is an autosomal dominant syndrome with three recognized sub-types: MEN 2A, B 
and C. In MEN 2A (Sipple’s syndrome), medullary thyroid carcinoma is associated with 
pheochromocytoma and hyperparathyroidism. Pheochromocytoma is frequently bilateral 
and the diagnosis is later than medullary carcinoma. Patients who have been treated for 
medullary carcinoma should be screened for pheochromocytoma.  
2. Epidemiology 
The prevalence of pheochromocytoma is not precisely known. However, the incidence is 
about 1-2 per 100,000 adults per year according study in Minnesota (Beard et al., 1983). In 
countries other than United States, a lesser incidence has been noted about 2 to 8 cases per 
million inhabitants per year (Stenström  & Svärdsudd, 1986). In a large series of patients 
screened biochemically for suspicion of pheochromocytoma, the incidence has been 
described to be as high as 1.9%. There was no difference between men and women (Smythe 
et al., 1992). Recently, a clinical review described the incidence between 2 and 8 cases per 
million per year in the United States (Golden et al., 2009). In an autopsy series described by 
McNeil et al. one pheochromocytoma occurred per 2301 autopsies (McNeil et al., 2000). With 
the routine use of computerized tomography (CT) for abdominal complaints, it is likely that 
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more tumors will be discovered. The tumor is discovered incidentally in approximately 10% 
of patients during CT or magnetic resonance imaging (MRI) of the abdomen for unrelated 
symptoms (Kudva et al., 2003). However, recently others authors reported a 30% rate of 
incidentally discovered pheochromocytomas in their cohort of patients (Kopetschke et al., 
2009; Shen et al., 2010). Pheochromocytoma is present in 0.1% to 1% of patients with 
hypertension (Omura et al., 2004)  
Approximately 10% of adrenal pheochromocytomas and 30% of paragangliomas are 
considered malignant (Suh et al., 2009). 70% to 80% of pheochromocytomas occur 
sporadically. The familial syndromes that may present with pheochromocytoma include 
multiple endocrine neoplasia type 2 (NEM 2), von Hippel-Lindau syndrome, Osler-Weber-
Rendu syndrome, and neurofibromatosis syndrome type 1 (Guerrero et al., 2009).  The peak 
incidence occurs in the third to fifth decades of life and the average age at diagnosis is 43.9 
years in sporadic cases (Neumann et al., 2002). However, the familial syndromes include 
younger patients (24.9 years), extra-adrenal and multiple tumors and the hypertension is 
persistent (Perel et al., 1997). Some authors studied genetic screening in pheochromocytoma 
and found younger patients with familial syndromes in their cohorts (Manelli et al., 2009; 
Cascon et al., 2009). 
Pheochromocytoma was the most frequent indication for adrenalectomy (23.2%) noted by 
Villar (Villar et al., 2010).  
The 10% rule is no longer applied. The ectopic pheochromocytoma is more prevalent than 
10% (Madani et al., 2007). Extra-adrenal tumors are extra-adrenal paragangliomas and the 
majority is located in the head and neck area (69%), followed by intra-abdominal (22%) and 
intrathoracic locations (10%) (Van Der Horst-Schrivers et al., 2010). The periaortic, pericaval 
regions and Zuckerkandl’s were the commonest sites of abdominal paragangliomas 
(Erickson et al., 2001). 
3. Pathophysiology 
3.1 The sympathetic nervous system (SNS) 
The hypertension of pheochromocytoma has been thought to result solely from the action of 
circulating catecholamines on cardiovascular adrenergic receptors. However, according to 
the studies of Bravo et al., blood pressure demonstrates no correlation with circulating 
catecholamines (Bravo et al., 1979). Bravo and collaborators related that sympathetic reflexes 
are intact, and blood pressure and heart rate are significantly reduced by clonidine despite 
maintained high circulating catecholamine (Bravo et al., 1982). 
In pheochromocytoma patients, the SNS activity is enhanced and maintains the elevated 
blood pressure by the catecholamine-induced hypertension. The paradoxical elevation of 
sympathetic activity during elevation of circulating catecholamine is postulated to be due 
three mechanisms: 1) loading of sympathetic vesicles with catecholamine, presumably 
reflecting a loading of noradrenergic terminal vesicles with neurotransmitter; 2) increased 
sympathetic neuronal impulse frequency; and 3) a selective desensitization of presynaptic α2 
–adrenergic receptors. These receptors inhibit release of neuronal NE. Thus, selective 
desensitization results in enhanced release of neuronal NE during nerve stimulation.  
The hypertensive crisis could be produced by any direct or reflexly mediated stimulus to the 
SNS, because of the enhanced SNS activity and excessive stores of NE in sympathetic nerve 
terminals (Bravo & Tagle, 2003). 
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3.2 The neurohumoral agents 
Angiotensin II has no direct role in pheochromocytoma, because the administration of 
clonidine reduces arterial blood pressure without significantly decreasing plasma renin 
activity (Bravo et al., 1982). Neuropeptide Y (NPY) levels are increased in plasma and in 
tumors of patients with pheochromocytoma (deS Senanayake et al., 1995; Lundberg et al., 
1986). NPY increases coronary and peripheral and vascular resistance independently of α-
adrenergic mechanisms by interacting with vascular G protein-coupled receptors (O’Hare & 
Schwartz, 1989; Lundberg et al., 1982). The hypertensive episodes that occur in 
pheochromocytoma patients receiving α-blockade might be due the NPY release by the 
pheochromocytoma.  
3.3 Hemodynamic characteristics 
Pheochromocytoma patients have hemodynamic features similar to patients with essential 
hypertension. Thus, increased peripheral vascular resistance seems to be primarily 
responsible for maintenance of hypertension (Bravo & Tagle, 2003).  
4. Diagnosis 
Before discussing the role of laboratory diagnosis and research of imaging methods would 
be interesting to present the patient with symptoms of pheochromocytoma and the reasons 
would lead to further investigation. The table 1 shows the main points of clinical 
presentation for screening of pheochromocytoma. In addition, the table 2 shows the main 







Episodic symptoms of headaches, tachycardia, and diaphoresis 
Remember the five “H” characterizing pheochromocytoma: hypertension, 
hyperglycemia, hypermetabolism, hyperhidrosis and headache 
Family history of pheochromocytoma or a MEN syndrome, VHL, or neurofibromatosis 
type 1 
Incidental adrenal or abdominal masses  
Unexplained paroxysms of tachyarrhythmias, bradyarrhythmias and /or hypertension 
during intubation, induction of anesthesia, parturition, or prolonged and unexplained 
hypotension after an operation 
Adverse cardiovascular responses to ingestion, inhalation or injection of certain drugs 
(anesthetic agents, histamine, glucagons, naloxone, antidopaminergic agents, tricyclic 
antidepressants) 




Table 1. Patients for screening of pheochromocytoma. 
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Table 1. Patients for screening of pheochromocytoma. 
 





 Primary hypogonadism (e.g, menopausal syndrome) 
 Pancreatite tumors (e.g., insulinoma) 
 Medullary thyroid carcinoma 
 “Hyperadrenergic” spells 
Cardiovascular 
 Essential hypertension, labile 
 Angina and cardiovascular deconditioning 
 Pulmonary edema 
 Dilated cardiomyopathy 
 Syncope 
 Orthostatic hypotension 
 Paroxysmal cardiac arrhythmia 
 Aortic dissection 
 Renovascular hypertension 
Psychological 
 Anxiety and panic attacks 
 Somatization disorder 
 Hyperventilation 
 Factitious (e.g., drugs, Valsalva) 
Pharmacologic 
 Withdrawal of adrenergic-inhibiting medication (e.g, clonidine) 
 Monoamine oxidase inhibitor treatment and concomitante ingestion of tyramine or a 
decongestant 
 Sympathomimetic ingestion 
 Ilicit drug ingestion (e.g, cocaine, phencyclidine, lysergic acid) 
 Acrodynia (Mercury poisoning) 
 Vancomycin (red man syndrome) 
Neurologic 
 Baroreflex failure 
 Postural orthostatic tachycardia syndrome  
 Autonomic neuropathy 
 Migraine headache 
 Diencephalic epilepsy  (autonomic seizures) 
 Cerebral infarction 
 Cerebrovascular insufficiency 
Miscellaneous 
 Mastocytosis (systemic or activation disorder) 
 Carcinoid syndrome 
 Recurrent idiopathic anaphylaxis 
 Unexplained flushing spells 
 
 
Table 2. Differential diagnosis of pheochromocytoma. 
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Approximately 50% of pheochromocytomas produce excessive amounts E and NE and the 
other 50% predominantely produce NE. Sympathetic paragangliomas produce mainly NE, 
frequently dopamine, and never E (Eisenhofer et al., 2003).  
Measurements of fractionated metanephrines in urine and in plasma or both are the initial 
testing for pheochromocytoma (Lenders et al., 2002) and no single analysis can achieve 100% 
accuracy for pheochromocytoma diagnosis. 
When the presence of a pheochromocytoma appears likely but with equivocal biochemical 
testing, a clonidine test is recommended to distinguish true from false positives results 
(Eisenhofer et al., 2003). 
Levels of normetanephrine, metanephrine, or both metabolites are increased in almost all 
patients with pheochromocytoma. However, in small or microscopic tumors (<1 cm) 
producing small amounts of catecholamines, the levels of normetanephrine and 
metanephrine might be normal (Eisenhofer et al., 1999; Lenders et al., 2002). If there is a 
hereditary predisposition or a previous history for pheochromocytoma, a testing at a later 
date remains mandatory. False-negative results also could include patients with 
pheochromocytoma that do not produce NE or E, a more rare exception (Sawka et al., 2003).  
4.1 Plasma metanephrines 
Normal plasma levels of normetanephrine and metanephrine exclude pheochromocytoma, 
and no immediate testing for the tumor should be necessary. Thus, measurements of plasma 
free metanephrines eliminate false-negative in the diagnosis of pheochromocytoma. In 
contrast, false-positive results remain a common problem, potentially time-consuming and 
expensive for follow-up. Plasma free metanephrines sensitivity is 99%, followed closely by 
urinary fractionated metanephrines at 97% (Lenders et al., 2002). The blood sample should 
be obtained in the supine position. The technique involves the determination of free 
metanephrines in plasma by high-performance liquid chromatography (HPLC). An 
elevation of at least four times the upper reference intervals is associated with nearly a 100% 
probability of pheochromocytoma or sympathetic paraganglioma (Lenders et al., 2005). 
Elevated catecholamine and metanephrine levels by one to three times the upper limits of 
normality are usually due to various medications or physiological responses. For tests of 
plasma free metanephrines the specificity is 89% (Bravo & Tagle, 2003). 
False-positive results include medical conditions, medications, inappropriate sampling 
conditions, and diet. An overnight fast and resting supine before blood sampling minimize 
the problem. Phenoxybenzamine and tricyclic antidepressants accounted for up to 45% of 
false-positive elevations of plasma or urinary norepinephrine and normetanephrine 
(Eisenhofer et al., 2003). However, selective serotonin reuptake inhibitors may provide an 
alternative medication because they are not a cause of false-positive results. 
Phenoxybenzamine is a nonspecific α-adrenoreceptor blocker, causing norepinephrine and 
normetanephrine elevation by attenuating α2-adrenoreceptor-mediated feedback inhibition 
of norepinephrine release, possibly combined with reflexive sympathetic activation. Thus, 
this drug should be avoided until biochemical testing is complete. Alternative medications 
for blood pressure control may include calcium channel blockers and selective α1-
adrenoreceptor blockers such as doxazosin and prazosin. Non-selective α-adrenoreceptor 
blockers were associated with 60% of all false-positive elevations of plasma metanephrine. 
Nevertheless, the false-positive rate was not high (12.5%). Only if an equivocal result has 
been obtained, it is necessary repeat testing after withdrawing these medications. 
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 Medullary thyroid carcinoma 
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Psychological 
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4.2 Urinary free catecholamines and metabolites 
Urinary free NE and E and two major metabolites of the catecholamines, metanephrines 
(normetanephrines and metanephrines) and vanillylmandelic acid (VMA) are relatively easy 
to perform and are usually readly available. A diagnosis can be confirmed or excluded on 
the basis of properly collected 24h urine samples (Mannelli, 1989). In MEN syndromes, 
either 24-h urinary excretion or the calculated ratio of E to NE is a very sensitive screening 
test (Gagel et al, 1988). The sensitivity of the tests used to detect pheochromocytoma is as 
follows: urinary NE 86%, urinary E 33%, urinary VMA 64%, plasma NE 58%, and plasma E 
33%. Among all tests for pheochromocytoma, the higher specificities are 95 % for test of 
urinary VMA and 93% for test of urinary total metanephrines (Bravo & Tagle, 2003). The 
table 3 shows the sensitivity and specificity values of diagnostic tests.  
 
 
Sensitivity %                 
Hereditary       Sporadic 
Specificity % 
Hereditary       Sporadic 
Plasma 
Free Metanephrines 97 99 96 82 
Catecholamines 69 92 89 72 
Urine 
Metanephrines 96 97 82 45 
Catecholamines 79 91 96 75 
Total Metanephrines 60 88 97 89 
Vanilmandelic acid 46 77 99 86 
Table 3. The sensitivity and specificity values of diagnostic tests. 
4.3 Patterns of biochemical test results 
Patients with pheochromocytoma usually have larger relative increases in metanephrines 
than catecholamines, whereas patients with false-positive results due sympathoadrenal 
activation usually have larger increases in catecholamines than metanephrines. These 
differences are possible because pheochromocytoma tumor cells produce metanephrines 
continuously and release into the circulation independently of variations in release of the 
parent catecholamines (Eisenhofer et al., 1998).  
A plasma normetanephrine to NE ratio above 0.52 or a metanephrine to E ratio above 4.2 can 
provide confirmatory evidence of pheochromocytoma in up to 30% of patients where increases 
in plasma metanephrines are insufficient to prove the tumor (Eisenhofer et al., 2003). 
4.4 Clonidine-suppression testing 
This test was introduced by Bravo et al. (Bravo et al., 1981) to distinguish patients with 
pheochromocytoma from those with false-positive biochemical results. Decreases in 
elevated NE concentrations after clonidine suggest sympathetic activation, whereas a lack of 
decrease suggests pheochromocytoma. However, normal suppression occurs and this test is 
recommended for patients with plasma catecholamine levels over 1000 ng/liter (5.9 
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nmol/liter), with a normal response defined as a fall to within normal range (Bravo & 
Gifford, 1984). 
Another criterion for a normal response has been a fall in plasma NE after clonidine of 
more than 50% in patients with normal or only mildly elevated plasma NE levels (Bravo & 
Tagle, 2003). Plasma normetanephrine is better than NE as end-point marker for the 
clonidine-supression test, because pheochromocytomas cause larger, more consistent, and 
less episodic increases of plasma normetanephrine than NE. 76% of plasma 
normetanephrine is derived from NE released by sympathetic nerves while 90% of 
circulating metanephrine is normally derived from metabolism of E within adrenal 
chromaffin cells. Lack of decrease of plasma normetanephrine combined with a high 
plasma level after clonidine establishes high probability of pheochromocytoma. Plasma 
normetanephrine concentrations remained elevated after clonidine in 96% of patients with 
pheochromocytoma compared with only 67% for NE. (Bravo et al., 1981; Eisenhofer et al., 
2003). 
4.5 Imaging 
Computed tomography (CT) and magnetic resonance imaging (MRI) are sensitive studies 
and are recommended for initial tumor localization. MRI is preferred for children, pregnant 
or lactating women, anyone who expresses concern about excessive radiation exposure, and 
individuals who have had previous surgical resection in abdominal, pelvic, and thoracic 
cavities. The tumor diameter in majority of pheochromocytomas is greater than 2 cm, thus it 
is possible diagnose them by CT. The CT sensibility for pheochromocytoma diagnosis is 
about 90%. However, CT is less sensitive in small tumors. The MRI has a sensibility of 95% 
for the adrenal tumor bigger than 0.5 cm (Timmers et al., 2009). 
Functional imaging agents that target the catecholamine synthesis, storage, and secretion 
pathways of chromaffin tumor cells are currently used. These techniques include 123/131 
metaiodobenzylguanidine (MIBG) scintigraphy, 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine 
(DOPA) positron emission tomography (PET), and 6-[18F]fluorodopamine (FDA) PET. 
Another modality for localization of metastatic paraganglioma is the 2-[18F]fluoro-2-deoxy-
D-glucose (FDG) PET, that is less tissuspecific than the other functional approaches 
(Timmers et al., 2009). 
The 123I-metaiodobenzylguanidine (MIBG) scan has better specificity than CT and MRI, 
however it is less sensitive in the context of familial paraganglioma syndrome, 
paragangliomas, and metastatic disease. 123I-MIBG is preferred over 131I-MIBG because of its 
higher sensitivity, lower radiation exposure, and improved imaging quality with single-
photon emission-computed tomography (Timmers et al., 2009). Previous studies suggest a 
sensitivity of 123I-MIBG scintigraphy of 92-98% for nonmetastatic paraganglioma and 57-79% 
for metastases (Van Der Horst-Schrivers et al., 2006). Recently a study confirmed that the 
sensitivity is high for primary tumors and relatively poor (50%) for metastases (Timmers et 
al., 2009). 
Non-metastatic paragangliomas are well localized by these techniques described previously 
according to Timmers and collaborators (Timmers et al., 2009). However, for the detection of 
metastases seen on CT, 18F-FDA-PET was superior to 18F-DOPA-PET and 123I-MIBG 
scanning. 18F-FDG-PET is superior in evaluating metastatic paraganglioma with mutations 
in succinate dehydrogenase subunit B (SDHB), whereas 18F-DOPA-PET performs best in 
non-SDHB patients (Timmers et al., 2007). The figure 1 shows the algorithm for biochemical 
and radiological diagnosis of pheochromocytoma. 
 
Pheochromocytoma – A New View of the Old Problem 
 
124 
4.2 Urinary free catecholamines and metabolites 
Urinary free NE and E and two major metabolites of the catecholamines, metanephrines 
(normetanephrines and metanephrines) and vanillylmandelic acid (VMA) are relatively easy 
to perform and are usually readly available. A diagnosis can be confirmed or excluded on 
the basis of properly collected 24h urine samples (Mannelli, 1989). In MEN syndromes, 
either 24-h urinary excretion or the calculated ratio of E to NE is a very sensitive screening 
test (Gagel et al, 1988). The sensitivity of the tests used to detect pheochromocytoma is as 
follows: urinary NE 86%, urinary E 33%, urinary VMA 64%, plasma NE 58%, and plasma E 
33%. Among all tests for pheochromocytoma, the higher specificities are 95 % for test of 
urinary VMA and 93% for test of urinary total metanephrines (Bravo & Tagle, 2003). The 
table 3 shows the sensitivity and specificity values of diagnostic tests.  
 
 
Sensitivity %                 
Hereditary       Sporadic 
Specificity % 
Hereditary       Sporadic 
Plasma 
Free Metanephrines 97 99 96 82 
Catecholamines 69 92 89 72 
Urine 
Metanephrines 96 97 82 45 
Catecholamines 79 91 96 75 
Total Metanephrines 60 88 97 89 
Vanilmandelic acid 46 77 99 86 
Table 3. The sensitivity and specificity values of diagnostic tests. 
4.3 Patterns of biochemical test results 
Patients with pheochromocytoma usually have larger relative increases in metanephrines 
than catecholamines, whereas patients with false-positive results due sympathoadrenal 
activation usually have larger increases in catecholamines than metanephrines. These 
differences are possible because pheochromocytoma tumor cells produce metanephrines 
continuously and release into the circulation independently of variations in release of the 
parent catecholamines (Eisenhofer et al., 1998).  
A plasma normetanephrine to NE ratio above 0.52 or a metanephrine to E ratio above 4.2 can 
provide confirmatory evidence of pheochromocytoma in up to 30% of patients where increases 
in plasma metanephrines are insufficient to prove the tumor (Eisenhofer et al., 2003). 
4.4 Clonidine-suppression testing 
This test was introduced by Bravo et al. (Bravo et al., 1981) to distinguish patients with 
pheochromocytoma from those with false-positive biochemical results. Decreases in 
elevated NE concentrations after clonidine suggest sympathetic activation, whereas a lack of 
decrease suggests pheochromocytoma. However, normal suppression occurs and this test is 
recommended for patients with plasma catecholamine levels over 1000 ng/liter (5.9 
 
Diagnosis: Laboratorial Investigation and Imaging Methods 
 
125 
nmol/liter), with a normal response defined as a fall to within normal range (Bravo & 
Gifford, 1984). 
Another criterion for a normal response has been a fall in plasma NE after clonidine of 
more than 50% in patients with normal or only mildly elevated plasma NE levels (Bravo & 
Tagle, 2003). Plasma normetanephrine is better than NE as end-point marker for the 
clonidine-supression test, because pheochromocytomas cause larger, more consistent, and 
less episodic increases of plasma normetanephrine than NE. 76% of plasma 
normetanephrine is derived from NE released by sympathetic nerves while 90% of 
circulating metanephrine is normally derived from metabolism of E within adrenal 
chromaffin cells. Lack of decrease of plasma normetanephrine combined with a high 
plasma level after clonidine establishes high probability of pheochromocytoma. Plasma 
normetanephrine concentrations remained elevated after clonidine in 96% of patients with 
pheochromocytoma compared with only 67% for NE. (Bravo et al., 1981; Eisenhofer et al., 
2003). 
4.5 Imaging 
Computed tomography (CT) and magnetic resonance imaging (MRI) are sensitive studies 
and are recommended for initial tumor localization. MRI is preferred for children, pregnant 
or lactating women, anyone who expresses concern about excessive radiation exposure, and 
individuals who have had previous surgical resection in abdominal, pelvic, and thoracic 
cavities. The tumor diameter in majority of pheochromocytomas is greater than 2 cm, thus it 
is possible diagnose them by CT. The CT sensibility for pheochromocytoma diagnosis is 
about 90%. However, CT is less sensitive in small tumors. The MRI has a sensibility of 95% 
for the adrenal tumor bigger than 0.5 cm (Timmers et al., 2009). 
Functional imaging agents that target the catecholamine synthesis, storage, and secretion 
pathways of chromaffin tumor cells are currently used. These techniques include 123/131 
metaiodobenzylguanidine (MIBG) scintigraphy, 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine 
(DOPA) positron emission tomography (PET), and 6-[18F]fluorodopamine (FDA) PET. 
Another modality for localization of metastatic paraganglioma is the 2-[18F]fluoro-2-deoxy-
D-glucose (FDG) PET, that is less tissuspecific than the other functional approaches 
(Timmers et al., 2009). 
The 123I-metaiodobenzylguanidine (MIBG) scan has better specificity than CT and MRI, 
however it is less sensitive in the context of familial paraganglioma syndrome, 
paragangliomas, and metastatic disease. 123I-MIBG is preferred over 131I-MIBG because of its 
higher sensitivity, lower radiation exposure, and improved imaging quality with single-
photon emission-computed tomography (Timmers et al., 2009). Previous studies suggest a 
sensitivity of 123I-MIBG scintigraphy of 92-98% for nonmetastatic paraganglioma and 57-79% 
for metastases (Van Der Horst-Schrivers et al., 2006). Recently a study confirmed that the 
sensitivity is high for primary tumors and relatively poor (50%) for metastases (Timmers et 
al., 2009). 
Non-metastatic paragangliomas are well localized by these techniques described previously 
according to Timmers and collaborators (Timmers et al., 2009). However, for the detection of 
metastases seen on CT, 18F-FDA-PET was superior to 18F-DOPA-PET and 123I-MIBG 
scanning. 18F-FDG-PET is superior in evaluating metastatic paraganglioma with mutations 
in succinate dehydrogenase subunit B (SDHB), whereas 18F-DOPA-PET performs best in 
non-SDHB patients (Timmers et al., 2007). The figure 1 shows the algorithm for biochemical 
and radiological diagnosis of pheochromocytoma. 
 




Fig. 1. The algorithm for biochemical and radiological diagnosis of pheochromocytoma. 
4.6 Genetics 
In actuality, 17 - 35% of pheochromocytomas and paragangliomas have a hereditary 
background. These hereditary tumors have been described in patients with 
neurofibromatosis type 1 (NF1), von Hippel Lindau syndrome (VHL), multiple endocrine 
neoplasia type 2 (MEN 2), and paraganglioma/ pheochromocytoma syndromes types 1-4 
(PGL1, PGL2, PGL3, and PGL4) (Gill et al., 2011). The mutated genes are, respectively, 
NF1, VHL, RET proto-oncogene (Rearranged in Transfection), and subunits of the enzyme 
succinate dehydrogenase (SDHD, SDH5, SDHC, and SDHB) (Gimenez-Roqueplo et al., 
2003). Hereditary pheochromocytomas and paragangliomas can be found at any age. 
However, most of these tumors are diagnosed in people younger than 50 years of age 
(Eisenhofer et al., 2011a). The most prevalent among these syndromes is PGL 1, caused  
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by germline SDHD mutations, followed by PGL 4, whereas PGL 3 is rare (Amar et al.,  
2005). 
The genetic screening should be considered in patients with history for paraganglial tumors, 
multiple tumors, young age at diagnosis, malignant pheochromocytoma because the 
prognosis in carriers of SDHB mutations is worse compared with non-SDHB-positive ones 
(Jiménez et al., 2006). Identification of a patient as a carrier of a germline mutation should be 
as early as possible. Mutation analysis of NF1 gene is not indicated because patients who 
have   pheochromocytoma and carry this gene mutation also have neurofibromas or other 
signs of the syndrome. In general, patients presenting with pheochromocytoma who have 
MEN 2 and a RET mutation will have a personal or family history of MEN 2 features 
(Eisenhofer et al., 2011b). Mutations of VHL, NF 1 and RET genes are rare. Therefore, 
mutation analysis of VHL, RET, and NF 1 should not be performed unless there is clear 
clinical evidence of these syndromic features in the patient and/or family (Neumann & Eng, 
2010). 
The pathological examination of surgically resected or biopsied tumor tissue or a diagnosis 
of inoperable malignant pheochromocytoma based on findings of metastatic disease by 
imaging studies is required to confirm pheochromocytoma.  
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Pheochromocytoma is a rare catecholamine secreting tumor of the chromaffin of the body 
derived from the neural crest tissue and accounts for 0.1% to 1% of all cases of chronic 
hypertension (Manger et al, 1985). The common presenting signs and symptoms are 
paroxysmal hypertension, headache, excessive sweating, and palpitation. The hypertension 
is episodic in nature in up to 50% of cases. Also, 10% of patients remain normotensive 
(Bravo & Gifford, 1984). Thus, pheochromocytoma may go unrecognized and up to 50% of 
the cases are diagnosed only at postmortem examination. A proportion of patients are 
diagnosed at the time of incidental surgery, when induction of anesthesia and surgical 
manipulations may precipitate catastrophic hemodynamic crisis and even multiple organ 
failure (Siddik-Sayyid et al. 2007; Dabbous et al.2007; O’Riordan JA, 1997). In this situation, 
mortality is close to 80% (O’Riordan, 1997). The dramatic improvement in surgical outcome 
of diagnosed pheochromocytoma can be attributed to adequate preoperative imaging, 
appropriate medical preparation, and improved surgical and anesthetic techniques (Schiff & 
Welsh, 2003).  
2. Pheochromocytoma the “10% tumor” 
Pheochromocytoma has been referred to as the “10% tumor” because 10% are extraadrenal, 
10% are malignant, 10% bilateral, 10% in children, and finally 10% are hereditary. The extra-
adrenal tumors are more likely to be multiple and malignant. 
3. Plasma catecholamines 
Plasma adrenaline concentrations >400 pg/ml, and plasma noradrenaline concentrations> 
1000 pg/ml are generally diagnostic of pheochromocytoma. However, there is no significant 
correlation between the plasma catecholamine levels and the degree of hypertension. This 
may be attributed to different factors such as the decreased blood volume in the 
pheochromocytoma patient, the episodic secretion of catecholamines, the associated down 
regulation of the adrenergic receptors, as well as the paroxysmal attacks of hypertension. 
The presence of normotension despite an increased plasma concentration of catecholamines 
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presumably reflects a decrease in the number of alpha-adrenergic receptors (down 
regulation) in response to increased circulating concentration of the neurotransmitter. 
Clonidine (0.3mg orally, suppresses the plasma concentrations of catecholamines in a 
hypertensive patient but not in the pheochromocytoma patient.  Clonidine acts as α2-
adrenergic agonist and hence can suppress an increase in the plasma catecholamine 
resulting from neurogenic release, but not secondary to diffusion of excess catecholamines 
from a pheochromocytoma into the circulation (Bravo & Gifford, 1984) 
4. Preoperative preparation 
Patients with pheochromocytoma are chronically vasoconstricted as a result of the high 
levels of circulating catecholamines, and have a secondary decrease in their blood volume. 
Preparation for surgery in patients with diagnosed pheochromocytoma should begin at least 
2 weeks preoperatively to allow full alpha-adrenergic blockade along with the gradual 
restoration of blood volume. A standard protocol for adrenergic blockade is to administer 
phenoxyhenzamine, starting at a dose of 40mg per day, and gradually increasing to 80-120 
mg per day. This single precaution may decrease perioperative mortality down from 43% to 
3%. The most common side effect of phenoxybenzamine is postural hypotension. Beta-
blockade can be given after starting alpha-blockade, if tachycardia or other arrhythmias 
develop. Beta-blockers must never be started prior to adequate alpha-blockade, since in the 
absence of beta2 mediated vasodilation, profound unopposed alpha-mediated 
vasoconstriction may lead to hypertensive crisis or pulmonary edema (MyKlejard, 2004; 
Kinney et al. 2002; O’Riordan, 2007; Geogheghan et al. 1998).  
Whereas norepinephrine released from sympathetic nerve fibers activates the junctional α1-
adrenergic receptors, it is thought that the α2-receptors are extrajunctional, and are 
preferentially stimulated by circulating catecholamines (Hamdan & Limbird, 1996). Also the 
α2-receptors are located prejunctional and function as a negative feedback. Despite its 
selective α1-receptor antagonist effect, prazosin has little or no α2-receptor blocking effect at 
concentrations achieved clinically (Hamdan & Limbird, 1996). Nicholson and colleagues 
found that pheochromocytoma patients pretreated with prazosin exhibited marked 
hypertensive responses to tumor handling requiring phentolamine (Nicholson et al. 1983). 
In another study by Russel and colleagues, phenoxybenzamine, which is a nonselective α1 
and α2-receptor blocker, provided superior intraoperative stability compared to prazosin 
(Russell et al. 1998). Also, in contrast to phenoxybenzamine, prazosin has a short elimination 
half-life (2-3 hours); therefore prazosin blood concentrations may decrease to ineffective 
levels at the time of surgery (Prys-Roberts, 2000). 
Prys-Roberts suggested that doxazosin, a long-acting and selective α1-adrenergic blocking 
agent is preferable to phenoxybenzamine when used in the dose range 2-8 mg/day. He 
suggests that because doxazosin does not block α2-adrenergic activity, many patients do not 
require β-adrenergic blocking agents. The selective α1-antagonsist prazosin and doxazosin 
have been used in the management of pheochromocytoma. They do not block the 
presynaptic α2-adrenergic receptors; thus by allowing norepinephrine reuptake by nerve 
endings, the tachycardia following the administration of the nonselective α1 and α2 
adrenergic blocker phenoxybenzamine does not occur. However, it has the disadvantage of 
being long-acting and the patient may develop postoperative hypotension refractory to 
norepinephrine (Nicholson et al.,1983; Hull, 1986). To help assess the adequacy of 
Undiagnosed Pheochromocytoma Complicated with  
Perioperative Hemodynamic Crisis and Multiple Organ Failure 
 
137 
preoperative management of pheochromocytoma, the following Roizen criteria should be 
met in order to reduce perioperative morbidity and mortality (Table 1) (Roizen et al., 1982). 
 
_________________________________________________________________________________ 
Roizen et al proposed treatment for at least 10 days and until: 
1. There are no marked symptoms 
2. Arterial blood pressure does not exceed 160/90 mmHg on more than four 
measurements in 24hr 
3. Systolic blood pressure has decreased by at least 15% when moving from lying to 
standing position, but was more than 80/45 mmHg 
4. The ECG was free of changes in ST segment and T wave for 2 weeks 
_________________________________________________________________________________ 
Table 1. Preoperative Preparation 
There is no accepted rule regarding the duration of adequate preoperative preparation; 
however, the study of Russels et al suggested that 5-7 days will be generally sufficient. MFH 
James practice is to increase α-blockade on a daily basis until adequate hemodynamic 
control is achieved and then to proceed to surgery, rather than use any predetermined time 
period. Failure to achieve adequate control by medical means, particularly in patients with 
large tumors, may be an indication for relatively urgent surgery as the only mechanism for 
controlling the excessive catecholamine production. Also, catecholamine-induced 
cardiomyopathy, as well as ST and T-wave abnormalities appear to have little advantage in 
attempting to control them with medical management prior to tumor excision. These 
changes generally regress once the catecholamine source is removed (James, 2010).  
Alpha-adrenergic blockade attenuates or prevents catecholamine-induced vasoconstriction, 
leading to decreased blood pressure as well as to expansion of the blood volume. 
Satisfactory alpha blockade is implied if the hematocrit decreases by about 5%, for example 
from 45% to 40%. Serial monitoring of the hematocrit is a useful method of evaluating the 
adequacy of intravascular volume expansion. Normalization of the intravascular blood 
volume and blood pressure by the alpha adrenergic blockade before surgery can decrease 
the risk of intraoperative hypertension during manipulation of the tumor, and may even 
decrease the degree of hypotension following excision of the tumor. Continuation of alpha 
adrenergic blockade therapy until the day of surgery is recommended in order to minimize 
the hypertensive response during surgery. Also, because of the expanded blood volume, 
concern that sustained alpha blockade could contribute to refractory hypotension when 
vascular isolation of the tumor is accomplished has not been substantiated (Stoelting & 
Dierdorf, 1993). 
5. Undiagnosed pheochromocytoma 
The classic symptoms of pheochromocytoma consist of the triad of excessive sweating, 
headache and palpitation, in addition to paroxysmal hypertension. However, all three 
symptoms occur together in less than 50% of patients. Also, hypertension may be sustained 
in 50% of patients who will be managed as essential hypertension. Also, patients who 
present with anxiety, palpitation, sweating and tremors may be misdiagnosed as stressed or 
menopausal. Abdominal pain, presumably due to bowel ischemia may lead to the erroneous 
diagnosis of acute abdomen. Hyperglycemia may occur and the patient is diagnosed as 
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diabetic (James, 2010). In all these situations, the diagnosis of pheochromocytoma may be 
missed, and hence the patient can develop severe pheochromocytoma crisis during 
incidental surgery or during pregnancy. 
Anesthesia and surgery in unsuspected cases have a high reported mortality. In a 
postmortem series, 27% of patients with undiagnosed pheochromocytoma died during or 
shortly after surgery (Sutton et al, 1981). Headache, palpitation, sweating and hypertension 
are considered to be 90% predictive of pheochromocytoma (Bravo & Gifford, 1984). In 
practice, such symptoms are often dismissed as psychologic or stress related, and the 
diagnosis may be missed until the patient presents with hypertension. Also, excess 
catecholamines produce hyperglycemia, which may be mistaken for insulin-deficient 
diabetes mellitus. Even worse, patients may suffer a whole series of major cardiovascular 
“events” only to suffer an unheralded intraoperative pheochromocytoma crisis (Hull & 
Batchelor, 2003). 
6. Pheochromocytoma crisis 
Although less than 0.1% patients with hypertension actually have a pheochromocytoma, 
nearly 50% of deaths in patients with unsuspected pheochromocytoma occur during 
anesthesia and surgery or during parturition (Kirkendahl et al., 1965). 
The factors triggering intraoperative pheochromocytoma crisis can be attributed to excessive 
release of catecholamines from the undiagnosed tumor secondary to anxiety of the awake 
patient, or secondary to light general anesthesia during surgery (Table 2). 
 
_________________________________________________________________________________ 
 Anxiety of the awake patient 
 Light anesthesia during tracheal intubation and surgery 
 Mechanical Factors 
 Straining 
 Scrubbing 
 Abdominal manipulations of the tumor 
 CO2 insufflation during laparoscopy 
 Excessive uterine contractions or fetal movements 
 Excessive uterine contractions or fetal movements during pregnancy 
_________________________________________________________________________________ 
Table 2. Factors precipitating pheochromocytoma crisis. 
Excessive release of catecholamines may be also drug-induced secondary to histamine 
release, dopamine receptor blockade, or sympathomimetic action (Table 3). 
In addition, excessive release of catecholamines from the pheochromocytoma may be 
attributed to mechanical factors such as squeeze of the tumor during straining, positioning 
of the patient, by scrubbing, by intraperitoneal carbon dioxide insufflations during 
laparoscopy, or by direct manipulation of the tumor. It should be also remembered that 
radiocontrast media has been also associated with pheochromocytoma crisis. 
In the pregnant patient, having pheochromocytoma, excessive uterine contractions or fetal 
movements, as well as normal vaginal delivery or Cesarean section may precipitate the 
crisis; the symptoms and signs may mimic that of severe preeclampsia. However, 
preeclampsia is associated with hypertension and proteinuria usually after the 20th week of 
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gestation, while pheochromocytoma is rarely associated with proteinuria and may cause 




 e.g. atropine 
Sympathomimetic drugs 
 e.g. pancuronium 
Histamine releasing drugs 
 e.g. morphine 
  atracurium, mivacurium 
Dopamine receptor blocker 
 e.g. droperidol (inhibits reuptake of catecholamines) 
Catecholamine-sensitizing anesthetics 
 e.g.  halothane 
  desflurane 
____________________________________________________________________ 
Table 3. Drugs precipitating pheochromocytoma crisis. 
The perioperative pheochromocytoma crisis may mimic other conditions such as thyroid 
storm (Hirvonen et al.,2004) or malignant hyperthermia (Crowley et al.,1988; Allen & 
Rosenberg, 1990). However, the absence of any increase of end-tidal CO2, the lack of 
rigidity, and the near limited increase in temperature may exclude the diagnosis of 
malignant hyperthermia. The presentation of thyroid storm usually includes fever and 
tachycardia, with infection commonly being a precipitating factor. Profuse sweating with a 
high fever out of proportion to the infection may be a due to the presence of a thyroid storm. 
Systolic hypertension and widened pulse pressure is also a common occurrence. Dramatic 
changes in heart rate and/or blood pressure should alert the anesthesiologist to consider 
pheochromocytoma crisis as a possible cause. However, circulatory shock and/or 
pulmonary oedema may be the first manifestation of undiagnosed pheochromocytoma (3). 
The anesthesiologist faced with a patient developing severe hypertension which may 
alternate with hypotension, with developing tachycardia, sweating, heart failure, 
pulmonary edema and acidosis should consider the diagnosis of pheochromocytoma. 
Another sign which may help to confirm the diagnosis is pupillary dilation due to high 
levels of catecholamines (Larson & Herman, 1992). Emergency treatment will usually 
involve shot-acting vasodilator such as the α-adrenergic blocker phentolamine. In the case 
of epinephrine-secreting tumor, the severe tachycardia can be controlled by the short-acting 
and selective B1-adrenergic blocker esmolol. 
7. Incidental surgery 
Occasionally, patients undergoing incidental surgery are found to have undiagnosed 
pheochromocytoma. This may occur when a tumor is found by the surgeon. Also, dramatic 
changes in heart rate and/or blood pressure should alert the anesthesiologist to consider 
pheochromocytoma as a cause. This will require judicious use of short-acting vasodilator 
drugs such as phentolamine or sodium nitroprusside to control the hypertension. Whenever 
hypertension is associated with extreme tachycardia, the use of short-acting and selective 
 
Pheochromocytoma – A New View of the Old Problem 
 
138 
diabetic (James, 2010). In all these situations, the diagnosis of pheochromocytoma may be 
missed, and hence the patient can develop severe pheochromocytoma crisis during 
incidental surgery or during pregnancy. 
Anesthesia and surgery in unsuspected cases have a high reported mortality. In a 
postmortem series, 27% of patients with undiagnosed pheochromocytoma died during or 
shortly after surgery (Sutton et al, 1981). Headache, palpitation, sweating and hypertension 
are considered to be 90% predictive of pheochromocytoma (Bravo & Gifford, 1984). In 
practice, such symptoms are often dismissed as psychologic or stress related, and the 
diagnosis may be missed until the patient presents with hypertension. Also, excess 
catecholamines produce hyperglycemia, which may be mistaken for insulin-deficient 
diabetes mellitus. Even worse, patients may suffer a whole series of major cardiovascular 
“events” only to suffer an unheralded intraoperative pheochromocytoma crisis (Hull & 
Batchelor, 2003). 
6. Pheochromocytoma crisis 
Although less than 0.1% patients with hypertension actually have a pheochromocytoma, 
nearly 50% of deaths in patients with unsuspected pheochromocytoma occur during 
anesthesia and surgery or during parturition (Kirkendahl et al., 1965). 
The factors triggering intraoperative pheochromocytoma crisis can be attributed to excessive 
release of catecholamines from the undiagnosed tumor secondary to anxiety of the awake 
patient, or secondary to light general anesthesia during surgery (Table 2). 
 
_________________________________________________________________________________ 
 Anxiety of the awake patient 
 Light anesthesia during tracheal intubation and surgery 
 Mechanical Factors 
 Straining 
 Scrubbing 
 Abdominal manipulations of the tumor 
 CO2 insufflation during laparoscopy 
 Excessive uterine contractions or fetal movements 
 Excessive uterine contractions or fetal movements during pregnancy 
_________________________________________________________________________________ 
Table 2. Factors precipitating pheochromocytoma crisis. 
Excessive release of catecholamines may be also drug-induced secondary to histamine 
release, dopamine receptor blockade, or sympathomimetic action (Table 3). 
In addition, excessive release of catecholamines from the pheochromocytoma may be 
attributed to mechanical factors such as squeeze of the tumor during straining, positioning 
of the patient, by scrubbing, by intraperitoneal carbon dioxide insufflations during 
laparoscopy, or by direct manipulation of the tumor. It should be also remembered that 
radiocontrast media has been also associated with pheochromocytoma crisis. 
In the pregnant patient, having pheochromocytoma, excessive uterine contractions or fetal 
movements, as well as normal vaginal delivery or Cesarean section may precipitate the 
crisis; the symptoms and signs may mimic that of severe preeclampsia. However, 
preeclampsia is associated with hypertension and proteinuria usually after the 20th week of 
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gestation, while pheochromocytoma is rarely associated with proteinuria and may cause 




 e.g. atropine 
Sympathomimetic drugs 
 e.g. pancuronium 
Histamine releasing drugs 
 e.g. morphine 
  atracurium, mivacurium 
Dopamine receptor blocker 
 e.g. droperidol (inhibits reuptake of catecholamines) 
Catecholamine-sensitizing anesthetics 
 e.g.  halothane 
  desflurane 
____________________________________________________________________ 
Table 3. Drugs precipitating pheochromocytoma crisis. 
The perioperative pheochromocytoma crisis may mimic other conditions such as thyroid 
storm (Hirvonen et al.,2004) or malignant hyperthermia (Crowley et al.,1988; Allen & 
Rosenberg, 1990). However, the absence of any increase of end-tidal CO2, the lack of 
rigidity, and the near limited increase in temperature may exclude the diagnosis of 
malignant hyperthermia. The presentation of thyroid storm usually includes fever and 
tachycardia, with infection commonly being a precipitating factor. Profuse sweating with a 
high fever out of proportion to the infection may be a due to the presence of a thyroid storm. 
Systolic hypertension and widened pulse pressure is also a common occurrence. Dramatic 
changes in heart rate and/or blood pressure should alert the anesthesiologist to consider 
pheochromocytoma crisis as a possible cause. However, circulatory shock and/or 
pulmonary oedema may be the first manifestation of undiagnosed pheochromocytoma (3). 
The anesthesiologist faced with a patient developing severe hypertension which may 
alternate with hypotension, with developing tachycardia, sweating, heart failure, 
pulmonary edema and acidosis should consider the diagnosis of pheochromocytoma. 
Another sign which may help to confirm the diagnosis is pupillary dilation due to high 
levels of catecholamines (Larson & Herman, 1992). Emergency treatment will usually 
involve shot-acting vasodilator such as the α-adrenergic blocker phentolamine. In the case 
of epinephrine-secreting tumor, the severe tachycardia can be controlled by the short-acting 
and selective B1-adrenergic blocker esmolol. 
7. Incidental surgery 
Occasionally, patients undergoing incidental surgery are found to have undiagnosed 
pheochromocytoma. This may occur when a tumor is found by the surgeon. Also, dramatic 
changes in heart rate and/or blood pressure should alert the anesthesiologist to consider 
pheochromocytoma as a cause. This will require judicious use of short-acting vasodilator 
drugs such as phentolamine or sodium nitroprusside to control the hypertension. Whenever 
hypertension is associated with extreme tachycardia, the use of short-acting and selective 
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β1-adrenergic blocker such as esmolol may be administered. Except when there is extreme 
tachycardia, the use of β -blockade in this acute situation without previous α-blockade is 
best avoided. Where surgery can be reasonably be aborted, that is likely to be the wise 
option (Hull & Batchelor, 2003). 
7.1 Case report (Siddik-Sayyid et al.,2007) 
A 43-year-old female patient was admitted to the hospital for right modified radical 
mastectomy. She had a past history of headache and palpitations with no hypertension: her 
preoperative blood pressure (BP) was 130/80 mmHg and her heart rate (HR) was 80 
beats/min. Preoperative electrocardiogram and chest x-ray were normal. General anesthesia 
was induced with propofol, 2 mg/kg, fentanyl, 2 µg/kg, and cisatracurium, 0.15 mg/kg, 
and was maintained with isoflurane in a mixture of nitrous oxide and oxygen (2:1) by using 
intermittent positive-pressure ventilation. Thirty minutes after the start of surgery, the 
patient developed severe hypertension (BP 230/135 mmHg) and marked tachycardia (HR 
160-180 beats/min). The anesthetic level was deepened by increasing the concentration of 
isoflurane and by additional doses of fentanyl (3 µg/kg) and midazolam (2 mg). Also, 
intravenous boluses of nitroglycerin (100 µg) and propranolol (1 mg) were given. The BP 
decreased to 100/50 mmHg and the HR to 130 beats/min. Right mastectomy and lymph 
node dissection were continued. Twenty minutes later, oxygen saturation as monitored by 
pulse oximetry dropped to 92%. Also, chest auscultation revealed diffuse crepitations over 
both lung fields. Arterial blood gas analysis showed hypoxemia associated with 
uncompensated metabolic acidosis. Esophageal temperature increased to 38.5oC. Surgery 
lasted for 2 hours, and the patient was transferred intubated and ventilated to the intensive 
care unit for further management. 
A chest x-ray showed widespread alveolar infiltration suggestive of pulmonary edema. 
Echocardiography revealed severe global hypokinesia of the left ventricle with an estimated 
ejection fraction of 20% to 25%. Cardiac catheterization showed normal coronaries. The 
patient’s clinical condition deteriorated rapidly; she developed MOF including acute renal 
failure, hepatitis, pancreatitis, and disseminated intravascular coagulation. A computed 
tomography (CT) scan of the abdomen showed a 5.8cm mass in the left adrenal region, 
which raised suspicions of a pheochromocytoma. Spot urine vanillylmandelic acid (VMA) 
was 50.8 µg/mg of creatinine (normal range in this laboratory is 10.4 µg/mg of creatinine) 
with a creatinine of 12.6 mg/dl. A presumptive diagnosis of pheochromocytoma was made. 
The patient remained on mechanical ventilation and required daily hemodialysis. She was 
transfused with packed cells, platelets, and fresh frozen plasma. Blood cultures grew no 
pathogens; however, she was started on imipenem and vancomycin. The patient had 
marked fluctuations of BP between 85/55 mmHg and 220/120 mmHg, which necessitated 
aggressive inotropic support alternating with the combination of nitroglycerin and sodium 
nitroprusside infusion. A pulmonary artery catheter was inserted and showed a cardiac 
index varying between 2.3 and 3.0 L/min/m2 and a pulmonary artery pressure varying 
between 26/11 and 43/22 mmHg. During the following days, the patient’s temperature 
normalized, and there was improvement of the pulmonary, hepatic, pancreatic, and 
coagulation systems. However, the blood urea nitrogen and creatinine remained markedly 
elevated despite daily hemodialysis for 3 to 4 hours. On the 13th day after the surgery, it was 
decided to proceed with an emergency excision of the pheochromocytoma.  
Two days before surgery, prazosin was started at a dose of 1 mg orally 3 times a day. The 
antihypertensive regimen was maintained until the morning of surgery. The hemodynamic 
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profile before anesthesia showed BP of 140/70 mmHg, heart rate of 120 beats/min, and 
central venous pressure of 12 mmHg. In the operating room, the patient was monitored 
continuously with 5-lead electrocardiogram, pulse oximetry, capnography, intraarterial 
blood pressure, and central venous pressure measurements. Anesthesia was induced with 
propofol, 1 mg/kg, midazolam, 0.03 mg/kg and cisatracurium, 0.2 mg/kg, and a 
remifentanil infusion was initiated at a rate of 2 µg/kg.min. Anesthesia was maintained 
with 2% to 5% isoflurane in a mixture of air/oxygen (3:1), remifentanil, 1 to 2 µg/kg/min, 
and incremental doses of cisatracurium. Blood volume was expanded carefully throughout 
the procedure by normal saline solution to maintain an adequate central venous pressure. 
Through a midline abdominal incision, the left kidney was exposed, and the patient 
underwent resection of her left adrenal gland. During manipulation of the tumor, the BP 
went up to 220/120 mmHg and required increasing concentrations of isoflurane up to 6% 
end-tidal) and nitroprusside (1-3 µg/kg/min). The patient also developed severe 
tachycardia, which was controlled by intravenous esmolol, 0.5 mg/kg, followed by an 
intravenous infusion at a rate of 25 µg/kg/min. Ligation of the efferent vein of the tumor 
resulted in an abrupt fall in BP to 50/20 mmHg, which was managed with a norepinephrine 
infusion and rapid infusion of normal saline solution and colloid solution (Hemaccel: 
Hoechst Marion Roussel, Frankfurt am Main, Germany). Postoperatively, the patient made a 
quick recovery, and her trachea was extubated after 48 hours. Hemodialysis support was 
discontinued after 4 days. Pathology of the resected tissue confirmed the presence of 
encapsulated pheochromocytoma with focal areas of hemorrhage. 
8. Pheochromocytoma during pregnancy (Hamilton,1997; Takahashi et 
al.,1998; Strachan et al., 2000; Mudsmith et al., 2006) 
Pheochromocytoma is a dangerous condition, particularly in pregnancy, when it is difficult 
to diagnose, uncommon and has often been confused with preeclampsia. 
Pheochromocytoma during pregnancy may mimic the usual symptoms and signs of 
preeclampsia, either as simple hypertension or fulminant eclampsia.  
Paroxysmal attacks during pregnancy may be precipitated by postural changes, the 
mechanical effect of the gravid uterus in the last trimester, uterine contractions during labor 
and increased fetal movements. Pheochromocytoma can mimic the symptoms and signs of 
preeclampsia and is therefore often missed. However, hypertension associated with 
pheochromocytoma is seldom accompanied by oedema or proteinuria, while glycosuria is 
often present. 
The use of intravenous labetalol or hydralazine is well established in preeclampsia, and its 
use in combination with magnesium sulphate has been described in patients with 
pheochromocytoma. The pharmacodynamic properties of magnesium sulphate (direct 
vasodilator, inhibition of catecholamine release from the adrenal medulla) make it useful for 
the management of pheochromocytoma(James, 2010). Magnesium also has powerful anti-
arrhythmic action in the presence of catecholamines. 
When pheochromocytoma develops in pregnancy, there is a high risk of maternal and/or 
fetal mortality. Even vigorous fetal movements may be associated with hypertensive crisis. 
For cases diagnosed during pregnancy, there is a clear choice between early intervention 
and conservative management until fetal viability permits elective cesarean section. 
Hamilton et al reported the use of prazosin and propranolol followed by surgical removal of 
a pheochromocytoma at 7 weeks gestation, followed by an uneventful pregnancy and 
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β1-adrenergic blocker such as esmolol may be administered. Except when there is extreme 
tachycardia, the use of β -blockade in this acute situation without previous α-blockade is 
best avoided. Where surgery can be reasonably be aborted, that is likely to be the wise 
option (Hull & Batchelor, 2003). 
7.1 Case report (Siddik-Sayyid et al.,2007) 
A 43-year-old female patient was admitted to the hospital for right modified radical 
mastectomy. She had a past history of headache and palpitations with no hypertension: her 
preoperative blood pressure (BP) was 130/80 mmHg and her heart rate (HR) was 80 
beats/min. Preoperative electrocardiogram and chest x-ray were normal. General anesthesia 
was induced with propofol, 2 mg/kg, fentanyl, 2 µg/kg, and cisatracurium, 0.15 mg/kg, 
and was maintained with isoflurane in a mixture of nitrous oxide and oxygen (2:1) by using 
intermittent positive-pressure ventilation. Thirty minutes after the start of surgery, the 
patient developed severe hypertension (BP 230/135 mmHg) and marked tachycardia (HR 
160-180 beats/min). The anesthetic level was deepened by increasing the concentration of 
isoflurane and by additional doses of fentanyl (3 µg/kg) and midazolam (2 mg). Also, 
intravenous boluses of nitroglycerin (100 µg) and propranolol (1 mg) were given. The BP 
decreased to 100/50 mmHg and the HR to 130 beats/min. Right mastectomy and lymph 
node dissection were continued. Twenty minutes later, oxygen saturation as monitored by 
pulse oximetry dropped to 92%. Also, chest auscultation revealed diffuse crepitations over 
both lung fields. Arterial blood gas analysis showed hypoxemia associated with 
uncompensated metabolic acidosis. Esophageal temperature increased to 38.5oC. Surgery 
lasted for 2 hours, and the patient was transferred intubated and ventilated to the intensive 
care unit for further management. 
A chest x-ray showed widespread alveolar infiltration suggestive of pulmonary edema. 
Echocardiography revealed severe global hypokinesia of the left ventricle with an estimated 
ejection fraction of 20% to 25%. Cardiac catheterization showed normal coronaries. The 
patient’s clinical condition deteriorated rapidly; she developed MOF including acute renal 
failure, hepatitis, pancreatitis, and disseminated intravascular coagulation. A computed 
tomography (CT) scan of the abdomen showed a 5.8cm mass in the left adrenal region, 
which raised suspicions of a pheochromocytoma. Spot urine vanillylmandelic acid (VMA) 
was 50.8 µg/mg of creatinine (normal range in this laboratory is 10.4 µg/mg of creatinine) 
with a creatinine of 12.6 mg/dl. A presumptive diagnosis of pheochromocytoma was made. 
The patient remained on mechanical ventilation and required daily hemodialysis. She was 
transfused with packed cells, platelets, and fresh frozen plasma. Blood cultures grew no 
pathogens; however, she was started on imipenem and vancomycin. The patient had 
marked fluctuations of BP between 85/55 mmHg and 220/120 mmHg, which necessitated 
aggressive inotropic support alternating with the combination of nitroglycerin and sodium 
nitroprusside infusion. A pulmonary artery catheter was inserted and showed a cardiac 
index varying between 2.3 and 3.0 L/min/m2 and a pulmonary artery pressure varying 
between 26/11 and 43/22 mmHg. During the following days, the patient’s temperature 
normalized, and there was improvement of the pulmonary, hepatic, pancreatic, and 
coagulation systems. However, the blood urea nitrogen and creatinine remained markedly 
elevated despite daily hemodialysis for 3 to 4 hours. On the 13th day after the surgery, it was 
decided to proceed with an emergency excision of the pheochromocytoma.  
Two days before surgery, prazosin was started at a dose of 1 mg orally 3 times a day. The 
antihypertensive regimen was maintained until the morning of surgery. The hemodynamic 
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profile before anesthesia showed BP of 140/70 mmHg, heart rate of 120 beats/min, and 
central venous pressure of 12 mmHg. In the operating room, the patient was monitored 
continuously with 5-lead electrocardiogram, pulse oximetry, capnography, intraarterial 
blood pressure, and central venous pressure measurements. Anesthesia was induced with 
propofol, 1 mg/kg, midazolam, 0.03 mg/kg and cisatracurium, 0.2 mg/kg, and a 
remifentanil infusion was initiated at a rate of 2 µg/kg.min. Anesthesia was maintained 
with 2% to 5% isoflurane in a mixture of air/oxygen (3:1), remifentanil, 1 to 2 µg/kg/min, 
and incremental doses of cisatracurium. Blood volume was expanded carefully throughout 
the procedure by normal saline solution to maintain an adequate central venous pressure. 
Through a midline abdominal incision, the left kidney was exposed, and the patient 
underwent resection of her left adrenal gland. During manipulation of the tumor, the BP 
went up to 220/120 mmHg and required increasing concentrations of isoflurane up to 6% 
end-tidal) and nitroprusside (1-3 µg/kg/min). The patient also developed severe 
tachycardia, which was controlled by intravenous esmolol, 0.5 mg/kg, followed by an 
intravenous infusion at a rate of 25 µg/kg/min. Ligation of the efferent vein of the tumor 
resulted in an abrupt fall in BP to 50/20 mmHg, which was managed with a norepinephrine 
infusion and rapid infusion of normal saline solution and colloid solution (Hemaccel: 
Hoechst Marion Roussel, Frankfurt am Main, Germany). Postoperatively, the patient made a 
quick recovery, and her trachea was extubated after 48 hours. Hemodialysis support was 
discontinued after 4 days. Pathology of the resected tissue confirmed the presence of 
encapsulated pheochromocytoma with focal areas of hemorrhage. 
8. Pheochromocytoma during pregnancy (Hamilton,1997; Takahashi et 
al.,1998; Strachan et al., 2000; Mudsmith et al., 2006) 
Pheochromocytoma is a dangerous condition, particularly in pregnancy, when it is difficult 
to diagnose, uncommon and has often been confused with preeclampsia. 
Pheochromocytoma during pregnancy may mimic the usual symptoms and signs of 
preeclampsia, either as simple hypertension or fulminant eclampsia.  
Paroxysmal attacks during pregnancy may be precipitated by postural changes, the 
mechanical effect of the gravid uterus in the last trimester, uterine contractions during labor 
and increased fetal movements. Pheochromocytoma can mimic the symptoms and signs of 
preeclampsia and is therefore often missed. However, hypertension associated with 
pheochromocytoma is seldom accompanied by oedema or proteinuria, while glycosuria is 
often present. 
The use of intravenous labetalol or hydralazine is well established in preeclampsia, and its 
use in combination with magnesium sulphate has been described in patients with 
pheochromocytoma. The pharmacodynamic properties of magnesium sulphate (direct 
vasodilator, inhibition of catecholamine release from the adrenal medulla) make it useful for 
the management of pheochromocytoma(James, 2010). Magnesium also has powerful anti-
arrhythmic action in the presence of catecholamines. 
When pheochromocytoma develops in pregnancy, there is a high risk of maternal and/or 
fetal mortality. Even vigorous fetal movements may be associated with hypertensive crisis. 
For cases diagnosed during pregnancy, there is a clear choice between early intervention 
and conservative management until fetal viability permits elective cesarean section. 
Hamilton et al reported the use of prazosin and propranolol followed by surgical removal of 
a pheochromocytoma at 7 weeks gestation, followed by an uneventful pregnancy and 
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delivery at 37 weeks. Nitroglycerine was used to control hypertension during surgery in 
preference to sodium nitroprusside on the grounds that the latter may reduce uterine blood 
flow. Also, phenoxyhenzamine is avoided during early pregnancy since it may have 
teratogenic effect. 
When the pheochromocytoma is diagnosed later at 29 weeks gestation, conservative 
treatment using labetalol may be continued until 35 weeks when the fetus is delivered and 
the tumor removed at the same operation. When the parturient commences labor with 
unsuspected pheochromocytoma, the hypertension may be managed by intravenous 
phentolamine or a combination of magnesium and hydralazine until delivery, followed by 
oral preparation of pheochromocytoma for delayed formal resection. 
9. Multicentric pheochromocytoma (Stoelting & Dierdorf, 1993; Wahlen et al., 
1992; Isselbacher et al., 1994; Baraka et al., 2002) 
Pheochromocytoma is a rare disorder occurring in 0.1% of the hypertensive population. It 
consists of a catecholamine secreting tumor, arising from chromaffin cells, either in the 
adrenal medulla in 75-85% of patients or in an extraadrenal location. Extraadrenal sites 
include any organ that contains paraganglionic tissue, along the paravertebral sympathetic 
chain, extending from the base of the skull to the pelvis. Most of the extraadrenal 
pheochromocytomas or paragangliomas are located below the diaphragm. 
Pheochromocytoma hemodynamic crisis may occur in patients with undiagnosed 
pheochromocytoma undergoing incidental surgery, in pregnant patients, as well as in 
patients with multicentric extraadrenal pheochromocytoma. 
Extraadrenal sites include any organ that contains paraganglionic tissue, along the 
paravertebral sympathetic chain extending from the base of the skull to the pelvis. Most of 
the extra adrenal pheochromocytomas or paragangliomas are located below the diaphragm. 
Approximately 18% of pheochromocytomas are extraadrenal. The most common location is 
the superior aortic region between the diaphragm and the inferior renal poles, in and 
around the renal hilum and accounts for approximately 46% of the extra adrenal tumors. 
Extra adrenal tumors in the inferior paraortic area between the lower renal poles and the 
aortic bifurcation have constituted 24% of the cases. Most of these tumors have arisen from 
the organ of Zucherkandl which consists of paraganglia found in the retroperitoneal region 
along the aorta around the inferior mesenteric artery.  
Most of extraadrenal pheochromocytoma secretes norepinephrine exclusively. If both 
norepinephrine and epinephrine are secreted, then the pheochromocytoma is very likely to 
be adrenal or Zucherkandl in origin. Serious hemodynamic fluctuations may occur during 
manipulations of the tumor of the organ of Zucherkandl which may be attributed to 
excessive catecholamine release secondary to its larger size and its more difficult resection. 
The present report describes the perioperative anesthetic management and the serious 
hemodynamic fluctuations observed in a patient undergoing resection of recurrent 
retroperitoneal multicentric extraadrenal pheochromocytomas. The report also shows that 
variable hemodynamic responses may occur during surgical excision of multicentric 
pheochromocytomas, suggesting that these tumors may be quite different functionally even 
if they grow concomitantly in the same patient. 
9.1 Case report (Baraka et al. 2002) 
The patient, a 28-year-old man, underwent at 12 year of age a laparotomy for the excision of 
an extraadrenal infrarenal pheochromocytoma adjacent to the lower pole of the left kidney. 
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He had been free of symptoms until three months before presentation, when he presented 
with paroxysmal headache, occasional sweating, palpitations, and abdominal discomfort. 
He was found to have a blood pressure (BP) of 200/100 mmHg. A 24-hr-urine collection 
showed catecholamines 5076 µg.24 hr-1 (normal <25µg.24 hr-1), vanillylmandylic acid of 13 
mg.24 hr-1 (normal < 8 mg.24 hr-1) and metanephrines 6009 µg.24hr-1 (normal < 900 µg.24 hr-
1). Computed tomography of the abdomen revealed two retroperitoneal masses, one 
adjacent to the lower pole of the right kidney and a second larger mass located at the aortic 
bifurcation in the region of the organ of Zuckerkandl. 
The patient was prepared preoperatively for two weeks with prazosin 1 mg po q six hours 
(because of the unavailability of phenoxyenazmine in our hospital), and propranolol 10 mg 
tid. The BP stabilized at 120/90 mmHg supine and standing, with a regular heart rate (HR) 
of 68 beats.min-1. Electrocardiogram (ECG) showed normal sinus rhythm, with non-specific 
T wave changes in V1-V4 leads. Hematocrit (Hct) was 43% and blood sugar level was 
normal. 
The patient was premedicated with diazepam 5 mg po. In the operating room, he was 
monitored continuously with a 5-lead ECG, pulse oximetry, capnography, intraarterial BP 
measurement, and pulmonary artery (PA) catheter. Prior to induction of anesthesia, BP was 
145/90 mmHg and HR was 75 beats.min. General anesthesia was induced with iv lidocaine 
1 mg.kg, propofol 3 mg.kg, fentanyl 2 µg/kg and rocuronium 1 mg.kg. The patient was 
ventilated with 4% sevoflurane in 100% O2 prior to proceeding with laryngoscopy and 
tracheal intubation. Anesthesia was then maintained with 4-8% sevoflurane in 100% O2, and 
by incremental doses of fentanyl and rocuronium, as needed. Blood volume was expanded 
throughout the procedure by lactated Ringer’s solution and by Haemaccel ® (Hoechst 
Marion Rousse. Frankfurt am Main, Germany) to maintain adequate central venous 
pressure and urine output. 
Through a midline abdominal incision, the right kidney was exposed and a mass was 
visualized, medial to the lower pole of the kidney, inferior to the renal helium and lateral to 
the vena cava. Dissection of the tumor from its surrounding structures was performed 
easily. Minimal hemodynamic changes occurred and responded to increasing 
concentrations of sevoflurane. 
The tumor of Zuckerkandl was overlying and adherent to the bifurcation of the aorta. 
Surgical dissection of the tumor was difficult and associated with excessive blood loss. 
Manipulation of the tumor resulted in severe hypertensive episodes with BP ranging from 
200/100 to 320/120 mmHg. Systemic hypertension was associated with elevation of PA 
pressure. Surgery was interrupted temporarily; sodium nitroprusside was infused in 
increasing doses up to 2µg.kg-1.min-1, and two doses of iv phentolamine 5 mg were 
administered. Hypertension also necessitated the bolus administration of esmolol 0.5 mg.kg-
1 iv to be followed by an iv infusion of 30 mg esmolol over 20 min. 
Ligation of the efferent vein of the tumor immediately resulted in a fall in BP which reached 
70/50 mmHg. This hypotension was treated by decreasing the concentration of sevoflurane, 
as well as by rapid iv infusion of lactated Ringer’s solution and 2 U of blood. In addition, a 
norepinephrine infusion (0.05 µg.kg.min) was required for 20 min. Thereafter, BP returned 
to normal without further treatment. The patient was kept sedated, intubated and 
transferred to the intensive care unit with a BP of 130/75 mmHg and a HR of 85 beats.min. 
His postoperative course was smooth and uneventful. 
Pathology examination of the resected tumors confirmed the diagnosis of 
pheochromocytoma; the first mass was slightly smaller (5 x 4 x 4 cm vs 6 x 4 x 3.5 cm) and 
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delivery at 37 weeks. Nitroglycerine was used to control hypertension during surgery in 
preference to sodium nitroprusside on the grounds that the latter may reduce uterine blood 
flow. Also, phenoxyhenzamine is avoided during early pregnancy since it may have 
teratogenic effect. 
When the pheochromocytoma is diagnosed later at 29 weeks gestation, conservative 
treatment using labetalol may be continued until 35 weeks when the fetus is delivered and 
the tumor removed at the same operation. When the parturient commences labor with 
unsuspected pheochromocytoma, the hypertension may be managed by intravenous 
phentolamine or a combination of magnesium and hydralazine until delivery, followed by 
oral preparation of pheochromocytoma for delayed formal resection. 
9. Multicentric pheochromocytoma (Stoelting & Dierdorf, 1993; Wahlen et al., 
1992; Isselbacher et al., 1994; Baraka et al., 2002) 
Pheochromocytoma is a rare disorder occurring in 0.1% of the hypertensive population. It 
consists of a catecholamine secreting tumor, arising from chromaffin cells, either in the 
adrenal medulla in 75-85% of patients or in an extraadrenal location. Extraadrenal sites 
include any organ that contains paraganglionic tissue, along the paravertebral sympathetic 
chain, extending from the base of the skull to the pelvis. Most of the extraadrenal 
pheochromocytomas or paragangliomas are located below the diaphragm. 
Pheochromocytoma hemodynamic crisis may occur in patients with undiagnosed 
pheochromocytoma undergoing incidental surgery, in pregnant patients, as well as in 
patients with multicentric extraadrenal pheochromocytoma. 
Extraadrenal sites include any organ that contains paraganglionic tissue, along the 
paravertebral sympathetic chain extending from the base of the skull to the pelvis. Most of 
the extra adrenal pheochromocytomas or paragangliomas are located below the diaphragm. 
Approximately 18% of pheochromocytomas are extraadrenal. The most common location is 
the superior aortic region between the diaphragm and the inferior renal poles, in and 
around the renal hilum and accounts for approximately 46% of the extra adrenal tumors. 
Extra adrenal tumors in the inferior paraortic area between the lower renal poles and the 
aortic bifurcation have constituted 24% of the cases. Most of these tumors have arisen from 
the organ of Zucherkandl which consists of paraganglia found in the retroperitoneal region 
along the aorta around the inferior mesenteric artery.  
Most of extraadrenal pheochromocytoma secretes norepinephrine exclusively. If both 
norepinephrine and epinephrine are secreted, then the pheochromocytoma is very likely to 
be adrenal or Zucherkandl in origin. Serious hemodynamic fluctuations may occur during 
manipulations of the tumor of the organ of Zucherkandl which may be attributed to 
excessive catecholamine release secondary to its larger size and its more difficult resection. 
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weighed less (43 g vs 46 g) than the second tumor. The two tumors showed no evidence of 
necrosis or unusual meiotic activity. 
10. Pheochromocytoma cardiomyopathy and multiple organ failure 
A high mortality rate has been reported in pheochromocytoma patients with catecholamine-
induced cardiomyopathy presenting symptoms of congestive heart failure, arrhythmia, 
acute pulmonary oedema and nonspecific EKG changes, as well as in pheochromocytoma 
complicated with multiple organ failure. 
Echocardiography may reveal global cardiac hypokinesia secondary to cardiomyopathy in 
25% to 50% of pheochromocytoma as a result of sustained exposure of the myocardium to 
high levels of catecholamines. Studies have shown a global reduction in myocardial pump 
function caused by a down-regulated β-adrenergic receptors and a net reduction in viable 
myofibrils. Rabits’ hearts with catecholamine-induced cardiomyopathy have shown a 
reduced inotropic sensitivity to noradrenaline, and also a reduced response to calcium 
chloride. The pathogenesis of catecholamine-induced cardiomyopathy is probably 
multifactorial. Catecholamine-induced vasospasm leading to hypoxia is implicated. Excess 
noradrenaline also induces changes in permeability of the sarcolimmal membrane leading to 
increased calcium influx. Also, it has been proposed that the injury process might involve 
release of free radicals (Sardesai et al.,1990; Gilsanz et al.., 1983; Takaror et al., 1987; Fripp et 
al., 1981). Left atrial enlargement secondary to catecholamine-induced left ventricular 
diastolic dysfunction is quite common (around 20%), but seldom poses a management 
problem unless accompanied by left ventricular systolic dysfunction. Left ventricular 
hypertrophy is frequently seen, as are ST and T-wave abnormalities. These appear to be 
little advantage in attempting to correct these changes by medical management prior to 
tumor excision. These changes generally regress once the excess catecholamines source is 
removed. Left ventricular failure and pulmonary edema may be present, particularly if the 
patient has developed signs of catecholamine-induced cardiomyopathy (James, 2010). 
Multiple organ failure (MOF) may be the initial presentation, and is called 
pheochromocytoma multisystem crisis. MOF may result from the high levels of circulating 
catecholamines, which can trigger excessive vascular spasm, volume contraction, platelet 
aggregation and thrombosis. The splanchnic vessels are highly susceptible to catecholamine-
induced vasoconstriction, and hence the ischemic gut mucosa may allow bacterial 
translocation or the passage of endotoxins across the intestinal barrier to extraintestinal sites 
including the lung which is the first organ to fail. Also, acute renal failure can be attributed 
to acute tubular necrosis because of the combination of cardiogenic shock reducing the renal 
perfusion, associated with renal vasoconstriction induced by a surge of catecholamines 
(Sardesai et al.,1990; Gilsanz et al.., 1983; Takaror et al., 1987; Fripp et al., 1981). 
Gut-derived factors, contained primarily in the mesenteric lymph rather than the portal 
system, potentiate the development of distant multiple organ failure. Because the lung is the 
first organ exposed to mesenteric lymph, via the thoracic duct and the subclavian vein, the 
lung is generally the first organ to fail in severely injured patients. The role of the gut injury 
and loss of gut barrier function contributes to the development of a systemic inflammatory 
state and distant organ injury (Fukushima et al.,1998). 
During the decade from 1985 to 1995, gut barrier and the ensuing translocation of bacteria 
and endotoxins gained acceptance as a major contribution to the development of multiple 
organ dysfunction syndrome (MODS). It now appears that pheochromocytoma similar to 
Undiagnosed Pheochromocytoma Complicated with  
Perioperative Hemodynamic Crisis and Multiple Organ Failure 
 
145 
shock, trauma, or sepsis-induced gut injury can result in the gut becoming a cytokine-
generating organ, and that the mesenteric circulation can become a priming bed for 
circulating neutrophils. Many of the same insults that cause intestinal mucosal injury and 
promote bacterial translocation also appear able to induce the gut and the gut-associated 
lymphatic tissue to produce cytokines and other inflammatory mediators that may 
contribute to MODS (Fukushima et al., 1998; Deitch,2001). 
In a review of 54 autopsy-proven cases of unsuspected pheochromocytoma seen at the 
Mayo Clinic over a 50-year period, hypertensive or hypotensive crisis precipitated by 
surgery for unrelated conditions was a common cause of death. Intraoperative deaths have 
been ascribed variously to ventricular arrhythmias, wide fluctuations in systemic blood 
pressure, myocardial infarction, acute pulmonary oedema, and subarachnoid hemorrhage 
(St. John Sutton, et al.,1981). Barale et al., 1978 described two patients with circulatory shock, 
vasoconstriction, and pulmonary edema as the first manifestation of undiagnosed 
pheochromocytoma (Barale et al.,1978). Also, MOF may be the initial presentation of 
undiagnosed pheochromocytoma and has a poor prognosis (Barale et al.,1978; Kohle et 
al.,2001). Newell et al.,1988 reported 3 patients with unusual presentations of 
pheochromocytomas, which they called “pheochromocytoma multisystem crisis”, a tetrad 
of symptoms including MOF, encephalopathy, high fever, and severe derangements in BP 
consisting of hypertension and/or hypotension. Siddik-Sayyid et al.,2007 reported a patient 
with an undiagnosed pheochromocytoma undergoing radical mastectomy; the patient 
developed intraoperative severe hemodynamic changes and pulmonary oedema, 
complicated by postoperative MOF; the postoperative hemodynamic instability and the 
persistent renal failure rapidly recovered after excision of the pheochromocytoma (Siddik-
Sayyid et al., 2007). 
Management of intraoperative pheochromocytoma crisis in patients undergoing incidental 
surgery consists of elimination of the triggering factors, as well as controlling hypertension 
by the administration of short-acting vasodilators such as the alpha-adrengergic blocker 
phentolamine, or sodium nitroprusside infusion. Whenever hypertension is associated with 
severe tachycardia, beta-adrenergic blocker can be administered; the short-acting and 
selective beta 1 blocker esmolol is preferred to the long-acting and nonselective propranolol. 
The administration of beta-adrenergic blocker without prior α-adrenergic blockade may be 
complicated by cardiac failure and pulmonary oedema secondary to its negative inotropic 
effect on the heart, associated with an increased after load. Initiation of nonselective beta 
blocker therapy without preceding alpha blockade in a patient with pheochromocytoma my 
precipitate a crisis with hemodynamic collapse. Nonselective beta blockade leads to loss of 
beta 2 receptor-mediated vasodilation, while the unopposed effects of alpha receptors 
causes vasoconstriction, resulting in increased after load, causing myocardial dysfunction 
and pulmonary oedema (Siddik-Sayyid et al., 2007). Thus, nonselective beta blockers should 
be avoided in any patient who could conceivably have a pheochromocytoma, until that 
possibility has been excluded. Also, unexplained cardiopulmonary dysfunction, and 
pulmonary oedema after the institution of beta blockade, should alert the anesthesiologist to 
the possibility of a pheochromocytoma (Sibal et al., 2006).  
In patients with undiagnosed pheochromocytoma undergoing incidental surgery, many 
authors recommend urgent operation whenever their condition deteriorates despite 
maximal medical therapy. Newell et al.,1988 recommend urgent adrenalectomy when 
multisystem injury is present and in cases of progressive deterioration despite medical 
therapy. Also, Wood (Case 6-1986) stated that preparation for operation involves a balance 
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between severity of the illness and quality of α-blockade, and suggested that certain patients 
undergo surgical tumor excision with incomplete α--blockade. Freier et al.,1980 
recommended urgent tumor excision after brief attempts at medical stabilization in patients 
presenting with alternating hypertension or hypotension, severe tachycardia, cardiac 
arrhythmias, encephalopathy, and renal failure.  
11. Conclusion 
In conclusion, patients with undiagnosed pheochromocytoma undergoing incidental 
surgery may develop intraoperative hemodynamic crisis complicated by postoperative 
multiple organ failure. 
Management of intraoperative pheochromocytoma crisis consists of elimination of the 
triggering factors, as well as the administration of short-acting vasodilators such as the 
alpha-adrenergic blocker phentolamine, or sodium nitroprusside infusion. The 
administration of beta adrenergic blocker without prior α-adrenergic blockade may be 
complicated by cardiac failure and pulmonary edema secondary to its negative inotropic 
effect associated with an increased after load. 
When the pheochromocytoma is surgically accessible during incidental surgery as 
laparotomy, the surgeon may be tempted to excise the tumor. However, tumor handling in 
unprepared patients may result in dramatic increases in arterial blood pressure followed by 
intractable hypotension after tumor excision.  A safer option is planned resection of the 
pheochromocytoma after confirmation of the diagnosis and optimal preoperative 
pharmacologic preparation. However, urgent adrenalectomy is recommended whenever 
multisystem injury deteriorates despite maximal medical therapy. 
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1. Introduction 
Phaeochromocytomas (PHEOs) and paragangliomas (PGLs) are catecholamine-secreting 
tumors, that arise from chromaffin cells of the adrenal medulla and extra-adrenal sites. 
Extra-adrenal phaeochromocytomas are called paragangliomas (Landers et al., 2005). The 
Prevalence of these tumors is 1:4500 and 1:1700 and an annual incidence of 3-8 cases per 1 
million per year in the general population. PHEOs/PGLs arise from three anatomically 
parts of the neural crest derived sympathy-adrenal system: adrenal medulla, sympathetic, 
and parasympathetic paraganglia (Kantorovich et al., 2010).  Extra-adrenal parasympathetic 
paragangliomas which are located predominantly in the head and neck are approximately 
95% nonsecretory. Pheochromocytomas typically occur in about 85% of cases from adrenal 
medullary chromaffin tissue and in about 15% of cases from extra-adrenal chromaffin 
tissues (Elder et al., 2005). 
1.1 Malignant pheochromocytoma 
Malignant forms of catecholamine-secreting tumors are rare. The malignancy rate is 
variable, from 2.4-26%. There are no histological proofs of malignancy for such tumors to 
date and the only accepted criterion is the presence of metastasis. The distant metastases are 
usually of hematologic origin, mostly involving bone, liver and lung (Hasani-Ranjbar, 2009, 
2010). The prevalence of metastasis is up to 36-50% for extra adrenal abdominal 
pheochromocytoma and 10% and 5% for adrenal and familial forms respectively (Whalen et 
al., 1992; O Riordan et al., 1996). Some studies have suggested that the presence of necrosis, 
vascular invasion, extensive local invasion, and high rate of mitotic figures may indicate a 
malignant behavior in pheochromocytoma. A recent study by Thompson used clinical 
features, histologic findings, and immunophenotypic studies for identifying parameters that 
may help distinguish benign from malignant pheochromocytoma. This is an Adrenal Gland 
scale Score (PASS) which is weighted for 12 specific histologic features that are more 
frequently identified in malignant pheochromocytoma. Tumors with PASS more than 4 
were biologically more aggressive than tumors with a PASS less than 4. Some 
immunohistochemical markers such as Ki-67, P52, Bcl-2 were studied to differentiate 
malignant from benign pheochromocytoma too (Strong et al.,2008).  But practically the 
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diagnosis of malignant pheochromocytoma can only be determined by presence of 
recurrence or metastatic disease at a site where chromaffin cells do not normally exist.  
1.2 Familial pheochromocytoma 
Most pheochromocytomas represent sporadic tumors. However some patients have disease 
as part of a familial disorder (15-30%). Sporadic pheochromocytomas are usually unicentric 
and unilateral while familial pheochromocytomas are often multicentric and bilateral. 
Hereditary pheochromocytoma typically present at a younger age than sporadic forms 
(Nourmann et al 2002; Manger & Gifford, 2002). 
There are several familial disorders associated with pheochromocytoma, these syndromes 
include von Hippel-Lindau (VHL) syndrome, multiple endocrine neoplasia type 2 (MEN2), 
neurofibromatosis type 1 and SDH mutation-related tumours. The approximate frequency 
of pheochromocytoma in these disorders is 50 percent in MEN2, 10 to 20 percent in VHL 
syndrome, and 0.1 to 5.7 percent with neurofibromatosis type 1 (Hasani-Ranjbar etal., 2009, 
Walter et al., 1999b; Dluhy, 2002). All of these syndromes have autosomal dominant 
inheritance (Table 1).  
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant predisposition to 
tumors of the parathyroid glands, anterior pituitary, and pancreatic islet cells. 
pheochromocytoma is very rare in MEN1 syndrome (Brandi, 2001). 
1.2.1 Multiple Endocrine Neoplasia Type 2 (MEN 2A and MEN 2B ) 
The prevalence of MEN2 syndrome is 2.5 per 100,000 in the general population. MEN2 is 
sub classified into three syndromes: MEN2A; MEN2B; and familial medullary thyroid 
cancer (FMTC). 
Multiple endocrine neoplasia type 2 (MEN2A) is characterized by pheochromocytoma 
(usually bilateral and may be asynchronous), medullary thyroid carcinoma (MTC), and 
hyperparathyroidism due to primary parathyroid hyperplasia (Noumann et al., 1993). The 
respective frequency of these tumors in MEN2 is over 90 percent for medullary thyroid 
cancer, approximately 40 to 50 percent for pheochromocytoma, and 10 to 20 percent for 
multigland.  
MEN2A is a heritable predisposition to medullary thyroid cancer, pheochromocytoma, and 
primary parathyroid hyperplasia. MEN2B shares the inherited predisposition to medullary 
thyroid cancer and pheochromocytoma that occurs in MEN2A. But in patients with MEN2B 
other clinical disorders including mucosal neuromas, typically involving the lips and 
tongue, and intestinal ganglioneuromas have to be considered. FMTC is a variant of 
MEN2A, which is associated with medullary thyroid cancer but not the other clinical 
manifestations of MEN2 syndromes (Brandi etal., 2001; Pacak et al., 2005 ). In patients with 
MEN2B, Medullary thyroid cancer is often more aggressive and of earlier onset than in 
MEN2A; so; early diagnosis and prevention are particularly critical (Donovan et al., 1989; 
Mathew et al., 1987). 
In contrast to MEN1, early diagnosis via screening of "at-risk" family members in MEN2A 
kindreds is essential because medullary thyroid cancer is a life-threatening disease that can 
be prevented by early thyroidectomy 
DNA testing has been the best screening test for this disorder since it was recognized 
that affected patients have germ-line mutations in the RET proto-oncogene on 
chromosome 10.   
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Abbreviations: VHL= von Hippel Lindau, MEN= multiple endocrine neoplasia, NF=Neurofibromatosis, 
PGL=Paraganglioma, PCC= Pheochromocytoma; MTC: Medullary thyroid cancer, SDH=succinate 
dehydrogenase type B,C,or D, AD=Autosomal Dominant, NE, norepinephrine; E, 
epinephrine,MT=Maternal Imprinting 
Table 1. Genetic conditions associated with pheochromocytoma- Clinical, biochemical and 
genetic facts. 
Numerous activating mutations throughout the RET proto-oncogene have been 
documented in persons with MEN 2A and pheochromocytoma is associated most frequently 
with mutations in codon 634 (in exon 11). MEN 2B is associated with mutations primarily in 
codon 918 (in exon 16) of the RET proto-oncogene (Mulligan et al., 1994; Carlson et al.,1994).  
1.2.2 VHL syndrome 
Von Hippel-Lindau (VHL) disease represents an alteration on VHL protein. The major 
physiological function of the VHL protein is to promote degradation of hypoxia-inducible 
factor (HIF1) that is a major factor involved in the regulation of hypoxia-related gene 
transcription (Figure 1). 
Von Hippel-Lindau (VHL) disease is manifested by a variety of benign and malignant tumors. 
The VHL phenotype includes pheochromocytoma (frequently bilateral), paraganglioma 
(rarely), retinal angiomas, cerebellar hemangioblastoma, epididymal cystadenoma, renal 
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Fig. 1. pVHL (1LQB.PDB) is shown in cartoon representation, in the upper part of the 
picture, interacting with HIF (which residues are shown as sticks). The 564 hydroxyproline 
residue of HIF, which is believed to be important in the interactions between the two 
proteins [REF: Science 296, 1886 (2002);Jung-Hyun Min,  et al.  Structure of an HIF-1a-pVHL 
Complex: Hydroxyproline Recognition in Signaling ] is indicated with a circle, and a view of the 
same hydroxyproline residue (stick) is shown in the inset image, alongside with some of the 
pVHL residues (labelled) that are located in its proximity. Mutations happening in these 
residues could be deleterious to the interaction between pVHL and HIF, and possibly 
involved in the disease phenotype. (This image has been created using PyMOL).  
and pancreatic cysts, pancreatic neuroendocrine tumors, and renal cell carcinoma (RCC) 
(Hasani Ranjbar etal., 2009; Lonser et al.,2003; Patocs et al.,2008) . 
VHL disease is divided into types I and II, based upon the likelihood of developing 
pheochromocytoma (Zbar et al., 1996). Type II families are more likely to carry a missense 
mutation in the VHL gene and are at higher risk for developing pheochromocytoma. Type II 
disease is subdivided based upon the risk of developing of RCC. Type IIA and IIB families 
have a low and high incidence of RCC, respectively, while type IIC kindreds are 
characterized by the development of pheochromocytomas only, without RCC or 
hemangioblastoma. Patients in kindreds with type I disease have a substantially lower risk 
of developing pheochromocytomas (Gomy et al., 2010).  
Clinical classification of VHL include: A. Classic VHL disease (A1: Families meeting current 
VHL diagnostic criteria with involvement of at least three VHL tumors in two distinct 
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organs; A2: Sporadic patients with involvement of at least two distinct tumors); B. 
nonclassic VHL disease, meeting criteria (B1:Families with less than 3 tumors in 2 distinct 
organs; B2: Cases meeting current diagnostic VHL criteria with limited VHL manifestations; 
C. Non classic, not meeting criteria(VHL-associated manifestations not meeting current 
diagnostic criteria) (Ciotti et al., 2009). 
The VHL tumor suppressor gene is located on chromosome 3p25-26. More than 300 
germline VHL mutations have been identified that lead to loss of function of the VHL 
protein (Kim & Kaelin,2004; Cruz et al., 2007). Missense, nonsense and splice site mutations, 
microdeletions and microinsertions are detected in approximately two-thirds of the families. 
Exon or entire gene deletions are found in 20-30% of the VHL families. Recently, real time 
quantitative PCR (RQ-PCR) and multiplex ligation-dependent probe amplification assay 
(MLPA) strategies have been proposed for detection of VHL deletions(Ciotti et al., 2009). 
Specific VHL gene mutations appear to correlate with clinical phenotype. About 95% of 
patients with VHL truncating or null mutations have VHL1 (without pheochromocytoma). 
In patients with VHL syndrome and pheochromocytoma(VHL2) 92-98% have missense 
mutations. 
1.2.3 Neurofibromatosis type 1 
Neurofibromatosis, or NF, is the term given to two neurocutaneous genetic conditions. 
Neurofibromatosis type 1, also known as von Recklinghausen's is the most common type of 
neurofibromatosis. The incidence of approximately 1 in 2600 to 1 in 3000 individuals (Lammert 
et al.,2005). Approximately one-half of the cases are familial; the remainder are new mutations 
(North K, 1993). The hallmarks of NF1 are the multiple café-au-lait spots (CALS) and 
associated cutaneous neurofibromas. Pheochromocytoma has been clinically identified in 0.1 
to 5.7 percent of patients with NF. The NF1 gene has been mapped to chromosome 17q11.2 
and cloned (ledbetter et al 1989; Shen et al., 1996; Feldkamp et al., 1998).  
Mutations in the NF1 gene result in loss of functional protein, causing the wide spectrum of 
clinical findings including NF1-associated tumors.  
No obvious genotype-phenotype correlation between small mutations (<20 base pairs) of 
the NF1 gene and a specific phenotype have been demonstrated, with the exception of the 
c.2970-2972 delAAT (p.M990del) mutation that is associated with a very mild phenotype in 
the majority of cases (Upadhyaya, et al., 2007).  
Genetic testing for NF1 is available but is not routinely performed, as the diagnosis is made 
based upon clinical phenotype.  
1.2.4 Familial paraganglioma 
Initial suggestion of genetic clustering of paraganglioma tumors date back to 1930, but mode 
of inheritance which is to be autosomal dominant with maternal imprinting in some cases 
was found by Van Der Mey in 1989. Later, several familial clusters of 
pheochromocytoma/paraganglima were described and defined as paraganglioma 
syndrome PGL1 through PGL4. PGL1 is to be related to mutation in the SDHD gene, PGL2 
to SDH5, PGL3 to mutation in SDHC and PGL4 to SDHB.  SDH-related tumorigenesis is 
believed to associate with hypoxia-inducible factor (HIF)/angiogenesis pathway 
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2. Patients and data collection 
Three families with familial pheochromocytoma were evaluated for past medical history 
and complete physical examination in endocrine ward, Shariati hospital, Tehran University 
of Medical science. The case-notes and hospital databases were examined for additional 
required data. The tumor size was taken as the widest diameter recorded on pathological 
report or radiological, if the tumor had not been removed.  Operative reports were reviewed 
to determine intra operative findings and types of surgical procedures. If there was evidence 
of extra-adrenal disease and if additional organ resection was necessary, specific notes were 
made.  
All pheochromocyroms in this study were arising from the adrenal gland and no extra 
adrenal or paraganglioma was included.  Adrenal bed recurrence was not a criterion for 
malignancy. The metastases were documented in all malignant cases.  Metastatic disease 
was defined as evidence of distant spread in tissue not normally containing chromaffin 
tissue i.e. bone, liver, lung or lymph nodes. 
2.1 Biochemical testing and localization studies 
Routine biochemical tests, evaluation of 24 hours urine catecholamine metabolites, 
abdominal computed tomography (CT) or magnetic resonance imaging (MRI) and/or 131 
Iodine_metaiodobenzylguanidine (MIBG) were done too. The malignant 
pheochromocytoma was diagnosed based on presence or absence of metastasis in 
radiological or pathological report.  
2.2 Genetic analysis 
2.2.1 RET proto-oncogene mutation screening 
Genetic screening tests were done in family members. RET proto-oncogene mutation 
screening for exones 10, 11, 13 ,14, 15, 16 were examined by PCR and direct DNA 
sequencing. In patient 1, 4 and 5: Exons 10, 11, 13, 14, 15, and 16 RET proto-oncogene were 
examined by PCR and direct DNA sequencing (Alvandi et al., 2007). 
2.2.2 VHL gene mutation screening 
For VHL gene mutation screening, analysis of VHL gene was performed using Cruz et al 
protocol (Hasani-Ranjbar et al., 2009; Cruz et al., 2007). Exons 1, 2, 3 of VHL gene was 
amplified by PCR with the following primers:  
1F - 5’ CCATCCTCTACCGAGCGCGCG 3’;  
1R - 5’ GGGCTTCAGACCGTGCTATCG2; 
3 F - 5’ TGCCCAGCCACCGGTGTG 2; 
3 R - 5’  GTCTATCCTGTACTTACCACAACA; 
3F - 5’ CACACTGCCACATACATGCACTC 3’; 
 3R - 5’ACTCATCAGTACCATCAAAAGCTG 3’.  
Both forward and reverse strands were subjected to direct sequencing after PCR 
amplification. (Hasani-Ranjbar et al., 2009). 
2.3 Protein modeling 
The PDB file 1LM8 and 1VCB were used in the modeling work in order to find the potential 
impact of the residue mutation on the protein structure. NCBI blast module was used to 
determine the degree of residue conservation. In silico mutation was achieved with Swiss-
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PdbViewer v.4 and minimization of the structure was done with the use of NOMAD-Ref 
server (http://lorentz.immstr.pasteur.fr/gromacs) (Lindahl  et al., 2006). 
3. Results 
3.1 Family 1 
The index patient was born to non related parents of Persian origin, Presented with thyroid 
nodule at the age of 48 years. His past medical history was unremarkable. He had no history 
of hypertensive crisis or headache. His daughter has had medullary thyroid cancer. And 
total thyroidectomy was done for her at the age of 23. Fine needle aspiration biopsy in the 
father was compatible with MTC and preoperational screening for pheochromocytoma was 
in favor of bilateral adrenal mass.  
 DNA was isolated from peripheral blood leucocytes using salting out method. Exones 10, 
11, 13, 14, 15, 16 of RET proto-oncogene localized to 10q11.2 was examined by direct DNA 
sequencing. This resulted in identification of mutations in Exon 11, codon 634, TGC>CGC 
(Cystein>Arginine), which was indicative of hereditary MTC and Pheochromocytoma. The 
presence of this mutation was confirmed by sequencing of the complementary strand as 
well. This mutation was found in 2 other daughters and one of his sons and one of his 
nephews too.  
One of the daughters  (Figure 2, Patient 1) had thyroid nodule and complete evaluation was 
consistent with medulary thyroid cancer. Biochemical tests and radiological study for 
pheochromocytoma was done and the results were against adrenal mass. There was no 
evidence in favor of pheochromocytoma or Medullary thyroid cancer in three other RET 
proto-oncogen cariers. However total prophylactic thyroidectomy was done for all of them.   
 
 
Fig. 2. Genetic relationship of multiple endocrine neoplasia type 2. 
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Bilateral adrenalectomy and then total thyroidectomy was done for the index patient (Figure 
2, index patient). 2 years after bilateral adrenalectomy the patient presented with 
hypertention crisis and headache as he was on replacement therapy with prednisolon,  
Fludrocortisone and levothyroxine. Biochemical tests for pheochromocytoma and 
abdominal MRI was in favor of a 30 mm right adrenal mass. Evaluation for 
hyperparathyroidism was negative in all family members. 
3.2 Family 2 
Five sisters of Persian origin with grave clinical features of pheochromocytoma have been 
reported in our previous work (Hasani-Ranjbar et al, 2009). The index patient presented 
with cerebal hemorrhage and coma at the age of 29 years. After complete evaluation 
malignant metastatic pheochromocytoma confirmed and the patient was operated. Clinical 
manifestation of VHL, MEN syndrome and neurofibromatosis were negative in this patient 
and his family. Evaluation of other family members was consistent with malignant 
pheochromocytoma in four sisters. Bilateral adrenalectomy was done for them. 2 of these 
sisters died because of complication of pheochromocytoma.  
3.2.1 Genetic analysis 
Genetic analysis of VHL gene was in favor of this syndromic pheochromocytoma. Sequence 
analysis of VHL gene exons showed presence of a missense mutation (499C>T in exon 3).  
3.2.2 Protein modeling  
Arg 167 was found to be highly conserved among various species. Its mutation to 
tryptophan was observed to affect the hydrogen bondings of that residue within pVHL 
itself, and probably causing changes in the tertiary structure of the protein. In silico mutation 
of the residue and subsequent minimization of the Trp167 containing structure was 
performed and an overall RMSD of 0.519 A ° was obtained for the mutated structure with 
the use of backbone only, and 0.597 A ° with the use of all atoms. The most affected residue 
was found to be Leu 169 with RMSD of 1.902 (backbone) and 2.665 A °(all atoms). Figure 3 
shows the position of Arg 167 in the pVHL tertiary structure (figure 3).  
3.3 Family 3  
A 45 year old man presented with abdominal pain and hypertension from 1 year ago. The 
patient was a known case of neurofibromatosis type 1 that presented at the age of 15 year 
with hyperpigmented and hypopigmented lesions in trunk, arms, feet and axillary areas. 
Family history was positive for neurofibromatosis in his mother and brother.  
Biochemical tests and imaging was compatible with malignant pheochromocytoma. The size 
of mass was 120*70 mm. Left adrenalectomy and nephrectomy and splenectomy were done 
for him. After surgery the symptoms improved and blood pressure was controlled. The 
patient had poor compliance in follow up.  
After 5 years he was admitted again for evaluation of hypertensive crisis. Again biochemical 
tests were consistent with pheochromocytoma and relapse. Imaging study and liver biopsy 
confirmed metastatic pheochromocytoma  to liver and para-aortic area. 131I-MIBG therapy 
was done for him. 
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Fig. 3. pVHL (1LQB.PDB) is shown in cartoon representation, in the left part of the picture, 
interacting with Elongin C (right). The location of Arg 167 and Leu 169 residues is indicated 
with labels, and the residues are shown as sticks . Mutation of Arg 167 to Trp is suggested to 
affect both secondary and tertiary structure of pVHL. (This image has been 
created using PyMOL).  
 
Pheochromocytoma – A New View of the Old Problem 156 
Bilateral adrenalectomy and then total thyroidectomy was done for the index patient (Figure 
2, index patient). 2 years after bilateral adrenalectomy the patient presented with 
hypertention crisis and headache as he was on replacement therapy with prednisolon,  
Fludrocortisone and levothyroxine. Biochemical tests for pheochromocytoma and 
abdominal MRI was in favor of a 30 mm right adrenal mass. Evaluation for 
hyperparathyroidism was negative in all family members. 
3.2 Family 2 
Five sisters of Persian origin with grave clinical features of pheochromocytoma have been 
reported in our previous work (Hasani-Ranjbar et al, 2009). The index patient presented 
with cerebal hemorrhage and coma at the age of 29 years. After complete evaluation 
malignant metastatic pheochromocytoma confirmed and the patient was operated. Clinical 
manifestation of VHL, MEN syndrome and neurofibromatosis were negative in this patient 
and his family. Evaluation of other family members was consistent with malignant 
pheochromocytoma in four sisters. Bilateral adrenalectomy was done for them. 2 of these 
sisters died because of complication of pheochromocytoma.  
3.2.1 Genetic analysis 
Genetic analysis of VHL gene was in favor of this syndromic pheochromocytoma. Sequence 
analysis of VHL gene exons showed presence of a missense mutation (499C>T in exon 3).  
3.2.2 Protein modeling  
Arg 167 was found to be highly conserved among various species. Its mutation to 
tryptophan was observed to affect the hydrogen bondings of that residue within pVHL 
itself, and probably causing changes in the tertiary structure of the protein. In silico mutation 
of the residue and subsequent minimization of the Trp167 containing structure was 
performed and an overall RMSD of 0.519 A ° was obtained for the mutated structure with 
the use of backbone only, and 0.597 A ° with the use of all atoms. The most affected residue 
was found to be Leu 169 with RMSD of 1.902 (backbone) and 2.665 A °(all atoms). Figure 3 
shows the position of Arg 167 in the pVHL tertiary structure (figure 3).  
3.3 Family 3  
A 45 year old man presented with abdominal pain and hypertension from 1 year ago. The 
patient was a known case of neurofibromatosis type 1 that presented at the age of 15 year 
with hyperpigmented and hypopigmented lesions in trunk, arms, feet and axillary areas. 
Family history was positive for neurofibromatosis in his mother and brother.  
Biochemical tests and imaging was compatible with malignant pheochromocytoma. The size 
of mass was 120*70 mm. Left adrenalectomy and nephrectomy and splenectomy were done 
for him. After surgery the symptoms improved and blood pressure was controlled. The 
patient had poor compliance in follow up.  
After 5 years he was admitted again for evaluation of hypertensive crisis. Again biochemical 
tests were consistent with pheochromocytoma and relapse. Imaging study and liver biopsy 
confirmed metastatic pheochromocytoma  to liver and para-aortic area. 131I-MIBG therapy 
was done for him. 
Familial Catecholamine-Secreting Tumors  


















Fig. 3. pVHL (1LQB.PDB) is shown in cartoon representation, in the left part of the picture, 
interacting with Elongin C (right). The location of Arg 167 and Leu 169 residues is indicated 
with labels, and the residues are shown as sticks . Mutation of Arg 167 to Trp is suggested to 
affect both secondary and tertiary structure of pVHL. (This image has been 
created using PyMOL).  
 
Pheochromocytoma – A New View of the Old Problem 158 
4. Discussion 
Here we present three distinct families with intra adrenal pheochromocytoma (Table 2).  
 
 
Abbreviations: VHL= von Hippel Lindau, MEN= multiple endocrine neoplasia, NF=Neurofibromatosis, 
Family 1=MEN2, Family 2= VHL, Family 3=NF, MTC=Medulary Thyroid Cancer, I131 MIBG = 131 
Iodine_metaiodobenzylguanidine 
Table 2. Genetic mutations and disease phenotype in the MEN 2, VHL and NF1 families. 
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4.1 Family 1 
The index patient in family 1 who presented with thyroid nodule diagnosed as MEN 2 
syndrome according to MTC and pheochromocytoma. The patient had no symptom or sign 
for pheochromocytoma. It is obviously known that when pheochromocytoma is associated 
with the multiple endocrine neoplasia type 2 (MEN2) syndrome, symptoms are present in 
only about one-half of patients and only one-third has hypertension (Pomares et al., 1998).  
Evaluation for primary parathyroid hyperplasia was negative in him and his family. In 
addition no mucosal neuromas on the lips and tongue were detected. The patient had 
MEN2B phenotype. As we mentioned before, MEN2B shares the inherited predisposition to 
medullary thyroid cancer and pheochromocytoma that occurs in MEN2A. There are, 
however, important clinical differences. Patients with MEN2B tend to have mucosal 
neuromas and intestinal ganglioneuromas. Many of these patients have development 
abnormalities, a Marfanoid habitus, and myelinated corneal nerves. Furthermore, the tumor 
is often more aggressive and of earlier onset than in MEN2A; as a result, early diagnosis and 
prevention for other family members was very critical (Donovan et al., 1989; Mathew et al., 
1987).  Since MEN2B is caused by specific RET mutations we conducted genetic evaluation 
for categorization of the syndrome (MEN2A versus MEN2B) (Eng et al., 1996). The clinical 
feature was matched with MEN2B which is actually more aggressive. On the other hand 
genetic evaluation was consistent with a known mutation related to MEN2A in which 
prophylactic thyroidectomy is recommend to be done in carriers later. As we showed in 
results we identified mutations in Exon 11, codon 634, TGC>CGC (Cystein>Arginine), 
which was indicative of MEN2A syndrome.  
The penetrance of hyperparathyroidism in those with mutations at this site is about 20 
percent. Even with the same mutation the penetrance of hyperparathyroidism within 
families varies from 9 to 34 percent (Schunffenecker et al., 1998).  
4.2 Family 2 
Family 2 is an unusual form of VHL syndrome with malignant intra adrenal 
pheochromocytoma and retinal angioma diagnosed as VHL type 2. Clinical manifestation of 
VHL, MEN syndrome and neurofibromatosis were negative in index patient and his family 
up to 9 years when retinal angioma was detected. All clinical manifestation and genetic and 
protein modeling methods have been described in our previous work which published in 
familial cancer journal (Hasani-Ranjbar et al., 2009). 
In this paper we reported the presence of a novel single nucleotide mutation in exon 3 of 
VHL gene c499 C>T causing substitution of Arginine by Tryptophan at position 167 (R 167 
W) (Hasani-Ranjbar et al., 2009). This family has been followed for at least 9 years as RET 
negative isolated familial pheochromocytoma, finally diagnosed as VHL disease according 
to retinal angioma and VHL gene mutation. As we noted before malignant 
pheochromocytoma is very rare in VHL disease and other familial forms of 
pheochromocytoma.  
Although clinical criteria were originally developed for the diagnosis of VHL based upon 
the finding of more than one VHL-associated tumor, now detection of a germline mutation 
in the VHL gene is typically used to establish the diagnosis, particularly in patients with a 
single manifestation of the condition (Lonser et al., 2003). 
On average about 10 to 20% of patients with VHL disease develop pheochromocytoma, but 
this incidence varies dramatically from family to family depending on the specific mutation 
(Koch et al., 2002; Karsdrop et al., 1994; Lamiell et al., 1989; Linehan et al., 1995) 
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In pheochromocytoma associated with von Hippel-Lindau disease, 35 percent of patients 
have no symptoms, a normal blood pressure, and normal laboratory values for fractionated 
catecholamines and metanephrines (Walter et al., 1999b). In our report all patients had 
aggressive disease and only one of the family members was asymptomatic diagnosed as 
adrenal pheochromocytoma based on  screening tests (Table2)(Hasani-Ranjbar et al., 2009).  
Malignant pheochromocytomas are histologically and biochemically the same as benign 
ones. The only reliable clue to the presence of a malignant pheochromocytoma is local 
invasion or distant metastases, which may occur as long as 20 years after resection 
(Goldstein et al., 1999; Pattarino & Bouloux 1996). 
A recent study showed high risk factors predictive factors of malignant pheochromocytoma 
include, large (5 cm or greater) or heavy (250 gm or greater) tumors, multifocal and extra-
adrenal tumors, early onset postoperative hypertension and higher plasma or urine 
metadrenaline (Feng et al., 2011). An initial report suggests that inhibin/activin beta-B 
subunit expression may help distinguish between benign and malignant disease; expression 
was strong or moderate in almost all benign adrenal pheochromocytomas (Salmenkivi et al., 
2001). Also, expression of the 3 angiogenesis or metastasis related genes VEGF, Cox-2 and 
MVD helps determine the diagnosis of malignancy and suggests strict followup (Gimenez-
Roqueplo et al., 2003; Brouwers et al., 2006). 
4.2.1 Protein modeling 
pVHL makes interactions with Elongin B and C, as well as HIF. The H1 helix of pVHL , 
where Arg 167 is located, is the interface between this protein and Elongin C, and a place 
where missense mutations occur frequently (Stebbinset et al., 1999). It seems that Arg 167 is  
involved in the correct positioning of the H1 helix, and that its mutation can also affect the 
hydrophobic interactions of Leu 168 with neighbour residues of Elongin C. the overall result  
is the disruption of some pVHL interactions with Elongin C (Figure 3).    
4.3 Family 3 
Family 3 is a kindred with neurofibromatosis and a member (A 45 year old man) with 
hypertension diagnosed as malignant pheochromocytoma. Hypertension is a frequent 
finding in adults with NF1 and may develop during childhood but pheochromocytoma is a 
much less common etiology. In these patients, the catecholamine-secreting tumor is usually 
a solitary benign adrenal pheochromocytoma, occasionally bilateral adrenal 
pheochromocytoma, and rarely a peri adrenal abdominal paraganglioma . Although 
neurofibromatosis type 1 as an autosomal dominant disorder is the most common familial 
cancer syndrome predisposing to pheochromocytoma, the risk of pheochromocytoma in this 
disorder is about 1% (Huson et al 1989; Riccardi et al., 1991). 
 Pheochromocytomas in patients with neurofibromatosis type 1 occur at the fifth decade. 
Our patient was a 45 years old man with an unusual presentation of pheochromocytma. 
Currently, except for the presence of the SDHB mutation, large size or an extra-adrenal 
location of the primary tumor, there are no reliable markers for predicting a high likelihood 
of developing metastatic disease.  Pheochromocytoma in neurofibromatosis is usually 
benign and unilateral. Based on genetic background our expectation before surgery was a 
benign non metastatic tumor. As we mentioned before, the patient had a metastatic tumor 
and after 5 years metastasis to liver and para-aortic lymph nodes deteriorated the clinical 
course of disease.  It seems to us that large mass (as detected in this patient firstly) beside 
local invasion  is a critical predicting factor to malignancy and may have the highest impact 
for detecting metastasis in future. 
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At first we treated the patient with surgical resection of the adrenal mass, but in follow up 
for treatment of distance metastasis the only available modality was MIBG therapy. 
Considering positive MIBG scan we predicted that the tumor could up take iodine. To date, 
beside surgery, 131I-MIBG therapy is the single most valuable therapy for malignant 
pheochromocytomas. Results of a phase II trial using high dose I131 MIBG demonstrated 
22% partial or complete response and 35% of patients having some degree of response (i.e. 
biochemical) without demonstrated progressive disease (Gonias  et al.,2009). For future our 
plan could be chemoembolization of the liver if there is persistent disease. 
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The book is divided into six sections. The first three sections focus on the 
pathophysiology of the disease, showing anatomo- and histopathological aspects, 
experimental models and signaling pathways and programmed cell death related to 
pheochromocytoma. The fourth discusses some specific aspects of clinical presentation, 
with emphasis on clinical manifestations of headache and heart. The fifth section 
focuses on clinical diagnosis, laboratory and imaging, including differential diagnosis. 
Finally, the last section discusses the treatment of pheochromocytoma showing clinical 
cases, a case about undiagnosed pheochromocytoma complicated with multiple organ 
failure and other cases about catecholamine-secreting hereditary tumors. Thus, this 
book shows the disease “pheochromocytoma” in a different perspective from the 
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